U.S. patent application number 15/780504 was filed with the patent office on 2018-12-13 for optimized anti-cd3 bispecific antibodies and uses thereof.
The applicant listed for this patent is Regeneron Pharmaceuticals, Inc.. Invention is credited to Robert Babb, Gang Chen, Lauric Haber, Douglas MacDonald, Eric Smith.
Application Number | 20180355038 15/780504 |
Document ID | / |
Family ID | 57130447 |
Filed Date | 2018-12-13 |
United States Patent
Application |
20180355038 |
Kind Code |
A1 |
Smith; Eric ; et
al. |
December 13, 2018 |
Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
Abstract
The present invention provides antibodies that bind to CD3 with
weak or no detectable binding affinity and methods of using the
same. According to certain embodiments, the antibodies of the
invention bind human CD3 with low affinity and induce human T cell
proliferation and hence induce T cell-mediated killing of tumor
cells with high efficacy. According to certain embodiments, the
present invention provides bispecific antigen-binding molecules
comprising a first antigen-binding domain that specifically binds
human CD3 with weak or no detectable binding affinity in an in
vitro assay, and a second antigen-binding molecule that
specifically binds human tumor-associated antigen. In certain
embodiments, the bispecific antigen-binding molecules of the
present invention are capable of inhibiting the growth of tumors
expressing target antigen, such as PSMA. The antibodies and
bispecific antigen-binding molecules of the invention are useful
for the treatment of diseases and disorders in which an upregulated
or induced targeted immune response is desired and/or
therapeutically beneficial. For example, the antibodies of the
invention are useful for the treatment of various cancers or other
diseases where immunotherapy, i.e. effector cell immunomodulation
is warranted.
Inventors: |
Smith; Eric; (New York,
NY) ; Haber; Lauric; (Rye Brook, NY) ; Babb;
Robert; (River edge, NY) ; Chen; Gang;
(Yorktown Heights, NY) ; MacDonald; Douglas; (New
York, NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Regeneron Pharmaceuticals, Inc. |
Tarrytown |
NY |
US |
|
|
Family ID: |
57130447 |
Appl. No.: |
15/780504 |
Filed: |
September 23, 2016 |
PCT Filed: |
September 23, 2016 |
PCT NO: |
PCT/US2016/053525 |
371 Date: |
May 31, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62222605 |
Sep 23, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 16/468 20130101;
C07K 2317/55 20130101; C07K 16/2863 20130101; C07K 2317/92
20130101; A61K 2039/505 20130101; C07K 2317/31 20130101; A61P 35/00
20180101; C07K 16/3069 20130101; C07K 16/40 20130101; C07K 16/2809
20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; C07K 16/46 20060101 C07K016/46; C07K 16/30 20060101
C07K016/30; C07K 16/40 20060101 C07K016/40; A61P 35/00 20060101
A61P035/00 |
Claims
1. A cytotoxic composition comprising a bispecific antigen-binding
molecule that (i) specifically binds an effector cell with an
EC.sub.50 of greater than about 100 nM and ii) specifically binds a
target tumor cell, wherein the EC.sub.50 is a binding affinity
value measured in an in vitro FACS binding assay.
2. The composition of claim 1, wherein the antigen-binding molecule
specifically binds human CD3 with an EC.sub.50 of greater than 500
nM or greater than about 1 .mu.M.
3. The composition of claim 1, wherein the bispecific
antigen-binding molecule comprises a first antigen-binding fragment
(Fab1), derived from a first antibody, that is not capable of
specifically binding to an effector cell, as measured in an in
vitro FACS binding assay or an in vitro surface plasmon resonance
binding assay.
4. The composition of claim 1, wherein the bispecific
antigen-binding molecule exhibits no detectable binding to an
effector cell or to CD3 antigen.
5. The composition of any one of claims 1-4, wherein the bispecific
antigen-binding molecule comprises a second antigen-binding
fragment (Fab2) derived from a second antibody that specifically
binds the target tumor cell with an EC.sub.50 value of less than
about 50 nM.
6. The composition of any one of claims 1-5, wherein the bispecific
antigen-binding molecule specifically binds each of human CD3 and
cynomolgus CD3 with an EC.sub.50 value of greater than about 500
nM, or greater than about 1 .mu.M.
7. The composition of any one of claims 1-6, wherein the target
tumor cell is a human tumor cell.
8. The composition of any one of claims 1-7, wherein the bispecific
antigen-binding molecule induces T cell-mediated tumor cell killing
with an EC.sub.50 value of less than about 1.3 nM, as measured in
an in vitro T cell-mediated tumor cell killing assay.
9. The composition of any one of claims 1-8, wherein the target
tumor cell expresses a tumor-associated antigen selected from the
group consisting of AFP, ALK, BAGE proteins, BIRC5 (survivin),
BIRC7, .beta.-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic
anhydrase IX, caspase-8, CALR, CCR5, CD19, CD20 (MS4A1), CD22,
CD30, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRvIII,
ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EpCAM, EphA2, Fra-1, FOLR1,
GAGE proteins (e.g., GAGE-1, -2), GD2, GD3, GloboH, glypican-3,
GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2,
MAGE proteins (e.g., MAGE-1, -2, -3, -4, -6, and -12), MART-1,
mesothelin, ML-IAP, Muc1, Muc2, Muc3, Muc4, Muc5, Muc16 (CA-125),
MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP,
PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE
proteins, Ras, RGS5, Rho, SART-1, SART-3, STEAP1, STEAP2, TAG-72,
TGF-.beta., TMPRSS2, Thompson-nouvelle antigen (Tn), TRP-1, TRP-2,
tyrosinase, and uroplakin-3.
10. The composition of any one of claims 1-9, wherein the
tumor-associated antigen is CD20, EGFRvIII, PSMA (FOLH1), STEAP2,
or MUC16.
11. The composition of any one of claims 1-10, wherein the
bispecific antigen-binding molecule comprises a first heavy chain
comprising: a CDR1 comprising amino acid residues 1-7 of SEQ ID
NO:178, a CDR2 comprising amino acid residues 1-7 of SEQ ID NO:179,
and/or a CDR3 comprising amino acid residues 4-11 of SEQ ID
NO:180.
12. The composition of claim 11, wherein the first heavy chain
comprises a CDR1 comprising the amino acid sequence set forth in
SEQ ID NO: 12 or 20.
13. The composition of any one of claim 11 or 12, wherein the first
heavy chain comprises a CDR2 comprising the amino acid sequence set
forth in SEQ ID NO: 14 or 54.
14. The composition of any one of claims 11 to 13, wherein the
first heavy chain comprises a CDR3 comprising the amino acid
sequence set forth in SEQ ID NO: 16, SEQ ID NO: 24, SEQ ID NO: 32,
SEQ ID NO: 40, SEQ ID NO: 48, SEQ ID NO: 56, SEQ ID NO: 64, SEQ ID
NO: 72, SEQ ID NO: 80, SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO:
104, SEQ ID NO: 112, SEQ ID NO: 120, SEQ ID NO: 128, SEQ ID NO:
136, SEQ ID NO: 144, or SEQ ID NO: 152.
15. The composition of any one of claims 11 to 14, wherein the
first heavy chain comprises variable domain framework regions
having an amino acid sequence selected from FR1 (SEQ ID NO: 174),
FR2 (SEQ ID NO: 175), FR3 (SEQ ID NO: 176), and FR4 (SEQ ID NO:
177).
16. The composition of any one of claims 1-11, wherein the
bispecific antigen-binding molecule comprises a HCVR and LCVR amino
acid sequence pair (HCVR/LCVR) selected from the group consisting
of: SEQ ID NOs: 2/162; 10/162; 18/162; 26/162; 34/162; 42/162;
50/162; 58/162; 66/162; 74/162; 82/162; 90/162; 98/162; 106/162;
114/162; 122/162; 130/162; 138/162; 146/162.
17. The composition of any one of claims 1-11, wherein the
bispecific antigen binding molecule comprises a first heavy chain
comprising a HCVR comprising HCDR1-HCDR2-HCDR3 domains having the
amino acid sequences of SEQ ID NOs: 178-179-180, respectively.
18. A method of making the composition of any one of claims 1-17,
the method comprising: a. identifying the amino acid sequence of a
first heavy chain derived from a first antibody that specifically
binds CD3 with an EC.sub.50 value of less than about 40 nM, b.
modifying selected amino acid residues in the heavy chain variable
region of the first antibody to produce a modified antibody, c.
pairing the modified antibody with a second heavy chain derived
from a second antibody that specifically binds a target tumor
antigen to produce a bispecific antibody, d. testing the bispecific
antibody in a binding affinity assay, and if the binding affinity
to CD3 has an EC.sub.50 value of greater than about 500 nM, then e.
preparing a composition comprising the bispecific antibody and a
pharmaceutically acceptable carrier or diluent.
19. The method of claim 18, wherein the first antibody heavy chain
comprises a first C.sub.H3 domain and the second antibody comprises
a second C.sub.H3 domain suitable for bispecific pairing and
isolation.
20. The method of claim 19, wherein the first and second C.sub.H3
domains differ from one another by at least one amino acid, and
wherein at least one amino acid difference reduces binding of the
bispecific antibody to Protein A as compared to a bi-specific
antibody lacking the amino acid difference.
21. A pharmaceutical composition comprising the composition of any
one of claims 1-17 or made by the method of any one of claims
18-20, comprising a pharmaceutically acceptable carrier or
diluent.
22. A method for treating cancer in a subject, the method
comprising administering to the subject the pharmaceutical
composition of claim 21.
23. The method of claim 22, wherein the cancer is selected from the
group consisting of: pancreatic cancer, melanoma, glioblastoma,
head and neck cancer, prostate cancer, malignant gliomas,
osteosarcoma, colorectal cancer, gastric cancer, malignant
mesothelioma, multiple myeloma, ovarian cancer, small cell lung
cancer, non-small cell lung cancer, synovial sarcoma, thyroid
cancer, breast cancer, melanomaglioma, breast cancer, squamous cell
carcinoma, esophageal cancer, clear cell renal cell carcinoma,
chromophobe renal cell carcinoma, renal oncocytoma, renal
transitional cell carcinoma, urothelial carcinoma, adenocarcinoma,
or small cell carcinoma.
24. The method of claim 22 or 23, wherein the subject is afflicted
with a tumor that is resistant to, or incompletely responsive to
monospecific therapy alone.
25. A method for mediating tumor cell lysis, or suppressing tumor
growth in a subject, the method comprising administering to the
subject a therapeutic amount of the composition of claim 21.
26. The method of claim 25, wherein the amount is sufficient to
reduce tumor burden, produce tumor regression, inhibit tumor growth
or reduce tumor development in the subject.
27. The method of claim 26, wherein subject is afflicted with a
tumor expressing a tumor-associated antigen selected from the group
consisting of AFP, ALK, BAGE proteins, BIRC5 (survivin), BIRC7,
.beta.-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX,
caspase-8, CALR, CCR5, CD19, CD20 (MS4A1), CD22, CD30, CD40, CDK4,
CEA, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRvIII, ErbB2/Her2, ErbB3,
ErbB4, ETV6-AML, EpCAM, EphA2, Fra-1, FOLR1, GAGE proteins (e.g.,
GAGE-1, -2), GD2, GD3, GloboH, glypican-3, GM3, gp100, Her2,
HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2, MAGE proteins
(e.g., MAGE-1, -2, -3, -4, -6, and -12), MART-1, mesothelin,
ML-IAP, Muc1, Muc2, Muc3, Muc4, Muc5, Muc16 (CA-125), MUM1, NA17,
NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5,
PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE proteins, Ras, RGS5,
Rho, SART-1, SART-3, STEAP1, STEAP2, TAG-72, TGF-.beta., TMPRSS2,
Thompson-nouvelle antigen (Tn), TRP-1, TRP-2, tyrosinase, and
uroplakin-3.
28. Use of a cytotoxic bispecific antibody having reduced clearance
for suppression of tumor growth in a subject, wherein the
bispecific antibody comprises no detectable binding affinity to an
effector cell or weak binding affinity to an effector cell at least
greater than 200 EC.sub.50 or K.sub.D, and specifically binds with
high affinity to a target tumor cell, wherein binding affinity is
measured in an in vitro FACS binding assay or in vitro surface
plasmon resonance assay.
29. A method of producing a cytotoxic bispecific antibody,
comprising: a. identifying a first human antibody or
antigen-binding fragment thereof that interacts with an effector
cell antigen from multiple species; b. identifying the germline
amino acid residues of the heavy chain variable region (HCVR) of
the first human antibody; c. comparing the amino acid sequence of
the HCVR of the first human antibody to the amino acid sequence of
the corresponding germline HCVR; d. identifying amino acids within
a modified region of the HCVR of the first human antibody; whereby
a modified region in the first human antibody displays at least one
amino acid modification by substitution, deletion or addition of a
single amino acid residue compared to the same region in the
germline HCVR; e. producing a plurality of modified antibodies each
comprising at least one modified region of the HCVR; f. screening
each of the plurality of modified antibodies for monovalent
affinity to the effector cell antigen; g. selecting those modified
antibodies that exhibit weaker binding affinity for the effector
cell antigen compared to the first human antibody; and h. pairing a
selected antibody with a second antibody that interacts with a
tumor-associated antigen to produce a cytotoxic bispecific
antibody.
Description
REFERENCE TO A SEQUENCE LISTING
[0001] This application incorporates by reference the Sequence
Listing submitted in Computer Readable Form as file
10151WO01_ST25.txt, created on Sep. 22, 2016 and containing 264,418
bytes.
FIELD OF THE INVENTION
[0002] The invention related to bispecific antibodies, targeting an
effector antigen, such as CD3 antigen, and a tumor associated
antigen, and methods of tumor killing. The invention relates to
methods of reducing or eliminating tumor burden and controlling the
toxic side effects that may be associated with tumor immunotherapy.
The present invention provides bispecific antibodies comprising an
effector arm which binds to an effector antigen with weak affinity
or with no detectable binding affinity, for example, an anti-CD3
antigen-binding arm which binds to CD3 with a K.sub.D of greater
than about 500 nM, in an in vitro affinity binding assay.
BACKGROUND
[0003] The promise of therapeutic bispecific antibodies (bsAbs),
particularly in cancer immunotherapies, aims to bridge multiple
antigen targets in order to elicit a more robust innate immune
response to the unwanted target-bearing cells or organism.
[0004] It is now well established that to mediate redirected lysis,
a bsAb must cluster a target cell directly to a triggering molecule
on an effector cell, such as a T cell. There are many factors to
consider in bsAb design, for example, size and composition will
affect biodistribution and stability in vivo (Segal, DM, Weiner, G
J, and Weiner, LM. Current Opinion in Immunol 1999, 11: 558-562;
Chames, P. and Baty, D. MAbs. 2009, 1(6): 539-547). Differential
outcomes are difficult to predict depending on the T cell subset
being triggered to respond, as well as the state of the T cell
being stimulated. It is well-known that bsAbs do not give
consistent results (Manzke O, et al. Cancer Immunol Immunother.
1997, 45:198-202). For example, without adequate cytokine
production, CD3 crosslinking can induce an apoptotic response in
the T cell (Noel P J, Boise L H, Thompson C B: Regulation of T cell
activation by CD28 and CTLA4. Adv Exp Med Biol 1996, 406:209-217).
The subset of T cells and differentiation state of such recruited T
cells, e.g. naive T cells, are important for efficacy, since naive
T cells cannot lyse target cells without preactiviation (such as
crosslinking with TCR in the presence of IL-2).
[0005] Certain bispecific therapies have been successful, yet, as
with many cancer therapies, it comes with a price. Toxicity is the
leading cause of failure among cancer therapeutics. It is well
known that toxicity of so-called chemotherapeutic drugs is the
leading cause of patient side effects and secondary maladies. The
act of "cell killing" itself is wrought with trouble for the
patient. A plethora of cytotoxic responses can be induced by
activation of effector cells e.g. T cells, and a cancer target
cell, yet which type of response is most beneficial in tumor
immunotherapy remains to be seen. A method of identifying anti-CD3
antibodies for use in a bispecific therapy having reduced side
effects while maintaining efficacy and desirable pharmacokinetic
(PK) properties would be advantageous.
[0006] Techniques such as affinity maturation have been described
which, based on structure/activity relationship (SAR), utilize
mutagenesis to optimize antibodies to have increased and improved
binding specificity or affinity for a target antigen compared to
the starting antibody (see, e.g. WO2011056997, published May 12,
2011). Modified OKT3 antibodies capable of binding to and
interacting with CD3 with varying degrees of affinity while still
exhibiting moderate to high T cell activation have been described
(U.S. Pat. No. 7,820,166). However, methods of reducing binding
affinity of antibody molecules to near or beyond the detectable
level of binding have not been described, nor shown to have the
requisite efficacy for tumor reduction or suppression.
[0007] Thus, there exists a need for alternative bispecific
antigen-binding molecules having controlled cytotoxicity and better
PK properties. Such cancer therapies would be quite useful in
therapeutic settings.
BRIEF SUMMARY OF THE INVENTION
[0008] In a first aspect, the present invention provides antibodies
and antigen-binding fragments thereof that bind human CD3 having
weak or no detectable affinity for human and/or cynomolgus CD3. The
antibodies according to this aspect of the invention are useful,
inter alia, for targeting T cells expressing CD3, and for
stimulating T cell activation, e.g., under circumstances where T
cell-mediated killing is beneficial or desirable. The anti-CD3
antibodies of the invention, or antigen-binding portions thereof,
may be included as part of a bispecific antibody that directs
CD3-mediated T cell activation to specific cell types such as tumor
cells or infectious agents.
[0009] Exemplary anti-CD3 antibodies of the present invention are
listed in Tables 2 and 3 herein. Table 2 sets forth the amino acid
sequence identifiers of the heavy chain variable regions (HCVRs),
as well as heavy chain complementarity determining regions (HCDR1,
HCDR2 and HCDR3). Table 3 sets forth the sequence identifiers of
the nucleic acid molecules encoding the HCVRs, HCDR1, HCDR2 and
HCDR3 regions of the exemplary anti-CD3 antibodies. Tables 4 and 5
set forth light chain variable regions (LCVRs), as well as
complementarity determining regions (LCDR1, LCDR2 and LCDR3) of the
exemplary anti-CD3 antibodies.
[0010] The present invention provides antibodies, or
antigen-binding fragments thereof, comprising an HCVR comprising an
amino acid sequence selected from any of the HCVR amino acid
sequences listed in Table 2, or a substantially similar sequence
thereof having having at least 90%, at least 95%, at least 98% or
at least 99% sequence identity thereto.
[0011] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising an HCVR and an LCVR
amino acid sequence pair (HCVR/LCVR) comprising any of the HCVR
amino acid sequences listed in Table 2 paired with any of the LCVR
amino acid sequences listed in Table 4, or a common light chain
derived from the cognate light chain of the anti-TAA heavy chain,
or derived from a known or public domain light chain variable
region derived from a light chain exhibiting promiscuity or ability
to pair with a wide variety of non-cognate heavy chains, i.e. a
universal or common light chain. According to certain embodiments,
the present invention provides antibodies, or antigen-binding
fragments thereof, comprising an HCVR/LCVR amino acid sequence pair
contained within any of the exemplary anti-CD3 antibodies listed in
Table 2 paired with exemplary light chain variable regions listed
in Table 4. In certain embodiments, the HCVR/LCVR amino acid
sequence pair is selected from the group consisting of SEQ ID NOs:
10/162 (e.g., CD3-VH-G2); 18/162 (e.g., CD3-VH-G3); 26/162 (e.g.,
CD3-VH-G4); 34/162 (e.g., CD3-VH-G5); 42/162 (e.g., CD3-VH-G8);
50/162 (e.g., CD3-VH-G9); 58/162 (e.g., CD3-VH-G10); 66/162 (e.g.,
CD3-VH-G11); 74/162 (e.g., CD3-VH-G12); 82/162 (e.g., CD3-VH-G13);
90/162 (e.g., CD3-VH-G14); 98/162 (e.g., CD3-VH-G15); 106/162
(e.g., CD3-VH-G16); 114/162 (e.g., CD3-VH-G17); 122/162 (e.g.,
CD3-VH-G18); 130/162 (e.g., CD3-VH-G19); 138/162 (e.g.,
CD3-VH-G20); and 146/162 (e.g., CD3-VH-G21).
[0012] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a heavy chain CDR1
(HCDR1) comprising an amino acid sequence selected from any of the
HCDR1 amino acid sequences listed in Table 2 or a substantially
similar sequence thereof having at least 95%, at least 98% or at
least 99% sequence identity. The present invention also provides
antibodies, or antigen-binding fragments thereof, comprising a
heavy chain CDR1 (HCDR1) comprising an amino acid sequence set
forth in SEQ ID NO: 178.
[0013] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a heavy chain CDR2
(HCDR2) comprising an amino acid sequence selected from any of the
HCDR2 amino acid sequences listed in Table 2 or a substantially
similar sequence thereof having at least 95%, at least 98% or at
least 99% sequence identity. The present invention also provides
antibodies, or antigen-binding fragments thereof, comprising a
heavy chain CDR2 (HCDR2) comprising an amino acid sequence set
forth in SEQ ID NO: 179.
[0014] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a heavy chain CDR3
(HCDR3) comprising an amino acid sequence selected from any of the
HCDR3 amino acid sequences listed in Table 2 or a substantially
similar sequence thereof having at least 95%, at least 98% or at
least 99% sequence identity. The present invention also provides
antibodies, or antigen-binding fragments thereof, comprising a
heavy chain CDR3 (HCDR3) comprising an amino acid sequence set
forth in SEQ ID NO: 180.
[0015] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a light chain CDR1
(LCDR1) comprising an amino acid sequence selected from any of the
LCDR1 amino acid sequences listed in Table 4 or a substantially
similar sequence thereof having at least 95%, at least 98% or at
least 99% sequence identity. The present invention also provides
antibodies, or antigen-binding fragments thereof, comprising a
light chain CDR1 (LCDR1) derived from a cognate light chain of the
anti-TAA heavy chain, or derived from a light chain exhibiting
promiscuity or ability to pair with a wide variety of non-cognate
heavy chains, i.e. a universal or common light chain.
[0016] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a light chain CDR2
(LCDR2) comprising an amino acid sequence selected from any of the
LCDR2 amino acid sequences listed in Table 4 or a substantially
similar sequence thereof having at least 95%, at least 98% or at
least 99% sequence identity. The present invention also provides
antibodies, or antigen-binding fragments thereof, comprising a
light chain CDR2 (LCDR2) derived from a cognate light chain of the
anti-TAA heavy chain, or derived from a light chain exhibiting
promiscuity or ability to pair with a wide variety of non-cognate
heavy chains, i.e. a universal or common light chain.
[0017] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a light chain CDR3
(LCDR3) comprising an amino acid sequence selected from any of the
LCDR3 amino acid sequences listed in Table 4 or a substantially
similar sequence thereof having at least 95%, at least 98% or at
least 99% sequence identity. The present invention also provides
antibodies, or antigen-binding fragments thereof, comprising a
light chain CDR3 (LCDR3) derived from a cognate light chain of the
anti-TAA heavy chain, or derived from a light chain exhibiting
promiscuity or ability to pair with a wide variety of non-cognate
heavy chains, i.e. a universal or common light chain.
[0018] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising an HCDR3 and an LCDR3
amino acid sequence pair (HCDR3/LCDR3) comprising any of the HCDR3
amino acid sequences listed in Table 2 paired with any of the LCDR3
amino acid sequences listed in Table 4. According to certain
embodiments, the present invention provides antibodies, or
antigen-binding fragments thereof, comprising an HCDR3/LCDR3 amino
acid sequence pair contained within any of the exemplary anti-CD3
antibodies listed in Table 2. In certain embodiments, the
HCDR3/LCDR3 amino acid sequence pair is selected from the group
consisting of SEQ ID NOs: 16/168 (e.g., CD3-VH-G2); 24/168 (e.g.,
CD3-VH-G3); 32/168 (e.g., CD3-VH-G4); 40/168 (e.g., CD3-VH-G5);
48/168 (e.g., CD3-VH-G8); 56/168 (e.g., CD3-VH-G9); 64/168 (e.g.,
CD3-VH-G10); 72/168 (e.g., CD3-VH-G11); 80/168 (e.g., CD3-VH-G12);
88/168 (e.g., CD3-VH-G13); 96/168 (e.g., CD3-VH-G14); 104/168
(e.g., CD3-VH-G15); 112/168 (e.g., CD3-VH-G16); 120/168 (e.g.,
CD3-VH-G17); 128/168 (e.g., CD3-VH-G18); 136/168 (e.g.,
CD3-VH-G19); 144/168 (e.g., CD3-VH-G20); and 152/168 (e.g.,
CD3-VH-G21).
[0019] The present invention also provides antibodies, or
antigen-binding fragments thereof, comprising a set of six CDRs
(i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within any of
the exemplary anti-CD3 antibodies listed in Tables 2 and 4. In
certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino
acid sequences set is selected from the group consisting of SEQ ID
NOs: 12-14-16-164-166-168 (e.g., CD3-VH-G2); 20-22-24-164-166-168
(e.g., CD3-VH-G3); 28-30-32-164-166-168 (e.g., CD3-VH-G4);
36-38-40-164-166-168 (e.g., CD3-VH-G5); 44-46-48-164-166-168 (e.g.,
CD3-VH-G8); 52-54-56-164-166-168 (e.g., CD3-VH-G9);
60-62-64-164-166-168 (e.g., CD3-VH-G10); 68-70-72-164-166-168
(e.g., CD3-VH-G11); 76-78-80-164-166-168 (e.g., CD3-VH-G12);
84-86-88-164-166-168 (e.g., CD3-VH-G13); 92-94-96-164-166-168
(e.g., CD3-VH-G14); 100-102-104-164-166-168 (e.g., CD3-VH-G15);
108-110-112-164-166-168 (e.g., CD3-VH-G16); 116-118-120-164-166-168
(e.g., CD3-VH-G17); 124-126-128-164-166-168 (e.g., CD3-VH-G18);
132-134-136-164-166-168 (e.g., CD3-VH-G19); 140-142-144-164-166-168
(e.g., CD3-VH-G20); and 148-150-152-164-166-168 (e.g.,
CD3-VH-G21).
[0020] In a related embodiment, the present invention provides
antibodies, or antigen-binding fragments thereof, comprising a set
of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained
within an HCVR/LCVR amino acid sequence pair as defined by any of
the exemplary anti-CD3 antibodies listed in Tables 2 and 4. For
example, the present invention includes antibodies, or
antigen-binding fragments thereof, comprising the
HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences set
contained within an HCVR/LCVR amino acid sequence pair selected
from the group consisting of SEQ ID NOs: 10/162 (e.g., CD3-VH-G2);
18/162 (e.g., CD3-VH-G3); 26/162 (e.g., CD3-VH-G4); 34/162 (e.g.,
CD3-VH-G5); 42/162 (e.g., CD3-VH-G8); 50/162 (e.g., CD3-VH-G9);
58/162 (e.g., CD3-VH-G10); 66/162 (e.g., CD3-VH-G11); 74/162 (e.g.,
CD3-VH-G12); 82/162 (e.g., CD3-VH-G13); 90/162 (e.g., CD3-VH-G14);
98/162 (e.g., CD3-VH-G15); 106/162 (e.g., CD3-VH-G16); 114/162
(e.g., CD3-VH-G17); 122/162 (e.g., CD3-VH-G18); 130/162 (e.g.,
CD3-VH-G19); 138/162 (e.g., CD3-VH-G20); and 146/162 (e.g.,
CD3-VH-G21).
[0021] Methods and techniques for identifying CDRs within HCVR and
LCVR amino acid sequences are well known in the art and can be used
to identify CDRs within the specified HCVR and/or LCVR amino acid
sequences disclosed herein. Exemplary conventions that can be used
to identify the boundaries of CDRs include, e.g., the Kabat
definition, the Chothia definition, and the AbM definition. In
general terms, the Kabat definition is based on sequence
variability, the Chothia definition is based on the location of the
structural loop regions, and the AbM definition is a compromise
between the Kabat and Chothia approaches. See, e.g., Kabat,
"Sequences of Proteins of Immunological Interest," National
Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J.
Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad.
Sci. USA 86:9268-9272 (1989). Public databases are also available
for identifying CDR sequences within an antibody.
[0022] The present invention also provides nucleic acid molecules
encoding anti-CD3 antibodies or portions thereof. For example, the
present invention provides nucleic acid molecules encoding any of
the HCVR amino acid sequences listed in Table 3; in certain
embodiments the nucleic acid molecule comprises a polynucleotide
sequence selected from any of the HCVR nucleic acid sequences
listed in Table 3, or a substantially similar sequence thereof
having at least 90%, at least 95%, at least 98% or at least 99%
sequence identity thereto.
[0023] The present invention also provides nucleic acid molecules
encoding any of the LCVR amino acid sequences listed in Table 4; or
an LCVR derived from a cognate light chain of the anti-TAA heavy
chain, or derived from a light chain exhibiting promiscuity or
ability to pair with a wide variety of non-cognate heavy chains,
i.e. a universal or common light chain. In certain embodiments, the
nucleic acid molecule comprises a polynucleotide sequence selected
from any of the LCVR nucleic acid sequences listed in Table 5, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity
thereto.
[0024] The present invention also provides nucleic acid molecules
encoding any of the HCDR1 amino acid sequences listed in Table 2;
in certain embodiments the nucleic acid molecule comprises a
polynucleotide sequence selected from any of the HCDR1 nucleic acid
sequences listed in Table 3, or a substantially similar sequence
thereof having at least 90%, at least 95%, at least 98% or at least
99% sequence identity thereto.
[0025] The present invention also provides nucleic acid molecules
encoding any of the HCDR2 amino acid sequences listed in Table 2;
in certain embodiments the nucleic acid molecule comprises a
polynucleotide sequence selected from any of the HCDR2 nucleic acid
sequences listed in Table 3, or a substantially similar sequence
thereof having at least 90%, at least 95%, at least 98% or at least
99% sequence identity thereto.
[0026] The present invention also provides nucleic acid molecules
encoding any of the HCDR3 amino acid sequences listed in Table 2;
in certain embodiments the nucleic acid molecule comprises a
polynucleotide sequence selected from any of the HCDR3 nucleic acid
sequences listed in Table 3, or a substantially similar sequence
thereof having at least 90%, at least 95%, at least 98% or at least
99% sequence identity thereto.
[0027] The present invention also provides nucleic acid molecules
encoding any of the LCDR1 amino acid sequences listed in Table 4;
or an LCDR1 derived from a cognate light chain of the anti-TAA
heavy chain, or derived from a light chain exhibiting promiscuity
or ability to pair with a wide variety of non-cognate heavy chains,
i.e. a universal or common light chain. In certain embodiments, the
nucleic acid molecule comprises a polynucleotide sequence selected
from any of the LCDR1 nucleic acid sequences listed in Table 5, or
a substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity
thereto.
[0028] The present invention also provides nucleic acid molecules
encoding any of the LCDR2 amino acid sequences listed in Table 4;
or an LCDR2 derived from a cognate light chain of the anti-TAA
heavy chain, or derived from a light chain exhibiting promiscuity
or ability to pair with a wide variety of non-cognate heavy chains,
i.e. a universal or common light chain. In certain embodiments, the
nucleic acid molecule comprises a polynucleotide sequence selected
from any of the LCDR2 nucleic acid sequences listed in Table 5, or
a substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity
thereto.
[0029] The present invention also provides nucleic acid molecules
encoding any of the LCDR3 amino acid sequences listed in Table 4;
or an LCDR3 derived from a cognate light chain of the anti-TAA
heavy chain, or derived from a light chain exhibiting promiscuity
or ability to pair with a wide variety of non-cognate heavy chains,
i.e. a universal or common light chain. In certain embodiments the
nucleic acid molecule comprises a polynucleotide sequence selected
from any of the LCDR3 nucleic acid sequences listed in Table 5, or
a substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity
thereto.
[0030] The present invention also provides nucleic acid molecules
encoding an HCVR, wherein the HCVR comprises a set of three CDRs
(i.e., HCDR1-HCDR2-HCDR3), wherein the HCDR1-HCDR2-HCDR3 amino acid
sequence set is as defined by any of the exemplary anti-CD3
antibodies listed in Table 2.
[0031] The present invention also provides nucleic acid molecules
encoding an LCVR, wherein the LCVR comprises a set of three CDRs
(i.e., LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid
sequence set is as defined by any of the exemplary universal light
chain antibodies listed in Table 4; or the LCDR1-LCDR2-LCDR3 is
derived from a cognate light chain of the anti-TAA heavy chain, or
derived from a light chain exhibiting promiscuity or ability to
pair with a wide variety of non-cognate heavy chains, i.e. a
universal or common light chain.
[0032] The present invention also provides nucleic acid molecules
encoding both an HCVR and an LCVR, wherein the HCVR comprises an
amino acid sequence of any of the HCVR amino acid sequences listed
in Table 2, and wherein the LCVR comprises an amino acid sequence
of any of the LCVR amino acid sequences listed in Table 4; or the
LCVR is derived from a cognate light chain of the anti-TAA heavy
chain, or derived from a light chain exhibiting promiscuity or
ability to pair with a wide variety of non-cognate heavy chains,
i.e. a universal or common light chain. In certain embodiments, the
nucleic acid molecule comprises a polynucleotide sequence selected
from any of the HCVR nucleic acid sequences listed in Table 2, or a
substantially similar sequence thereof having at least 90%, at
least 95%, at least 98% or at least 99% sequence identity thereto,
and a polynucleotide sequence selected from any of the LCVR nucleic
acid sequences listed in Table 5, or a substantially similar
sequence thereof having at least 90%, at least 95%, at least 98% or
at least 99% sequence identity thereto. In some embodiments, the
nucleic acid molecules encoding both an HCVR and an LCVR are fully
human sequences or derived from human germline immunoglobulin
sequences.
[0033] The present invention also provides recombinant expression
vectors capable of expressing a polypeptide comprising a heavy or
light chain variable region of an anti-CD3 antibody. For example,
the present invention includes recombinant expression vectors
comprising any of the nucleic acid molecules mentioned above, i.e.,
nucleic acid molecules encoding any of the HCVR, LCVR, and/or CDR
sequences as set forth in Table 2 or 4. Also included within the
scope of the present invention are host cells into which such
vectors have been introduced, as well as methods of producing the
antibodies or portions thereof by culturing the host cells under
conditions permitting production of the antibodies or antibody
fragments, and recovering the antibodies and antibody fragments so
produced.
[0034] The present invention includes anti-CD3 antibodies and/or
anti-TAA antibodies, as well as bispecific anti-CD3/anti-TAA
antibodies having a modified glycosylation pattern. In some
embodiments, modification to remove undesirable glycosylation sites
may be useful, or an antibody lacking a fucose moiety present on
the oligosaccharide chain, for example, to increase antibody
dependent cellular cytotoxicity (ADCC) function (see Shield et al.
(2002) JBC 277:26733). In other applications, modification of
galactosylation can be made in order to modify complement dependent
cytotoxicity (CDC).
[0035] In one aspect, the invention provides a cytotoxic
composition comprising a bispecific antigen-binding molecule that
i) is not capable of specifically binding to an effector cell, and
ii) specifically binds a target tumor cell, wherein specific
binding is measured in an in vitro FACS binding assay or an in
vitro surface plasmon resonance binding assay. In certain
embodiments, the invention provides a cytotoxic composition
comprising a bispecific antigen-binding molecule that exhibits no
detectable binding to an effector cell, and that specifically binds
to a target tumor cell with a measurable binding affinity, wherein
the binding affinity value is measured in an in vitro FACS binding
assay or an in vitro surface plasmon resonance binding assay.
[0036] In other embodiments, the invention provides a cytotoxic
composition comprising a bispecific antigen-binding molecule
comprising i) a first antigen-binding fragment (Fab1) that exhibits
no detectable binding to CD3, and ii) a second antigen-binding
fragment (Fab2) that specifically binds to a target tumor cell with
a measurable binding affinity, wherein the binding affinity value
is measured in an in vitro FACS binding assay or an in vitro
surface plasmon resonance binding assay. In some cases, the binding
affinity is monovalent binding affinity (e.g., in a bispecific
antibody construct).
[0037] In another aspect the invention provides a cytotoxic
composition comprising a bispecific antigen-binding molecule that
specifically binds an effector cell with a weak binding affinity,
for example exhibiting an EC.sub.50 value of about or greater than
about 100 nM, and that specifically binds a target tumor cell with
an appreciable EC.sub.50 value, or a high affinity EC.sub.50 value
such as less than 50 nM, wherein the EC.sub.50 binding affinity
value is measured in an in vitro FACS binding assay. In certain
embodiments, the invention provides a cytotoxic composition
comprising a bispecific antigen-binding molecule that specifically
binds an effector cell with an EC.sub.50 value of greater than
about 500 nM, and that specifically binds a target tumor cell with
an appreciable EC.sub.50 value, or a high affinity EC.sub.50 value
such as less than 50 nM, wherein the EC.sub.50 binding affinity
value is measured in an in vitro FACS binding assay.
[0038] In some examples, the bispecific antigen-binding molecule
includes a Fab1 that specifically binds human CD3 with an EC.sub.50
value of greater than about 40 nM, or greater than about 100 nM,
greater than about 200 nM, greater than about 300 nM, greater than
about 400 nM, greater than about 500 nM, or greater than about 1
.mu.M (e.g. in a monovalent binding context). In some embodiments,
the bispecific antigen-binding molecule includes a Fab2 derived
from a second antibody that specifically binds the target tumor
cell with high affinity, e.g. an EC.sub.50 value of less than less
than about 50 nM, less than about 40 nM, less than about 20 nM,
less than about 10 nM or less than about 6 nM (e.g., in a
monovalent binding context). In some cases, the Fab1 specifically
binds each of human CD3 and cynomolgus CD3 with an EC.sub.50 value
of greater than about 40 nM, or greater than about 100 nM, greater
than about 200 nM, or greater than about 1 .mu.M. In some cases,
the Fab1 specifically binds each of human CD3 and cynomolgus CD3
with weak or no measurable affinity.
[0039] In some embodiments, the target tumor cell is a human tumor
cell. In some embodiments, the Fab1 (or the bispecific
antigen-binding molecule) induces T cell-mediated tumor cell
killing with an EC.sub.50 value of less than about 1.3 nM, as
measured in an in vitro T cell-mediated tumor cell killing
assay.
[0040] In some applications, the Fab1 or the bispecific
antigen-binding molecule specifically binds human CD3 with an
K.sub.D value of greater than about 11 nM, as measured in an in
vitro surface plasmon resonance binding assay. In other instances,
the Fab1 or the bispecific antigen-binding molecule specifically
binds each of human CD3 and cynomolgus CD3 with an K.sub.D value of
greater than about 15 nM, or greater than about 30 nM, greater than
about 60 nM, greater than about 120 nM, or greater than about 300
nM, as measured in an in vitro surface plasmon resonance binding
assay. In still some applications, the Fab1 or the bispecific
antigen-binding molecule i) exhibits no detectable binding to human
CD3 as measured in each of an in vitro surface plasmon resonance
binding assay and a FACS binding assay, and ii) induces T
cell-mediated tumor cell killing, as measured in an in vitro T
cell-mediated tumor cell killing assay.
[0041] In some applications, the bispecific antigen-binding
molecule comprises a first heavy chain comprising a HCDR1 region
comprising an amino acid sequence set forth in SEQ ID NO: 12 or 20.
In some embodiments, the first heavy chain comprises a HCDR2 region
comprising an amino acid sequence set forth in SEQ ID NO: 14 or 54.
In other embodiments, the first heavy chain comprises a HCDR3
region comprising an amino acid sequence set forth in SEQ ID NO:
16, SEQ ID NO: 24, SEQ ID NO: 32, SEQ ID NO: 40, SEQ ID NO: 48, SEQ
ID NO: 56, SEQ ID NO: 64, SEQ ID NO: 72, SEQ ID NO: 80, SEQ ID NO:
88, SEQ ID NO: 96, SEQ ID NO: 104, SEQ ID NO: 112, SEQ ID NO: 120,
SEQ ID NO: 128, SEQ ID NO: 136, SEQ ID NO: 144, or SEQ ID NO: 152.
In other applications, the first heavy chain comprises a HCVR
comprising HCDR1-HCDR2-HCDR3 having the amino acid sequences of SEQ
ID NOs: 178-179-180. In other embodiments, a first heavy chain
comprises a CDR1 comprising amino acid residues 1-7 of SEQ ID
NO:178, a CDR2 comprising amino acid residues 1-7 of SEQ ID NO:179,
a CDR3 comprising amino acid residues 4-11 of SEQ ID NO:180.
[0042] In more embodiments, the first heavy chain comprises
variable domain framework regions having an amino acid sequence
selected from FR1 (SEQ ID NO: 174), FR2 (SEQ ID NO: 175), FR3 (SEQ
ID NO: 176), and FR4 (SEQ ID NO: 177).
[0043] The present invention provides bispecific antigen-binding
molecules comprising a Fab1 HCVR and LCVR amino acid sequence pair
(HCVR/LCVR) selected from the group consisting of: SEQ ID NOs:
10/162; 18/162; 26/162; 34/162; 42/162; 50/162; 58/162; 66/162;
74/162; 82/162; 90/162; 98/162; 106/162; 114/162; 122/162; 130/162;
138/162; 146/162.
[0044] The antibodies, and antigen-binding fragments and bispecific
antibodies thereof were made by replacing amino acid residues of a
parental in a stepwise manner based on differences between the
germline sequence and the parental antibody sequence. The present
invention provides a method of making a cytotoxic composition
comprising (a) identifying the amino acid sequence of the first
heavy chain derived from a first antibody that specifically binds
CD3 with high affinity, for example exhibits a binding affinity
EC.sub.50 value of less than about 40 nM, (b) modifying selected
amino acid residues in the heavy chain variable region of the first
antibody to produce a modified antibody, (c) pairing the modified
antibody with a second heavy chain derived from a second antibody
that specifically binds a target tumor antigen to produce a
bispecific antibody, (d) testing the bispecific antibody in a
binding affinity assay, and if the binding affinity to CD3 has an
EC.sub.50 value of greater than about 40 nM, or greater than 100 nM
or greater than 300 nM or greater than 500 nM, or no detectable
binding, then (e) preparing a composition comprising the bispecific
antibody and a pharmaceutically acceptable carrier or diluent. In
addition to modifying the heavy chain variable region of selected
antibodies to engineer antigen-binding arms having weak or no
affinity for, yet specifically target an effector cell, the
invention provides methods herein for modifying the heavy chain
constant region (e.g. C.sub.H3 domain) of each binding arm to
prepare and isolate bispecific antibodies.
[0045] An exemplary method provides a method of producing a
cytotoxic bispecific antibody, comprising: (a) identifying a first
human antibody or antigen-binding fragment thereof that interacts
with an effector cell antigen from multiple species; (b)
identifying the germline amino acid residues of the heavy chain
variable region (HCVR) of the human antibody; (c) comparing the
amino acid sequence of the HCVR of the first human antibody to the
amino acid sequence of the corresponding germline HCVR; (d)
identifying amino acids within a modified region of the HCVR of the
first antibody, whereby a modified region in the first antibody
displays at least one amino acid modification by substitution,
deletion or addition of a single amino acid residue compared to the
same region in the germline HCVR; (e) producing a plurality of
modified antibodies each comprising at least one modified region of
the HCVR; (f) screening each of the plurality of modified
antibodies for monovalent affinity to the effector cell antigen;
(g) selecting those modified antibodies that exhibit weaker binding
affinity or no detectable binding affinity to the effector cell
antigen compared to the first antibody; and (h) pairing the
selected first antibody with a second antibody that interacts with
a tumor-associated antigen to produce a cytotoxic bispecific
antibody.
[0046] In another aspect, the invention provides a pharmaceutical
composition comprising a recombinant human bispecific antibody or
fragment thereof which specifically binds CD3 and a
pharmaceutically acceptable carrier. In a related aspect, the
invention features a composition which is a combination of an
anti-CD3 antibody and a second therapeutic agent. In one
embodiment, the second therapeutic agent is any agent that is
advantageously combined with an anti-CD3 antibody. Exemplary agents
that may be advantageously combined with an anti-CD3 antibody
include, without limitation, other agents that bind and/or activate
CD3 signaling (including other antibodies or antigen-binding
fragments thereof, etc.) and/or agents which do not directly bind
CD3 but nonetheless activate or stimulate immune cell activation.
Additional combination therapies and co-formulations involving the
anti-CD3 antibodies of the present invention are disclosed
elsewhere herein.
[0047] In yet another aspect, the invention provides therapeutic
methods for stimulating T cell activation using an anti-CD3
antibody or antigen-binding portion of an antibody of the
invention, wherein the therapeutic methods comprise administering a
therapeutically effective amount of a pharmaceutical composition
comprising a bispecific antibody of the invention, or
antigen-binding fragment thereof, to a subject in need thereof. The
disorder treated is any disease or condition, which is improved,
ameliorated, inhibited or prevented by cytotoxic therapy targeted
to a tumor-associated antigen, such as cancer.
[0048] According to another aspect, the present invention provides
bispecific antigen-binding molecules that bind CD3 and a target
antigen, especially a tumor-associated antigen (TAA).
[0049] The present invention also includes the use of an
anti-CD3/anti-TAA bispecific antigen-binding molecule of the
invention in the manufacture of a medicament for the treatment of a
disease or disorder related to or caused by TAA expression. The
present invention also provides use of an anti-CD3/anti-TAA
bispecific antigen-binding molecule, exhibiting weak affinity to
CD3-expressing effector cells and reduced clearance, in the
manufacture of a medicament for the treatment of a disease or
disorder related to or caused by TAA expression, compared to an
anti-CD3/anti-TAA bispecific antigen-binding molecule exhibiting
high affinity to CD3-expressing effector cells.
[0050] Other embodiments will become apparent from a review of the
ensuing detailed description.
BRIEF DESCRIPTION OF THE FIGURES
[0051] FIG. 1 shows the amino acid alignment of the following
antibody heavy chain variable region (HCVR) sequences: germline
hIgHV (SEQ ID NO:181); CD3-VH-P (SEQ ID NO:154); CD3-VH-G (SEQ ID
NO:2); CD3-VH-G2 (SEQ ID NO:10); CD3-VH-G3 (SEQ ID NO:18);
CD3-VH-G4 (SEQ ID NO:26); CD3-VH-G5 (SEQ ID NO: 34); CD3-VH-G8 (SEQ
ID NO:42); CD3-VH-G9 (SEQ ID NO:50); CD3-VH-G10 (SEQ ID NO:58);
CD3-VH-G11 (SEQ ID NO:66); CD3-VH-G12 (SEQ ID NO:74); CD3-VH-G13
(SEQ ID NO:82); CD3-VH-G14 (SEQ ID NO:90); CD3-VH-G15 (SEQ ID
NO:98); CD3-VH-G16 (SEQ ID NO:106); CD3-VH-G17 (SEQ ID NO:114);
CD3-VH-G18 (SEQ ID NO:122); CD3-VH-G19 (SEQ ID NO:130); CD3-VH-G20
(SEQ ID NO:138); and CD3-VH-G21 (SEQ ID NO:146). Each derivative
HCVR is compared to the parent antibody and germline amino acid
residues, with rectangular boxes denoting mutations in the
CDRs.
[0052] FIGS. 2A, 2B and 2C illustrate mean concentrations of total
IgG in serum following a single 0.4 mg/kg intra-peritoneal
injection of BSMUC16/CD3-001, BSMUC16/CD3-005 and isotype control
antibodies in wild-type mice (FIG. 2A), humanized CD3 mice (FIG.
2B) and humanized MUC16.times.CD3 mice (FIG. 2C).
DETAILED DESCRIPTION
[0053] Before the present invention is described, it is to be
understood that this invention is not limited to particular methods
and experimental conditions described, as such methods and
conditions may vary. It is also to be understood that the
terminology used herein is for the purpose of describing particular
embodiments only, and is not intended to be limiting, since the
scope of the present invention will be limited only by the appended
claims.
[0054] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. As used
herein, the term "about," when used in reference to a particular
recited numerical value, means that the value may vary from the
recited value by no more than 1%. For example, as used herein, the
expression "about 100" includes 99 and 101 and all values in
between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0055] Although any methods and materials similar or equivalent to
those described herein can be used in the practice or testing of
the present invention, the preferred methods and materials are now
described.
Definitions
[0056] The expression "CD3" refers to an antigen which is expressed
on T cells as part of the multimolecular T cell receptor (TCR) and
which consists of a homodimer or heterodimer formed from the
association of two of four receptor chains: CD3-epsilon, CD3-delta,
CD3-zeta, and CD3-gamma. Human CD3-epsilon (hCD3E) comprises the
amino acid sequence as set forth in SEQ ID NO:169
(UniProtKB/Swiss-Prot: P07766.2). Human CD3-delta (hCD3.delta.)
comprises the amino acid sequence as set forth in SEQ ID NO:170
(UniProtKB/Swiss-Prot: P04234.1). All references to proteins,
polypeptides and protein fragments herein are intended to refer to
the human version of the respective protein, polypeptide or protein
fragment unless explicitly specified as being from a non-human
species. Thus, the expression "CD3" means human CD3 unless
specified as being from a non-human species, e.g., "mouse CD3,"
"monkey CD3," etc.
[0057] The phrase "an antibody that binds CD3" or an "anti-CD3
antibody" includes antibodies and antigen-binding fragments thereof
that specifically recognize and associate with a single CD3 subunit
(e.g., epsilon, delta, gamma or zeta), as well as antibodies and
antigen-binding fragments thereof that specifically recognize and
associate with a dimeric complex of two CD3 subunits (e.g.,
epsilon/delta, epsilon/gamma, and zeta/zeta CD3 dimers). The
antibodies and antigen-binding fragments of the present invention
may bind soluble CD3, bound CD3 and/or cell surface expressed CD3.
Soluble CD3 includes natural CD3 proteins as well as recombinant
CD3 protein variants such as, e.g., monomeric and dimeric CD3
constructs, that lack a transmembrane domain or are otherwise
unassociated with a cell membrane. The present invention provides
antibodies that bind and activate human and cynomolgus CD3 with
weak or no detectable binding affinity. "Binding to CD3 with no
detectable binding affinity" means that the antibody and or
antigen-binding fragment interaction with the CD3 target may not be
measurable or detectable with a known assay for detection, such as
a FACS (cell-based) binding assay as described herein or a surface
plasmon resonance binding assay as described herein and well-known
in the art. Other binding assays are well-known in the art. The
antibody and or antigen-binding fragment may recognize the CD3
target by very weak protein-protein biochemical interaction,
however a determination of specific KD or EC.sub.50 value cannot be
measured since the interaction is beyond the detection limit of the
assay, e.g. no measurement can be determined. In another instance,
"no detectable binding affinity" is determined if the affinity of
an antibody corresponding to a K.sub.D value is equal to or less
than ten-fold lower than a non-specific antigen such as, BSA,
casein, or the like. "Binding to CD3 with weak binding affinity"
includes interactions where binding affinity measurement is at or
slightly above the detection limit of the assay, or equivalent to
the binding affinity to a non-specific antigen.
[0058] The expression "cell surface-expressed CD3" means one or
more CD3 protein(s) that is/are expressed on the surface of a cell
in vitro or in vivo, such that at least a portion of a CD3 protein
is exposed to the extracellular side of the cell membrane and is
accessible to an antigen-binding portion of an antibody. "Cell
surface-expressed CD3" includes CD3 proteins contained within the
context of a functional T cell receptor in the membrane of a cell.
The expression "cell surface-expressed CD3" includes CD3 protein
expressed as part of a homodimer or heterodimer on the surface of a
cell (e.g., delta/epsilon, gamma/epsilon, and zeta/zeta CD3
dimers). The expression, "cell surface-expressed CD3" also includes
a CD3 chain (e.g., CD3-delta, CD3-epsilon or CD3-gamma) that is
expressed by itself, without other CD3 chain types, on the surface
of a cell. A "cell surface-expressed CD3" can comprise or consist
of a CD3 protein expressed on the surface of a cell which normally
expresses CD3 protein. Alternatively, "cell surface-expressed CD3"
can comprise or consist of CD3 protein expressed on the surface of
a cell that normally does not express human CD3 on its surface but
has been artificially engineered to express CD3 on its surface.
[0059] Effector cells include effector T cells (T lymphocytes), for
example CD4+ T cells, CD8+ T cells, Th1, Th2 and regulatory T cells
(Tregs). Effector cells may also include natural killer (NK) cells,
macrophages, granulocytes, plasma cells or B cells (lymphocytes).
It is understood that therapies may mediate a plethora of
cell-mediated immune responses, or effector functions, through Ig
interaction with effector cell surface receptors, such as CD3 (T
cell surface receptor), CD28 (T cells), Fc.gamma. receptors
(Fc.gamma.Rs) (NK cells, activated macrophages and the like).
Effector functions such as cell killing, complement activation,
phagocytosis and opsonisation are subsequently triggered through
these interactions. Binding to an effector cell and a tumor target
cell allows for a valuable and effective immunotherapy design that
propagates tumor cell killing and induces endogenous immune
functions to fight the tumor or cancer.
[0060] The expression "anti-CD3 antibody" includes both monovalent
antibodies with a single specificity, as well as bispecific
antibodies comprising a first arm that binds CD3 and a second arm
that binds a second (target) antigen, wherein the anti-CD3 arm
comprises any of the HCVR/LCVR or CDR sequences as set forth in
Tables 2, 3, 4 and/or 5 herein. Examples of anti-CD3 bispecific
antibodies are described elsewhere herein. The term
"antigen-binding molecule" includes antibodies and antigen-binding
fragments of antibodies, including, e.g., bispecific
antibodies.
[0061] The term "antibody" includes any antigen-binding molecule or
molecular complex comprising at least one complementarity
determining region (CDR) that specifically binds to or interacts
with a particular antigen (e.g., CD3). The term "antibody" includes
immunoglobulin molecules comprising four polypeptide chains, two
heavy (H) chains and two light (L) chains inter-connected by
disulfide bonds, as well as multimers thereof (e.g., IgM). Each
heavy chain comprises a heavy chain variable region (abbreviated
herein as HCVR or VH) and a heavy chain constant region. The heavy
chain constant region comprises three domains, C.sub.H1, C.sub.H2
and C.sub.H3. Each light chain comprises a light chain variable
region (abbreviated herein as LCVR or V.sub.L) and a light chain
constant region. The light chain constant region comprises one
domain (C.sub.L1). The V.sub.H and V.sub.L regions can be further
subdivided into regions of hypervariability, termed complementarity
determining regions (CDRs), interspersed with regions that are more
conserved, termed framework regions (FR). Each V.sub.H and V.sub.L
is composed of three CDRs and four FRs, arranged from
amino-terminus to carboxy-terminus in the following order: FR1,
CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the
invention, the FRs of the anti-CD3 antibody (or antigen-binding
portion thereof) may be identical to the human germline sequences,
or may be naturally or artificially modified. An amino acid
consensus sequence may be defined based on a side-by-side analysis
of two or more CDRs.
[0062] The term "antibody" also includes antigen-binding fragments
of full antibody molecules. The terms "antigen-binding portion" of
an antibody, "antigen-binding fragment" of an antibody, and the
like, as used herein, include any naturally occurring,
enzymatically obtainable, synthetic, or genetically engineered
polypeptide or glycoprotein that specifically binds an antigen to
form a complex. Antigen-binding fragments of an antibody may be
derived, e.g., from full antibody molecules using any suitable
standard techniques such as proteolytic digestion or recombinant
genetic engineering techniques involving the manipulation and
expression of DNA encoding antibody variable and optionally
constant domains. Such DNA is known and/or is readily available
from, e.g., commercial sources, DNA libraries (including, e.g.,
phage-antibody libraries), or can be synthesized. The DNA may be
sequenced and manipulated chemically or by using molecular biology
techniques, for example, to arrange one or more variable and/or
constant domains into a suitable configuration, or to introduce
codons, create cysteine residues, modify, add or delete amino
acids, etc.
[0063] Non-limiting examples of antigen-binding fragments include:
(i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv)
Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb
fragments; and (vii) minimal recognition units consisting of the
amino acid residues that mimic the hypervariable region of an
antibody (e.g., an isolated complementarity determining region
(CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4
peptide. Other engineered molecules, such as domain-specific
antibodies, single domain antibodies, domain-deleted antibodies,
chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies,
tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies,
bivalent nanobodies, etc.), small modular immunopharmaceuticals
(SMIPs), and shark variable IgNAR domains, are also encompassed
within the expression "antigen-binding fragment," as used
herein.
[0064] An antigen-binding fragment of an antibody will typically
comprise at least one variable domain. The variable domain may be
of any size or amino acid composition and will generally comprise
at least one CDR which is adjacent to or in frame with one or more
framework sequences. In antigen-binding fragments having a V.sub.H
domain associated with a V.sub.L domain, the V.sub.H and V.sub.L
domains may be situated relative to one another in any suitable
arrangement. For example, the variable region may be dimeric and
contain V.sub.H-V.sub.H, V.sub.H-V.sub.L or V.sub.L-V.sub.L dimers.
Alternatively, the antigen-binding fragment of an antibody may
contain a monomeric V.sub.H or V.sub.L domain.
[0065] In certain embodiments, an antigen-binding fragment of an
antibody may contain at least one variable domain covalently linked
to at least one constant domain. Non-limiting, exemplary
configurations of variable and constant domains that may be found
within an antigen-binding fragment of an antibody of the present
invention include: (i) V.sub.H-C.sub.H1; (ii) V.sub.H-C.sub.H2;
(iii) V.sub.H-C.sub.H3; (iv) V.sub.H-C.sub.H1-C.sub.H2; (v)
V.sub.H-C.sub.H1-C.sub.H2-C.sub.H3; (vi) V.sub.H-C.sub.H2-C.sub.H3;
(vii) V.sub.H-C.sub.L; (viii) V.sub.L-C.sub.H1; (ix)
V.sub.L-C.sub.H2; (x) V.sub.L-C.sub.H3; (xi) V.sub.L-CH1-C.sub.H2;
(xii) V.sub.L-C.sub.H1-C.sub.H2-C.sub.H3; (xiii)
V.sub.L-C.sub.H2-C.sub.H3; and (xiv) V.sub.L-C.sub.L. In any
configuration of variable and constant domains, including any of
the exemplary configurations listed above, the variable and
constant domains may be either directly linked to one another or
may be linked by a full or partial hinge or linker region. A hinge
region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or
more) amino acids which result in a flexible or semi-flexible
linkage between adjacent variable and/or constant domains in a
single polypeptide molecule. Moreover, an antigen-binding fragment
of an antibody of the present invention may comprise a homo-dimer
or hetero-dimer (or other multimer) of any of the variable and
constant domain configurations listed above in noncovalent
association with one another and/or with one or more monomeric
V.sub.H or V.sub.L domain (e.g., by disulfide bond(s)).
[0066] As with full antibody molecules, antigen-binding fragments
may be monospecific or multispecific (e.g., bispecific). A
multispecific antigen-binding fragment of an antibody will
typically comprise at least two different variable domains, wherein
each variable domain is capable of specifically binding to a
separate antigen or to a different epitope on the same antigen. Any
multispecific antibody format, including the exemplary bispecific
antibody formats disclosed herein, may be adapted for use in the
context of an antigen-binding fragment of an antibody of the
present invention using routine techniques available in the
art.
[0067] The antibodies of the present invention may function through
complement-dependent cytotoxicity (CDC) or antibody-dependent
cell-mediated cytotoxicity (ADCC). "Complement-dependent
cytotoxicity" (CDC) refers to lysis of antigen-expressing cells by
an antibody of the invention in the presence of complement.
"Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a
cell-mediated reaction in which nonspecific cytotoxic cells that
express Fc receptors (FcRs) (e.g., Natural Killer (NK) cells,
neutrophils, and macrophages) recognize bound antibody on a target
cell and thereby lead to lysis of the target cell. CDC and ADCC can
be measured using assays that are well known and available in the
art. (See, e.g., U.S. Pat. Nos. 5,500,362 and 5,821,337, and Clynes
et al. (1998) Proc. Natl. Acad. Sci. (USA) 95:652-656). The
constant region of an antibody is important in the ability of an
antibody to fix complement and mediate cell-dependent cytotoxicity.
Thus, the isotype of an antibody may be selected on the basis of
whether it is desirable for the antibody to mediate
cytotoxicity.
[0068] In certain embodiments of the invention, the anti-CD3
antibodies of the invention (monospecific or bispecific) are human
antibodies. The term "human antibody", as used herein, is intended
to include antibodies having variable and constant regions derived
from human germline immunoglobulin sequences. The human antibodies
of the invention may include amino acid residues not encoded by
human germline immunoglobulin sequences (e.g., mutations introduced
by random or site-specific mutagenesis in vitro or by somatic
mutation in vivo), for example in the CDRs and in particular CDR3.
However, the term "human antibody", as used herein, is not intended
to include antibodies in which CDR sequences derived from the
germline of another mammalian species, such as a mouse, have been
grafted onto human framework sequences.
[0069] The term "recombinant human antibody" is intended to include
all human antibodies that are prepared, expressed, created or
isolated by recombinant means, such as antibodies expressed using a
recombinant expression vector transfected into a host cell
(described further below), antibodies isolated from a recombinant,
combinatorial human antibody library (described further below),
antibodies isolated from an animal (e.g., a mouse) that is
transgenic for human immunoglobulin genes (see e.g., Taylor et al.
(1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared,
expressed, created or isolated by any other means that involves
splicing of human immunoglobulin gene sequences to other DNA
sequences. Such recombinant human antibodies have variable and
constant regions derived from human germline immunoglobulin
sequences. In certain embodiments, however, such recombinant human
antibodies are subjected to in vitro mutagenesis (or, when an
animal transgenic for human Ig sequences is used, in vivo somatic
mutagenesis) and thus the amino acid sequences of the V.sub.H and
V.sub.L regions of the recombinant antibodies are sequences that,
while derived from and related to human germline V.sub.H and
V.sub.L sequences, do not necessarily naturally exist within the
human antibody germline repertoire in vivo.
[0070] Human antibodies can exist in two forms that are associated
with hinge heterogeneity. In one form, an immunoglobulin molecule
comprises a stable four chain construct of approximately 150-160
kDa in which the dimers are held together by an interchain heavy
chain disulfide bond. In a second form, the dimers are not linked
via interchain disulfide bonds and a molecule of about 75-80 kDa is
formed composed of a covalently coupled light and heavy chain
(half-antibody). These forms have been extremely difficult to
separate, even after affinity purification.
[0071] The frequency of appearance of the second form in various
intact IgG isotypes is due to, but not limited to, structural
differences associated with the hinge region isotype of the
antibody. A single amino acid substitution in the hinge region of
the human IgG4 hinge can significantly reduce the appearance of the
second form (Angal et al. (1993) Molecular Immunology 30:105) to
levels typically observed using a human IgG1 hinge. The instant
invention encompasses antibodies having one or more mutations in
the hinge, C.sub.H2 or C.sub.H3 region which may be desirable, for
example, in production, to improve the yield of the desired
antibody form.
[0072] The antibodies of the invention may be isolated antibodies.
An "isolated antibody," as used herein, means an antibody that has
been identified and separated and/or recovered from at least one
component of its natural environment. For example, an antibody that
has been separated or removed from at least one component of an
organism, or from a tissue or cell in which the antibody naturally
exists or is naturally produced, is an "isolated antibody" for
purposes of the present invention. An isolated antibody also
includes an antibody in situ within a recombinant cell. Isolated
antibodies are antibodies that have been subjected to at least one
purification or isolation step. According to certain embodiments,
an isolated antibody may be substantially free of other cellular
material and/or chemicals.
[0073] The present invention also includes one-arm antibodies that
bind CD3. The phrase "one-arm antibody" means an antigen-binding
molecule comprising a single antibody heavy chain and a single
antibody light chain. The one-arm antibodies of the present
invention may comprise any of the HCVR/LCVR or CDR amino acid
sequences as set forth in Table 2 herein.
[0074] The term "epitope" refers to an antigenic determinant that
interacts with a specific antigen binding site in the variable
region of an antibody molecule known as a paratope. A single
antigen may have more than one epitope. Thus, different antibodies
may bind to different areas on an antigen and may have different
biological effects. Epitopes may be either conformational or
linear. A conformational epitope is produced by spatially
juxtaposed amino acids from different segments of the linear
polypeptide chain. A linear epitope is one produced by adjacent
amino acid residues in a polypeptide chain. In certain
circumstance, an epitope may include moieties of saccharides,
phosphoryl groups, or sulfonyl groups on the antigen.
[0075] The term "substantial identity" or "substantially
identical," when referring to a nucleic acid or fragment thereof,
indicates that, when optimally aligned with appropriate nucleotide
insertions or deletions with another nucleic acid (or its
complementary strand), there is nucleotide sequence identity in at
least about 95%, and more preferably at least about 96%, 97%, 98%
or 99% of the nucleotide bases, as measured by any well-known
algorithm of sequence identity, such as FASTA, BLAST or Gap, as
discussed below. A nucleic acid molecule having substantial
identity to a reference nucleic acid molecule may, in certain
instances, encode a polypeptide having the same or substantially
similar amino acid sequence as the polypeptide encoded by the
reference nucleic acid molecule.
[0076] As applied to polypeptides, the term "substantial
similarity" or "substantially similar" means that two peptide
sequences, when optimally aligned, such as by the programs GAP or
BESTFIT using default gap weights, share at least 95% sequence
identity, even more preferably at least 98% or 99% sequence
identity. Preferably, residue positions which are not identical
differ by conservative amino acid substitutions. A "conservative
amino acid substitution" is one in which an amino acid residue is
substituted by another amino acid residue having a side chain (R
group) with similar chemical properties (e.g., charge or
hydrophobicity). In general, a conservative amino acid substitution
will not substantially change the functional properties of a
protein. In cases where two or more amino acid sequences differ
from each other by conservative substitutions, the percent sequence
identity or degree of similarity may be adjusted upwards to correct
for the conservative nature of the substitution. Means for making
this adjustment are well-known to those of skill in the art. See,
e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331. Examples of
groups of amino acids that have side chains with similar chemical
properties include (1) aliphatic side chains: glycine, alanine,
valine, leucine and isoleucine; (2) aliphatic-hydroxyl side chains:
serine and threonine; (3) amide-containing side chains: asparagine
and glutamine; (4) aromatic side chains: phenylalanine, tyrosine,
and tryptophan; (5) basic side chains: lysine, arginine, and
histidine; (6) acidic side chains: aspartate and glutamate, and (7)
sulfur-containing side chains are cysteine and methionine.
Preferred conservative amino acids substitution groups are:
valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine,
alanine-valine, glutamate-aspartate, and asparagine-glutamine.
Alternatively, a conservative replacement is any change having a
positive value in the PAM250 log-likelihood matrix disclosed in
Gonnet et al. (1992) Science 256: 1443-1445. A "moderately
conservative" replacement is any change having a nonnegative value
in the PAM250 log-likelihood matrix.
[0077] Sequence similarity for polypeptides, which is also referred
to as sequence identity, is typically measured using sequence
analysis software. Protein analysis software matches similar
sequences using measures of similarity assigned to various
substitutions, deletions and other modifications, including
conservative amino acid substitutions. For instance, GCG software
contains programs such as Gap and Bestfit which can be used with
default parameters to determine sequence homology or sequence
identity between closely related polypeptides, such as homologous
polypeptides from different species of organisms or between a wild
type protein and a mutein thereof. See, e.g., GCG Version 6.1.
Polypeptide sequences also can be compared using FASTA using
default or recommended parameters, a program in GCG Version 6.1.
FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent
sequence identity of the regions of the best overlap between the
query and search sequences (Pearson (2000) supra). Another
preferred algorithm when comparing a sequence of the invention to a
database containing a large number of sequences from different
organisms is the computer program BLAST, especially BLASTP or
TBLASTN, using default parameters. See, e.g., Altschul et al.
(1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic
Acids Res. 25:3389-402.
Germline Mutations
[0078] The anti-CD3 antibodies disclosed herein comprise one or
more amino acid substitutions, insertions and/or deletions in the
framework and/or CDR regions of the heavy chain variable domains as
compared to the corresponding germline sequences from which the
antibodies were derived.
[0079] The present invention also includes antibodies, and
antigen-binding fragments thereof, which are derived from any of
the amino acid sequences disclosed herein, wherein one or more
amino acids within one or more framework and/or CDR regions are
mutated to the corresponding residue(s) of the germline sequence
from which the antibody was derived, or to the corresponding
residue(s) of another human germline sequence, or to a conservative
amino acid substitution of the corresponding germline residue(s)
(such sequence changes are referred to herein collectively as
"germline mutations"), and having weak or no detectable binding to
a CD3 antigen. Several such exemplary antibodies that recognize CD3
are described in Table 2 herein.
[0080] Furthermore, the antibodies of the present invention may
contain any combination of two or more germline mutations within
the framework and/or CDR regions, e.g., wherein certain individual
residues are mutated to the corresponding residue of a particular
germline sequence while certain other residues that differ from the
original germline sequence are maintained or are mutated to the
corresponding residue of a different germline sequence. Once
obtained, antibodies and antigen-binding fragments that contain one
or more germline mutations can be tested for one or more desired
properties such as, improved binding specificity, weak or reduced
binding affinity, improved or enhanced pharmacokinetic properties,
reduced immunogenicity, etc. Antibodies and antigen-binding
fragments obtained in this general manner given the guidance of the
present disclosure are encompassed within the present
invention.
[0081] The present invention also includes anti-CD3 antibodies
comprising variants of any of the HCVR, LCVR, and/or CDR amino acid
sequences disclosed herein having one or more conservative
substitutions. For example, the present invention includes anti-CD3
antibodies having HCVR, LCVR, and/or CDR amino acid sequences with,
e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc.
conservative amino acid substitutions relative to any of the HCVR,
LCVR, and/or CDR amino acid sequences set forth in Table 2 herein.
The antibodies and bispecific antigen-binding molecules of the
present invention comprise one or more amino acid substitutions,
insertions and/or deletions in the framework and/or CDR regions of
the heavy and light chain variable domains as compared to the
corresponding germline sequences from which the individual
antigen-binding domains were derived, while maintaining or
improving the desired weak-to-no detectable binding to CD3 antigen.
A "conservative amino acid substitution" is one in which an amino
acid residue is substituted by another amino acid residue having a
side chain (R group) with similar chemical properties (e.g., charge
or hydrophobicity). In general, a conservative amino acid
substitution will not substantially change the functional
properties of a protein, i.e. the amino acid substitution maintains
or improves the desired weak to no detectable binding affinity in
the case of anti-CD3 binding molecules. Examples of groups of amino
acids that have side chains with similar chemical properties
include (1) aliphatic side chains: glycine, alanine, valine,
leucine and isoleucine; (2) aliphatic-hydroxyl side chains: serine
and threonine; (3) amide-containing side chains: asparagine and
glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and
tryptophan; (5) basic side chains: lysine, arginine, and histidine;
(6) acidic side chains: aspartate and glutamate, and (7)
sulfur-containing side chains are cysteine and methionine.
Preferred conservative amino acids substitution groups are:
valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine,
alanine-valine, glutamate-aspartate, and asparagine-glutamine.
Alternatively, a conservative replacement is any change having a
positive value in the PAM250 log-likelihood matrix disclosed in
Gonnet et al. (1992) Science 256: 1443-1445. A "moderately
conservative" replacement is any change having a nonnegative value
in the PAM250 log-likelihood matrix.
[0082] The present invention also includes antigen-binding
molecules comprising an antigen-binding domain with an HCVR and/or
CDR amino acid sequence that is substantially identical to any of
the HCVR and/or CDR amino acid sequences disclosed herein, while
maintaining or improving the desired weak affinity to CD3 antigen.
The term "substantial identity" or "substantially identical," when
referring to an amino acid sequence means that two amino acid
sequences, when optimally aligned, such as by the programs GAP or
BESTFIT using default gap weights, share at least 95% sequence
identity, even more preferably at least 98% or 99% sequence
identity. Preferably, residue positions which are not identical
differ by conservative amino acid substitutions. In cases where two
or more amino acid sequences differ from each other by conservative
substitutions, the percent sequence identity or degree of
similarity may be adjusted upwards to correct for the conservative
nature of the substitution. Means for making this adjustment are
well-known to those of skill in the art. See, e.g., Pearson (1994)
Methods Mol. Biol. 24: 307-331.
[0083] Sequence similarity for polypeptides, which is also referred
to as sequence identity, is typically measured using sequence
analysis software. Protein analysis software matches similar
sequences using measures of similarity assigned to various
substitutions, deletions and other modifications, including
conservative amino acid substitutions. For instance, GCG software
contains programs such as Gap and Bestfit which can be used with
default parameters to determine sequence homology or sequence
identity between closely related polypeptides, such as homologous
polypeptides from different species of organisms or between a wild
type protein and a mutein thereof. See, e.g., GCG Version 6.1.
Polypeptide sequences also can be compared using FASTA using
default or recommended parameters, a program in GCG Version 6.1.
FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent
sequence identity of the regions of the best overlap between the
query and search sequences (Pearson (2000) supra). Another
preferred algorithm when comparing a sequence of the invention to a
database containing a large number of sequences from different
organisms is the computer program BLAST, especially BLASTP or
TBLASTN, using default parameters. See, e.g., Altschul et al.
(1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic
Acids Res. 25:3389-402.
[0084] Once obtained, antigen-binding domains that contain one or
more germline mutations were tested for decreased binding affinity
utilizing one or more in vitro assays. Although antibodies that
recognize a particular antigen are typically screened for their
purpose by testing for high (i.e. strong) binding affinity to the
antigen, the antibodies of the present invention exhibit weak
binding or no detectable binding. Bispecific antigen-binding
molecules comprising one or more antigen-binding domains obtained
in this general manner are also encompassed within the present
invention and were found to be advantageous as avidity-driven tumor
therapies.
[0085] Unexpected benefits, for example, improved pharmacokinetic
properties and low toxicity to the patient may be realized from the
methods described herein.
Binding Properties of the Antibodies
[0086] As used herein, the term "binding" in the context of the
binding of an antibody, immunoglobulin, antibody-binding fragment,
or Fc-containing protein to either, e.g., a predetermined antigen,
such as a cell surface protein or fragment thereof, typically
refers to an interaction or association between a minimum of two
entities or molecular structures, such as an antibody-antigen
interaction.
[0087] For instance, binding affinity typically corresponds to a
K.sub.D value of about 10.sup.-7 M or less, such as about 10.sup.-8
M or less, such as about 10.sup.-9 M or less when determined by,
for instance, surface plasmon resonance (SPR) technology in a
BIAcore 3000 instrument using the antigen as the ligand and the
antibody, Ig, antibody-binding fragment, or Fc-containing protein
as the analyte (or antiligand). Cell-based binding strategies, such
as fluorescent-activated cell sorting (FACS) binding assays, are
also routinely used, and FACS data correlates well with other
methods such as radioligand competition binding and SPR (Benedict,
C A, J Immunol Methods. 1997, 201(2):223-31; Geuijen, C A, et al. J
Immunol Methods. 2005, 302(1-2):68-77).
[0088] Accordingly, the antibody or antigen-binding protein of the
invention may bind to the predetermined antigen or cell surface
molecule (receptor such as CD3) having an affinity corresponding to
a K.sub.D value that is at least ten-fold lower than its affinity
for binding to a non-specific antigen (e.g., BSA, casein).
According to the present invention, if the affinity of an antibody
corresponding to a K.sub.D value is equal to or less than ten-fold
lower than a non-specific antigen, this may be considered
non-detectable binding, however such an antibody may be paired with
a second antigen binding arm for the production of a bispecific
antibody of the invention.
[0089] The term "K.sub.D" (M) refers to the dissociation
equilibrium constant of a particular antibody-antigen interaction,
or the dissociation equilibrium constant of an antibody or
antibody-binding fragment binding to an antigen. There is an
inverse relationship between K.sub.D and binding affinity,
therefore the smaller the K.sub.D value, the higher, i.e. stronger,
the affinity. Thus, the terms "higher affinity" or "stronger
affinity" relate to a higher ability to form an interaction and
therefore a smaller K.sub.D value, and conversely the terms "lower
affinity" or "weaker affinity" relate to a lower ability to form an
interaction and therefore a larger K.sub.D value. In some
circumstances, a higher binding affinity (or K.sub.D of a
particular molecule (e.g. antibody) to its interactive partner
molecule (e.g. antigen X) compared to the binding affinity of the
molecule (e.g. antibody) to another interactive partner molecule
(e.g. antigen Y) may be expressed as a binding ratio determined by
dividing the larger K.sub.D value (lower, or weaker, affinity) by
the smaller K.sub.D (higher, or stronger, affinity), for example
expressed as 5-fold or 10-fold greater binding affinity, as the
case may be. For example, "low affinity" refers to less strong
binding interaction. In some embodiments, the low binding affinity
corresponds to greater than about 1 nM K.sub.D, greater than about
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
25, 30, 35, or greater than about 40 nM K.sub.D, wherein such
K.sub.D binding affinity value is measured in an in vitro surface
plasmon resonance binding assay, or equivalent biomolecular
interaction sensing assay. In some embodiments, the low binding
affinity corresponds to greater than about 10 nM EC.sub.50, greater
than about 15 nM EC.sub.50, 20 nM EC.sub.50, greater than about 25
nM EC.sub.50, 30 nM EC.sub.50, greater than about 35 nM EC.sub.50,
or greater than about 40 nM EC.sub.50, wherein such EC.sub.50
binding affinity value is measured in an in vitro FACS binding
assay, or equivalent cell-based binding assay. "Weak affinity"
refers to weak binding interaction. In some embodiments, the weak
binding affinity corresponds to greater than about 100 nM K.sub.D
or EC.sub.50, greater than about 200, 300, or greater than about
500 nM K.sub.D or EC.sub.50, wherein such K.sub.D binding affinity
value is measured in an in vitro surface plasmon resonance binding
assay, or equivalent biomolecular interaction sensing assay, and
such EC.sub.50 binding affinity value is measured in an in vitro
FACS binding assay, or equivalent cell-based interaction detecting
assay to detect monovalent biding. No detectable binding means that
the affinity between the two biomolecules, for example, especially
between the monovalent antibody binding arm and its target antigen,
is beyond the detection limit of the assay being used.
[0090] The term "k.sub.d" (sec -1 or 1/s) refers to the
dissociation rate constant of a particular antibody-antigen
interaction, or the dissociation rate constant of an antibody or
antibody-binding fragment. Said value is also referred to as the
k.sub.off value.
[0091] The term "k.sub.a" (M-1.times.sec-1 or 1/M) refers to the
association rate constant of a particular antibody-antigen
interaction, or the association rate constant of an antibody or
antibody-binding fragment.
[0092] The term "K.sub.A" (M-1 or 1/M) refers to the association
equilibrium constant of a particular antibody-antigen interaction,
or the association equilibrium constant of an antibody or
antibody-binding fragment. The association equilibrium constant is
obtained by dividing the k.sub.a by the k.sub.d.
[0093] The term "EC.sub.50" or "EC.sub.50" refers to the half
maximal effective concentration, which includes the concentration
of an antibody which induces a response halfway between the
baseline and maximum after a specified exposure time. The EC.sub.50
essentially represents the concentration of an antibody where 50%
of its maximal effect is observed. In certain embodiments, the
EC.sub.50 value equals the concentration of an antibody of the
invention that gives half-maximal binding to cells expressing CD3
or tumor-associated antigen, as determined by e.g. a FACS binding
assay. Thus, reduced or weaker binding is observed with an
increased EC.sub.50 value, or half maximal effective concentration
value such that 500 nM EC.sub.50 is indicative of a weaker binding
affinity than 50 nM EC.sub.50.
[0094] In one embodiment, decreased binding can be defined as an
increased EC.sub.50 antibody concentration which enables binding to
the half-maximal amount of target cells.
[0095] In other experimental measurements, the EC.sub.50 value
represents the concentration of an antibody of the invention that
elicits half-maximal depletion of target cells by T cell cytotoxic
activity. Thus, increased cytotoxic activity (e.g. T cell-mediated
tumor cell killing) is observed with a decreased EC.sub.50, or half
maximal effective concentration value.
Bispecific Antigen-Binding Molecules
[0096] The antibodies of the present invention may be bi-specific,
or multispecific. Multispecific antibodies may be specific for one
effector molecule, such as CD3, in combination with different
epitopes of one target polypeptide or may contain antigen-binding
domains specific for more than one target polypeptide. See, e.g.,
Tutt et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004,
Trends Biotechnol. 22:238-244. The anti-CD3 antibodies of the
present invention can be linked to or co-expressed with another
functional molecule, e.g., another peptide or protein. For example,
an antibody or fragment thereof can be functionally linked (e.g.,
by chemical coupling, genetic fusion, noncovalent association or
otherwise) to one or more other molecular entities, such as another
antibody or antibody fragment to produce a bi-specific or a
multispecific antibody with a second binding specificity.
[0097] Use of the expression "anti-CD3 antibody" herein is intended
to include both monospecific anti-CD3 antibodies as well as
bispecific antibodies comprising a CD3-binding arm and a second arm
that binds a target antigen. Thus, the present invention includes
bispecific antibodies wherein one arm of an immunoglobulin binds
human CD3, and the other arm of the immunoglobulin is specific for
a target antigen. The target antigen that the other arm of the CD3
bispecific antibody binds can be any antigen expressed on or in the
vicinity of a cell, tissue, organ, microorganism or virus, against
which a targeted immune response is desired. The CD3-binding arm
can comprise any of the HCVR or CDR amino acid sequences as set
forth in Table 2 herein. In certain embodiments, the CD3-binding
arm binds weakly to human CD3 and induces human T cell activation.
In other embodiments, the CD3-binding arm binds weakly to human CD3
and induces tumor-associated antigen-expressing cell killing in the
context of a bispecific or multispecific antibody. In other
embodiments, the CD3-binding arm binds or associated weakly with
human and cynomolgus (monkey) CD3, yet the binding interaction is
not detectable by in vitro assays known in the art. In some
embodiments of the invention, the CD3-binding arm does not bind or
associate with human and cynomolgus (monkey) CD3, yet the
bispecific molecule still elicits tumor-associated cell
killing.
[0098] In the context of bispecific antibodies of the present
invention wherein one arm of the antibody binds CD3 and the other
arm binds a target antigen, the target antigen can be a
tumor-associated antigen (TAA). Non-limiting examples of specific
tumor-associated antigens include, e.g., AFP, ALK, BAGE proteins,
BIRC5 (survivin), BIRC7, .beta.-catenin, brc-abl, BRCA1, BORIS,
CA9, carbonic anhydrase IX, caspase-8, CALR, CCR5, CD19, CD20
(MS4A1), CD22, CD30, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYP1B1,
EGFR, EGFRvIII, ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EpCAM, EphA2,
Fra-1, FOLR1, GAGE proteins (e.g., GAGE-1, -2), GD2, GD3, GloboH,
glypican-3, GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3,
hTERT, LMP2, MAGE proteins (e.g., MAGE-1, -2, -3, -4, -6, and -12),
MART-1, mesothelin, ML-IAP, Muc1, Muc2, Muc3, Muc4, Muc5, Muc16
(CA-125), MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15,
p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1),
RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, STEAP1, STEAP2,
TAG-72, TGF-.beta., TMPRSS2, Thompson-nouvelle antigen (Tn), TRP-1,
TRP-2, tyrosinase, and uroplakin-3.
[0099] The inventors envision that the present invention includes
numerous examples of bispecific antibodies having a weak anti-CD3
binding arm made in accordance with the invention.
[0100] According to certain exemplary embodiments, the present
invention includes bispecific antigen-binding molecules that
specifically bind CD3 and PSMA. Such molecules may be referred to
herein as, e.g., "anti-CD3/anti-PSMA," or "anti-CD3.times.PSMA" or
"CD3.times.PSMA" bispecific molecules, and so forth. The term
"PSMA," as used herein, refers to the human PSMA protein unless
specified as being from a non-human species (e.g., "mouse PSMA,"
"monkey PSMA," etc.).
[0101] The term "PSMA" refers to prostate-specific membrane
antigen, also known as folate hydrolase 1 (FOLH1)
(UniProtKB/Swiss-Prot. No. Q04609; SEQ ID NO: 171). PSMA is an
integral, non-shed membrane glycoprotein that is highly expressed
in prostate epithelial cells and is a cell-surface marker for
prostate cancer.
[0102] According to other exemplary embodiments, the present
invention includes bispecific antigen-binding molecules that
specifically bind CD3 and EGFRvIII. Such molecules may be referred
to herein as, e.g., "anti-CD3/anti-EGFRvIII" or "anti-CD3.times.
EGFRvIII" or "CD3.times. EGFRvIII" bispecific molecules, and so
forth. The term "EGFRvIII" refers to the human EGFRvIII protein
unless specified as being from a non-human species (e.g., "mouse
EGFRvIII," "monkey EGFRvIII," etc.).
[0103] The term "EGFRvIII" refers to the class III variant of the
epidermal growth factor receptor (EGFRvIII; SEQ ID NO: 172) which
is the most frequently found EGFR variant in glioblastoma (Bigner
et al., 1990, Cancer Res 50:8017-8022; Humphrey et al., 1990, Proc
Natl Acad Sci USA 87:4207-4211; Yamazaki et al., 1990, Jap J Cancer
Res 81:773-779; Ekstrand et al., 1992, Proc Natl Acad Sci USA
89:4309-4313; Wikstrand et al., 1995, Cancer Res 55:3140-3148; and
Frederick et al., 2000, Cancer Res 60:1383-1387). EGFRvIII is
characterized by a deletion of exons 2-7 of the EGFR gene,
resulting in an in-frame deletion of 801 base pairs of the coding
region, i.e., deletion of 6-273 amino acid residues (based on the
residue numbers of mature EGFR; see UniProtKB/Swiss-Prot. No.
P00533), as well as the generation of a new glycine at the fusion
junction (Humphrey et al., 1988, Cancer Res 48:2231-2238; Yamazaki
et al., 1990, supra). EGFRvIII has been shown to have a
ligand-independent, weak but constitutively active kinase activity
as well as enhanced tumorigenicity (Nishikawa et al., 1994, Proc
Natl Acad Sci USA 91:7727-7731; and Batra et al., 1995, Cell Growth
and Differentiation 6:1251-1259). In addition to gliomas, EGFRvIII
has been detected in ductal and intraductal breast carcinoma
(Wikstrand et al., 1995, Cancer Res 55:3140-3148), non-small cell
lung carcinomas (Garcia de Palazzo et al., 1993, Cancer Res
53:3217-3220), ovarian carcinomas (Moscatello et al., 1995, Cancer
Res 55:5536-5539), prostate cancer (Olapade-Olaopa et al., 2000,
British J Cancer 82:186-194), and squamous cell carcinoma of the
head and neck (Tinhofer et al., 2011, Clin Cancer Res
17(15):5197-5204).
[0104] In still other exemplary embodiments, the present invention
includes bispecific antigen-binding molecules that specifically
bind CD3 and MUC16. Such molecules may be referred to herein as,
e.g., "anti-CD3/anti-MUC16" or "anti-CD3.times.MUC16" or
"CD3.times.MUC16" bispecific molecules, and so forth. The term
"MUC16" refers to the human MUC16 protein unless specified as being
from a non-human species (e.g., "mouse MUC16," "monkey MUC16,"
etc.).
[0105] Mucin 16 (MUC16; NCBI Reference Sequence: NP_078966.2, SEQ
ID NO: 173), otherwise known as cancer antigen 125 (CA-125), is a
mucin encoded by MUC16 gene in humans. The family of mucin proteins
are known to protect the body from infection by pathogen binding to
oligosaccharides in the extracellular domain, preventing the
pathogen form reaching the cell surface. For many years,
overexpression of MUC16/CA125 has been used as a prognostic and
diagnostic marker for ovarian cancer (Yin and Lloyd, 2001, J. Biol.
Chem. 276 (29), 27371-27375; O'Brien, T J, et al, 2001, Tumour
Biol. 22 (6), 348-366; Leggieri, C. et al., 2014, Eur. J. Gynaecol.
Oncol. 35 (4), 438-441). MUC16 has been shown to protect tumor
cells from the immune system with its heavily glycosylated tandem
repeat domain which can bind to galectin-1 (an immunosuppressive
protein) (Seelenmeyer, C., et al., 2003, J. Cell. Sci. 116 (Pt 7):
1305-18; O'Brien, T J, et al., 2002, Tumour Biol. 23 (3), 154-169).
Natural killer cells and monocytes are unable to attack tumor cells
expressing high levels of MUC16. In its normal physiologic role,
MUC16-galactin interaction serves as a barrier for bacterial and
viral infection, however MUC16 is believed to be immunoprotective
in the context of tumor cells, thereby preventing cancer cell
cytolysis (Felder, M. et al., 2014, Molecular Cancer, 13:129).
MUC16 is therefore a desirable target for immunotherapeutic
bispecific antibody molecules administered to treat ovarian cancer
by activating immune effector cells.
[0106] In still other exemplary embodiments, the present invention
includes bispecific antigen-binding molecules that specifically
bind CD3 and STEAP2. Such molecules may be referred to herein as,
e.g., "anti-CD3/anti-STEAP2" or "anti-CD3.times.STEAP2" or
"CD3.times.STEAP2" bispecific molecules, and so forth. The term
"STEAP2" refers to the human STEAP2 protein unless specified as
being from a non-human species (e.g., "mouse STEAP2," "monkey
STEAP2," etc.). Six transmembrane epithelial antigen of the
prostate 2 (STEAP2; UniProtKB/Swiss-Prot: Q8NFT2.3) is a 490-amino
acid protein encoded by STEAP2 gene located at the chromosomal
region 7q21 in humans.
[0107] The aforementioned bispecific antigen-binding molecules that
specifically bind tumor-associated antigen comprise an anti-CD3
antigen-binding molecule which binds to CD3 with a weak or no
detectable binding affinity such as exhibiting a K.sub.D of greater
than about 100 nM, 300 nM or 500 nM, as measured by an in vitro
affinity binding assay.
[0108] As used herein, the expression "antigen-binding molecule"
means a protein, polypeptide or molecular complex comprising or
consisting of at least one complementarity determining region (CDR)
that alone, or in combination with one or more additional CDRs
and/or framework regions (FRs), specifically binds to a particular
antigen. In certain embodiments, an antigen-binding molecule is an
antibody or a fragment of an antibody, as those terms are defined
elsewhere herein.
[0109] As used herein, the expression "bispecific antigen-binding
molecule" means a protein, polypeptide or molecular complex
comprising at least a first antigen-binding domain and a second
antigen-binding domain. Each antigen-binding domain within the
bispecific antigen-binding molecule comprises at least one CDR that
alone, or in combination with one or more additional CDRs and/or
FRs, specifically binds to a particular antigen. In the context of
the present invention, the first antigen-binding domain
specifically binds a first antigen (e.g., CD3), and the second
antigen-binding domain specifically binds a second, distinct
antigen (e.g., PSMA, MUC16, EGFRvIII or STEAP2).
[0110] In certain exemplary embodiments of the present invention,
the bispecific antigen-binding molecule is a bispecific antibody.
Each antigen-binding domain of a bispecific antibody comprises a
heavy chain variable domain (HCVR) and a light chain variable
domain (LCVR). In the context of a bispecific antigen-binding
molecule comprising a first and a second antigen-binding domain
(e.g., a bispecific antibody), the CDRs of the first
antigen-binding domain may be designated with the prefix "A1" and
the CDRs of the second antigen-binding domain may be designated
with the prefix "A2". Thus, the CDRs of the first antigen-binding
domain may be referred to herein as A1-HCDR1, A1-HCDR2, and
A1-HCDR3; and the CDRs of the second antigen-binding domain may be
referred to herein as A2-HCDR1, A2-HCDR2, and A2-HCDR3.
[0111] The first antigen-binding domain and the second
antigen-binding domain may be directly or indirectly connected to
one another to form a bispecific antigen-binding molecule of the
present invention. Alternatively, the first antigen-binding domain
and the second antigen-binding domain may each be connected to a
separate multimerizing domain. The association of one multimerizing
domain with another multimerizing domain facilitates the
association between the two antigen-binding domains, thereby
forming a bispecific antigen-binding molecule. As used herein, a
"multimerizing domain" is any macromolecule, protein, polypeptide,
peptide, or amino acid that has the ability to associate with a
second multimerizing domain of the same or similar structure or
constitution. For example, a multimerizing domain may be a
polypeptide comprising an immunoglobulin C.sub.H3 domain. A
non-limiting example of a multimerizing component is an Fc portion
of an immunoglobulin (comprising a C.sub.H2-C.sub.H3 domain), e.g.,
an Fc domain of an IgG selected from the isotypes IgG1, IgG2, IgG3,
and IgG4, as well as any allotype within each isotype group.
[0112] Bispecific antigen-binding molecules of the present
invention will typically comprise two multimerizing domains, e.g.,
two Fc domains that are each individually part of a separate
antibody heavy chain. The first and second multimerizing domains
may be of the same IgG isotype such as, e.g., IgG1/IgG1, IgG2/IgG2,
IgG4/IgG4. Alternatively, the first and second multimerizing
domains may be of different IgG isotypes such as, e.g., IgG1/IgG2,
IgG1/IgG4, IgG2/IgG4, etc.
[0113] In certain embodiments, the multimerizing domain is an Fc
fragment or an amino acid sequence of 1 to about 200 amino acids in
length containing at least one cysteine residues. In other
embodiments, the multimerizing domain is a cysteine residue, or a
short cysteine-containing peptide. Other multimerizing domains
include peptides or polypeptides comprising or consisting of a
leucine zipper, a helix-loop motif, or a coiled-coil motif.
[0114] Any bispecific antibody format or technology may be used to
make the bispecific antigen-binding molecules of the present
invention. For example, an antibody or fragment thereof having a
first antigen binding specificity can be functionally linked (e.g.,
by chemical coupling, genetic fusion, noncovalent association or
otherwise) to one or more other molecular entities, such as another
antibody or antibody fragment having a second antigen-binding
specificity to produce a bispecific antigen-binding molecule.
Specific exemplary bispecific formats that can be used in the
context of the present invention include, without limitation, e.g.,
scFv-based or diabody bispecific formats, IgG-scFv fusions, dual
variable domain (DVD)-Ig, Quadroma, knobs-into-holes, common light
chain (e.g., common light chain with knobs-into-holes, etc.),
CrossMab, CrossFab, (SEED)body, leucine zipper, Duobody, IgG1/IgG2,
dual acting Fab (DAF)-IgG, and Mab.sup.2 bispecific formats (see,
e.g., Klein et al. 2012, mAbs 4:6, 1-11, and references cited
therein, for a review of the foregoing formats).
[0115] In the context of bispecific antigen-binding molecules of
the present invention, the multimerizing domains, e.g., Fc domains,
may comprise one or more amino acid changes (e.g., insertions,
deletions or substitutions) as compared to the wild-type, naturally
occurring version of the Fc domain. For example, the invention
includes bispecific antigen-binding molecules comprising one or
more modifications in the Fc domain that results in a modified Fc
domain having a modified binding interaction (e.g., enhanced or
diminished) between Fc and FcRn. In one embodiment, the bispecific
antigen-binding molecule comprises a modification in a C.sub.H2 or
a C.sub.H3 region, wherein the modification increases the affinity
of the Fc domain to FcRn in an acidic environment (e.g., in an
endosome where pH ranges from about 5.5 to about 6.0). Non-limiting
examples of such Fc modifications include, e.g., a modification at
position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g.,
L/Y/F/W or T), 254 (e.g., S or T), and 256 (e.g., S/R/Q/E/D or T);
or a modification at position 428 and/or 433 (e.g., L/R/S/P/Q or K)
and/or 434 (e.g., H/F or Y); or a modification at position 250
and/or 428; or a modification at position 307 or 308 (e.g., 308F,
V308F), and 434. In one embodiment, the modification comprises a
428L (e.g., M428L) and 434S (e.g., N434S) modification; a 428L,
259I (e.g., V259I), and 308F (e.g., V308F) modification; a 433K
(e.g., H433K) and a 434 (e.g., 434Y) modification; a 252, 254, and
256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L
modification (e.g., T250Q and M428L); and a 307 and/or 308
modification (e.g., 308F or 308P).
[0116] The present invention also includes bispecific
antigen-binding molecules comprising a first C.sub.H3 domain and a
second Ig C.sub.H3 domain, wherein the first and second Ig C.sub.H3
domains differ from one another by at least one amino acid, and
wherein at least one amino acid difference reduces binding of the
bispecific antibody to Protein A as compared to a bi-specific
antibody lacking the amino acid difference. In one embodiment, the
first Ig C.sub.H3 domain binds Protein A and the second Ig C.sub.H3
domain contains a mutation that reduces or abolishes Protein A
binding such as an H95R modification (by IMGT exon numbering; H435R
by EU numbering). The second C.sub.H3 may further comprise a Y96F
modification (by IMGT; Y436F by EU). Further modifications that may
be found within the second C.sub.H3 include: D16E, L18M, N44S,
K52N, V57M, and V821 (by IMGT; D356E, L358M, N384S, K392N, V397M,
and V4221 by EU) in the case of IgG1 antibodies; N44S, K52N, and
V821 (IMGT; N384S, K392N, and V4221 by EU) in the case of IgG2
antibodies; and Q15R, N44S, K52N, V57M, R69K, E79Q, and V821 (by
IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V4221 by EU) in
the case of IgG4 antibodies.
[0117] In certain embodiments, the Fc domain may be chimeric,
combining Fc sequences derived from more than one immunoglobulin
isotype. For example, a chimeric Fc domain can comprise part or all
of a C.sub.H2 sequence derived from a human IgG1, human IgG2 or
human IgG4 C.sub.H2 region, and part or all of a C.sub.H3 sequence
derived from a human IgG1, human IgG2 or human IgG4. A chimeric Fc
domain can also contain a chimeric hinge region. For example, a
chimeric hinge may comprise an "upper hinge" sequence, derived from
a human IgG1, a human IgG2 or a human IgG4 hinge region, combined
with a "lower hinge" sequence, derived from a human IgG1, a human
IgG2 or a human IgG4 hinge region. A particular example of a
chimeric Fc domain that can be included in any of the
antigen-binding molecules set forth herein comprises, from N- to
C-terminus: [IgG4 C.sub.H1]- [IgG4 upper hinge]-[IgG2 lower
hinge]-[IgG4 C.sub.H2]- [IgG4 C.sub.H3]. Another example of a
chimeric Fc domain that can be included in any of the
antigen-binding molecules set forth herein comprises, from N- to
C-terminus: [IgG1 C.sub.H1]- [IgG1 upper hinge]-[IgG2 lower
hinge]-[IgG4 C.sub.H2]- [IgG1 C.sub.H3]. These and other examples
of chimeric Fc domains that can be included in any of the
antigen-binding molecules of the present invention are described in
PCT International Publication No. WO2014/121087 A1, published Aug.
7, 2014, which is herein incorporated by reference in its entirety.
Chimeric Fc domains having these general structural arrangements,
and variants thereof, can have altered Fc receptor binding, which
in turn affects Fc effector function.
[0118] In certain embodiments, the invention provides an antibody
heavy chain wherein the heavy chain constant region (C.sub.H)
region comprises an amino acid sequence at least 95%, at least 96%,
at least 97%, at least 98%, at least 99% identical to any one of
SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ
ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID
NO: 190 or SEQ ID NO: 191. In some embodiments, the heavy chain
constant region (C.sub.H) region comprises an amino acid sequence
selected form the group consisting of SEQ ID NO: 182, SEQ ID NO:
183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO:
187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190 and SEQ ID NO:
191.
[0119] In other embodiments, the invention provides an antibody
heavy chain wherein the Fc domain comprises an amino acid sequence
at least 95%, at least 96%, at least 97%, at least 98%, at least
99% identical to any one of SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID
NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO:
198, SEQ ID NO: 199, SEQ ID NO: 200 or SEQ ID NO: 201. In some
embodiments, the Fc domain comprises an amino acid sequence
selected form the group consisting of SEQ ID NO: 192, SEQ ID NO:
193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO:
197, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200 and SEQ ID NO:
201.
Other Fc Variants
[0120] According to certain embodiments of the present invention,
anti-CD3 antibodies, and anti-CD3/anti-TAA bispecific
antigen-binding molecules, are provided comprising an Fc domain
comprising one or more mutations which enhance or diminish antibody
binding to the FcRn receptor, e.g., at acidic pH as compared to
neutral pH. For example, the present invention includes antibodies
comprising a mutation in the C.sub.H2 or a C.sub.H3 region of the
Fc domain, wherein the mutation(s) increases the affinity of the Fc
domain to FcRn in an acidic environment (e.g., in an endosome where
pH ranges from about 5.5 to about 6.0). Such mutations may result
in an increase in serum half-life of the antibody when administered
to an animal. Non-limiting examples of such Fc modifications
include, e.g., a modification at position 250 (e.g., E or Q); 250
and 428 (e.g., L or F); 252 (e.g., L/Y/F/W or T), 254 (e.g., S or
T), and 256 (e.g., S/R/Q/E/D or T); or a modification at position
428 and/or 433 (e.g., H/L/R/S/P/Q or K) and/or 434 (e.g., H/F or
Y); or a modification at position 250 and/or 428; or a modification
at position 307 or 308 (e.g., 308F, V308F), and 434. In one
embodiment, the modification comprises a 428L (e.g., M428L) and
434S (e.g., N434S) modification; a 428L, 259I (e.g., V259I), and
308F (e.g., V308F) modification; a 433K (e.g., H433K) and a 434
(e.g., 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T,
and 256E) modification; a 250Q and 428L modification (e.g., T250Q
and M428L); and a 307 and/or 308 modification (e.g., 308F or
308P).
[0121] For example, the present invention includes anti-CD3
antibodies, and anti-CD3/anti-TAA bispecific antigen-binding
molecules, comprising an Fc domain comprising one or more pairs or
groups of mutations selected from the group consisting of: 250Q and
248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y,
S254T and T256E); 428L and 434S (e.g., M428L and N434S); and 433K
and 434F (e.g., H433K and N434F). All possible combinations of the
foregoing Fc domain mutations, and other mutations within the
antibody variable domains disclosed herein, are contemplated within
the scope of the present invention.
Biological Characteristics of the Antibodies and Bispecific
Antigen-Binding Molecules
[0122] The present invention includes bispecific antigen-binding
molecules (e.g., bispecific antibodies) which are capable of
simultaneously binding to human CD3 and a human TAA. According to
certain embodiments, the bispecific antigen-binding molecules of
the invention specifically interact with cells that express CD3
and/or TAA, such as PSMA, EGFRvIII or MUC16. The binding arm that
interacts with cells that express CD3 may have weak to no
detectable binding as measured in a suitable in vitro binding
assay. The extent to which a bispecific antigen-binding molecule
binds cells that express CD3 and/or TAA can be assessed by
fluorescence activated cell sorting (FACS), as illustrated in
Example 4 herein.
[0123] For example, the present invention includes antibodies,
antigen-binding fragments, and bispecific antibodies thereof which
specifically bind human T-cell lines which express CD3 but not the
TAA (e.g., Jurkat), primate T-cells (e.g., cynomolgus peripheral
blood mononuclear cells [PBMCs]), and/or TAA-expressing cells. The
present invention includes bispecific antigen-binding molecules
which bind any of the aforementioned T cells and T cell lines with
an EC.sub.50 value of from about 1.8.times.10.sup.-9 (18 nM) to
about 2.1.times.10.sup.-7 (210 nM), or more (i.e. weaker affinity),
and includes bispecific antibodies for which EC.sub.50 is
undetectable, as determined using a FACS binding assay as set forth
in Example 4 or a substantially similar assay. In certain
embodiments, the antibodies, antigen-binding fragments, and
bispecific antibodies of the present invention bind CD3 with an
EC.sub.50 of greater than about 30 nM, greater than about 40 nM,
greater than about 45 nM, greater than about 50 nM, greater than
about 55 nM, greater than about 60 nM, greater than about 65 nM,
greater than about 70 nM, greater than about 75 nM, at least 80 nM,
greater than about 90 nM, greater than about 100 nM, greater than
about 110 nM, at least 120 nM, greater than about 130 nM, greater
than about 140 nM, greater than about 150 nM, at least 160 nM,
greater than about 170 nM, greater than about 180 nM, greater than
about 190 nM, greater than about 200 nM, greater than about 250 nM,
greater than about 300 nM, greater than about 500 nM, greater than
about 1 .mu.M, greater than about 2 .mu.M, or greater than about 3
.mu.M, or no detectable binding affinity, as measured by FACS
binding, e.g., using an assay format as defined in Example 4
herein, or a substantially similar assay.
[0124] The present invention also includes antibodies,
antigen-binding fragments, and bispecific antibodies thereof which
bind to TAA-expressing cells and cell lines, such as PSMA-,
EGFRvIII-, STEAP2- and MUC16-expressing cell lines, with an
EC.sub.50 value of less than about 100 nM, or even less
concentration necessary for binding (i.e. stronger affinity) such
as less than 5.6 nM (5.6.times.10.sup.-9), as determined using a
FACS binding assay as set forth in Example 4 or a substantially
similar cell-based assay. The present invention includes bispecific
antigen-binding molecules which bind any of the aforementioned
tumor cell lines with an EC.sub.50 value of less than about 50 nM,
less than about 45 nM, less than less 40 nM, less than about 35 nM,
less than about 30 nM, less than about 25 nM, less than about 20
nM, less than about 15 nM, less than about 10 nM, less than about 6
nM, less than about 5 nM, or less than about 1 nM, e.g. using the
aforementioned assay.
[0125] The present invention includes antibodies, antigen-binding
fragments, and bispecific antibodies thereof that bind human CD3
with low, weak or even no detectable affinity. According to certain
embodiments, the present invention includes antibodies and
antigen-binding fragments of antibodies that bind human CD3 (e.g.,
at 37.degree. C.) with a K.sub.D of greater than about 11 nM,
includes antibodies that bind CD3 with a K.sub.D of greater than
about 100 nM or 500 nM, and also includes antibodies having no
detectable binding affinity, as measured by surface plasmon
resonance, e.g., using an assay format as defined in Example 5
herein. In certain embodiments, the antibodies or antigen-binding
fragments of the present invention bind CD3 with a K.sub.D of
greater than about 15 nM, greater than about 20 nM, greater than
about 25 nM, greater than about 30 nM, greater than about 35 nM,
greater than about 40 nM, greater than about 45 nM, greater than
about 50 nM, greater than about 55 nM, greater than about 60 nM,
greater than about 65 nM, greater than about 70 nM, greater than
about 75 nM, at least 80 nM, greater than about 90 nM, greater than
about 100 nM, greater than about 110 nM, at least 120 nM, greater
than about 130 nM, greater than about 140 nM, greater than about
150 nM, at least 160 nM, greater than about 170 nM, greater than
about 180 nM, greater than about 190 nM, greater than about 200 nM,
greater than about 250 nM, greater than about 300 nM, greater than
about 1 .mu.M, greater than about 2 .mu.M, or greater than about 3
.mu.M, or no detectable affinity, as measured by surface plasmon
resonance, e.g., using an assay format as defined in Example 5
herein (e.g., mAb-capture or antigen-capture format), or a
substantially similar assay.
[0126] The present invention includes antibodies, antigen-binding
fragments, and bispecific antibodies thereof that bind monkey (i.e.
cynomolgus) CD3 with low, weak, or even no detectable affinity.
According to certain embodiments, the present invention includes
antibodies, antigen-binding fragments, and bispecific antibodies
thereof that bind human CD3 (e.g., at 37.degree. C.) with a K.sub.D
of greater than about 10 nM, includes antibodies that bind CD3 with
a K.sub.D of greater than about 100 nM or 500 nM, and also includes
antibodies having no detectable binding affinity, as measured by
surface plasmon resonance, e.g., using an assay format as defined
in Example 5 herein. In certain embodiments, the antibodies or
antigen-binding fragments of the present invention bind CD3 with a
K.sub.D of greater than about 15 nM, greater than about 20 nM,
greater than about 25 nM, greater than about 30 nM, greater than
about 35 nM, greater than about 40 nM, greater than about 45 nM,
greater than about 50 nM, greater than about 55 nM, greater than
about 60 nM, greater than about 65 nM, greater than about 70 nM,
greater than about 75 nM, at least 80 nM, greater than about 90 nM,
greater than about 100 nM, greater than about 110 nM, at least 120
nM, greater than about 130 nM, greater than about 140 nM, greater
than about 150 nM, at least 160 nM, greater than about 170 nM,
greater than about 180 nM, greater than about 190 nM, greater than
about 200 nM, greater than about 250 nM, greater than about 300 nM,
greater than about 1 .mu.M, greater than about 2 .mu.M, or greater
than about 3 .mu.M, or no detectable affinity, as measured by
surface plasmon resonance, e.g., using an assay format as defined
in Example 5 herein (e.g., mAb-capture or antigen-capture format),
or a substantially similar assay.
[0127] The present invention includes antibodies, antigen-binding
fragments, and bispecific antibodies thereof that bind human CD3
and induce T cell activation. For example, the present invention
includes anti-CD3 antibodies that induce human T cell activation
with an EC.sub.50 value of less than about 113 pM, as measured by
an in vitro T cell activation assay, e.g., using the assay format
as defined in Example 6 herein [e.g., assessing the percent
activated (CD69+) cells out of total T cells (CD2+) in the presence
of anti-CD3 antibodies], or a substantially similar assay that
assesses T cell in their activated state. In certain embodiments,
the antibodies or antigen-binding fragments of the present
invention induce human T cell activation [e.g., percent activated
(CD69+) T cells] with an EC.sub.50 value of less than about 100 pM,
less than about 50 pM, less than about 20 pM, less than about 19
pM, less than about 18 pM, less than about 17 pM, less than about
16 pM, less than about 15 pM, less than about 14 pM, less than
about 13 pM, less than about 12 pM, less than about 11 pM, less
than about 10 pM, less than about 9 pM, less than about 8 pM, less
than about 7 pM, less than about 6 pM, less than about 5 pM, less
than about 4 pM, less than about 3 pM, less than about 2 pM, or
less than about 1 pM, as measured by an in vitro T cell activation
assay, e.g., using the assay format as defined in Example 6 herein,
or a substantially similar assay. Anti-CD3 antibodies that have
weak or no detectable binding to CD3 have the ability to induce T
cell activation with high potency (i.e. pM range), despite having
weak or no detectable binding affinity to CD3, as exemplified in
Example 6 herein.
[0128] The present invention also includes antibodies,
antigen-binding fragments, and bispecific antibodies that bind
human CD3 and induce T cell-mediated killing of tumor
antigen-expressing cells. For example, the present invention
includes anti-CD3 antibodies that induce T cell-mediated killing of
tumor cells with an EC.sub.50 of less than about 1.3 nM, as
measured in an in vitro T cell-mediated tumor cell killing assay,
e.g., using the assay format as defined in Example 6 herein (e.g.,
assessing the extent of tumor antigen-expressing cells, such as
PSMA-expressing, EGFRvIII-expressing or MUC16-expressing cell
killing by human PBMCs in the presence of anti-CD3 antibodies), or
a substantially similar assay. In certain embodiments, the
antibodies or antigen-binding fragments of the present invention
induce T cell-mediated tumor cell killing (e.g., PBMC-mediated
killing of OVCAR3 cells) with an EC.sub.50 value of less than about
1 nM, less than about 400 pM, less than about 250 pM, less than
about 100 pM, less than about 50 pM, less than about 40 pM, less
than about 30 pM, less than about 20 pM, less than about 10 pM,
less than about 9 pM, less than about 8 pM, less than about 7 pM,
less than about 6 pM, less than about 5 pM, less than about 4 pM,
less than about 3 pM, less than about 2 pM, or less than about 1
pM, as measured by an in vitro T cell-mediated tumor cell killing
assay, e.g., using the assay format as defined in Example 6 herein,
or a substantially similar assay.
[0129] The present invention also includes antibodies,
antigen-binding fragments, and bispecific antibodies that bind CD3
with a dissociative half-life (t1/2) of less than about 10 minutes
as measured by surface plasmon resonance at 25.degree. C. or
37.degree. C., e.g., using an assay format as defined in Example 5
herein, or a substantially similar assay. In certain embodiments,
the antibodies or antigen-binding fragments of the present
invention bind CD3 with a t1/2 of less than about 9 minutes, of
less than about 8 minutes, of less than about 7 minutes, of less
than about 6 minutes, of less than about 5 minutes, of less than
about 4 minutes, of less than about 3 minutes, of less than about 2
minutes, of less than about 1.9 minutes, or less than about 1.8
minutes, or exhibit very weak or no detectable binding as measured
by surface plasmon resonance at 25.degree. C. or 37.degree. C.,
e.g., using an assay format as defined in Example 5 herein (e.g.,
mAb-capture or antigen-capture format), or a substantially similar
assay.
[0130] The anti-CD3/anti-TAA bispecific antigen-binding molecules
of the present invention may additionally exhibit one or more
characteristics selected from the group consisting of: (a) inducing
PBMC proliferation in vitro; (b) activating T-cells via inducing
IFN-gamma release and CD25 up-regulation in human whole blood; and
(c) inducing T-cell mediated cytotoxicity on anti-TAA-resistant
cell lines.
[0131] The present invention includes anti-CD3/anti-TAA bispecific
antigen-binding molecules which are capable of depleting tumor
antigen-expressing cells in a subject (see, e.g., Example 7). For
example, according to certain embodiments, anti-CD3/anti-PSMA,
anti-CD3/anti-MUC16, or anti-CD3/anti-STEAP2 bispecific
antigen-binding molecules are provided, wherein a single
administration of 1 .mu.g, or 10 .mu.g, or 100 .mu.g of the
bispecific antigen-binding molecule to a subject (e.g., at a dose
of about 0.1 mg/kg, about 0.08 mg/kg, about 0.06 mg/kg about 0.04
mg/kg, about 0.04 mg/kg, about 0.02 mg/kg, about 0.01 mg/kg, or
less) causes a reduction in the number of tumor antigen-expressing
cells in the subject (e.g., tumor growth in the subject is
suppressed or inhibited) below detectable levels. In certain
embodiments, a single administration of the anti-CD3/anti-PSMA
bispecific antigen-binding molecule at a dose of about 0.4 mg/kg
causes a reduction in tumor growth in the subject below detectable
levels by about day 7, about day 6, about day 5, about day 4, about
day 3, about day 2, or about day 1 after administration of the
bispecific antigen-binding molecule to the subject. According to
certain embodiments, a single administration of an
anti-CD3/anti-PSMA bispecific antigen-binding molecule of the
invention, at a dose of at least about 0.01 mg/kg, causes the
number of PSMA-expressing tumor cells to remain below detectable
levels until at least about 7 days, 8 days, 9 days, 10 days, 11
days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days or more,
following the administration. As used herein, the expression "below
detectable levels" means that no tumor cells can be directly or
indirectly detected growing subcutaneously in a subject using
standard caliper measurement methods, e.g., as set forth in Example
7, herein. In certain embodiments, a single administration of the
anti-CD3/anti-MUC16 bispecific antigen-binding molecule at a dose
of about 10 .mu.g causes a suppression of tumor growth in the
subject at about day 6, and maintains tumor suppression until at
least day 26 after administration of the bispecific antigen-binding
molecule to the subject. In subjects receiving a single
administration of the anti-CD3/anti-MUC16 bispecific
antigen-binding molecule at a dose of about 10 .mu.g at least 7
days after tumor implantation, the bispecific antigen-binding
molecule exhibits efficacy in suppression of established tumors
from further growth in the subject at about day 26 after tumor
implantation in the subject. According to certain embodiments, a
single administration of an anti-CD3/anti-MUC16 bispecific
antigen-binding molecule of the invention, at a dose of at least
about 0.1 mg/kg, inhibits growth of MUC16-expressing tumor cells
for at least about 7 days, 8 days, 9 days, 10 days, 11 days, 12
days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19
days, 20 days or more, following administration of the bispecific
molecule. See, e.g. Example 8.
[0132] In certain embodiments, a single administration of the
anti-CD3/anti-STEAP2 bispecific antigen-binding molecule at a dose
of about 0.1 mg/kg or 0.01 mg/kg maintains a suppression of tumor
growth until at least day 46 after administration of the bispecific
antigen-binding molecule and tumor to the subject. According to
certain embodiments, a single administration of an
anti-CD3/anti-STEAP2 bispecific antigen-binding molecule of the
invention, at a dose of at least about 0.1 mg/kg, about 0.08 mg/kg,
about 0.06 mg/kg, about 0.05 mg/kg, about 0.04 mg/kg, about 0.03
mg/kg, about 0.02 mg/kg, about 0.01 mg/kg, or less inhibits growth
of STEAP2-expressing tumor cells for at least about 20 days, 30
days, 35 days, 40 days, 45 days or more, following administration
of the bispecific molecule. See, e.g. Example 10.
[0133] In other embodiments, anti-CD3/anti-TAA bispecific
antigen-binding molecules having a CD3 targeted binding arm having
weak binding affinity to effector cells exhibit reduced drug
elimination rates compared to the bispecific antibodies comprising
the same anti-TAA binding arm and a strong CD3 binding arm
administered in an in vivo pharmacokinetic study. The results
suggest that the bispecific molecules comprising weaker binding of
the CD3 targeting arm may exhibit beneficial drug exposure levels
(AUC.sub.last) and drug elimination profiles (antibody clearance).
See, e.g., Example 9.
[0134] The present invention provides anti-CD3/anti-PSMA,
anti-CD3/anti-MUC16 and anti-CD3/anti-STEAP2 bispecific
antigen-binding molecules (i.e. anti-CD3/anti-TAA bispecific
antigen-binding molecules) which exhibit one or more
characteristics selected from the group consisting of: (a)
inhibiting tumor growth in immunocompromised mice bearing human
prostate cancer xenografts; (b) inhibiting tumor growth in
immunocompetent mice bearing human prostate cancer xenografts; (c)
suppressing tumor growth of established tumors in immunocompromised
mice bearing human prostate cancer xenografts; and (d) reducing
tumor growth of established tumors in immunocompetent mice bearing
human prostate cancer xenografts (see, e.g., Examples 7, 8 and 10).
The present invention also provides anti-CD3/anti-PSMA,
anti-CD3/anti-MUC16 and anti-CD3/anti-STEAP2 bispecific antibodies
(i.e. anti-CD3/anti-TAA bispecific antibodies) comprising a first
heavy chain directed to an effector T cell (i.e. CD3), and ii) a
second heavy chain directed to a target tumor cell, wherein the
bispecific antibodies exhibit weak binding or no detectable binding
to the effector cells, and exhibit tumor growth suppression and
reduced antibody clearance (i.e. elimination) from the body
compared to bispecific antibodies that exhibit strong binding to
effector cells.
Epitope Mapping and Related Technologies
[0135] The epitope on CD3 to which the antigen-binding molecules of
the present invention bind may consist of a single contiguous
sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20 or more) amino acids of a CD3 protein.
Alternatively, the epitope may consist of a plurality of
non-contiguous amino acids (or amino acid sequences) of CD3. The
antibodies of the invention may interact with amino acids contained
within a single CD3 chain (e.g., CD3-epsilon, CD3-delta or
CD3-gamma), or may interact with amino acids on two or more
different CD3 chains. The term "epitope," as used herein, refers to
an antigenic determinant that interacts with a specific antigen
binding site in the variable region of an antibody molecule known
as a paratope. A single antigen may have more than one epitope.
Thus, different antibodies may bind to different areas on an
antigen and may have different biological effects. Epitopes may be
either conformational or linear. A conformational epitope is
produced by spatially juxtaposed amino acids from different
segments of the linear polypeptide chain. A linear epitope is one
produced by adjacent amino acid residues in a polypeptide chain. In
certain circumstances, an epitope may include moieties of
saccharides, phosphoryl groups, or sulfonyl groups on the
antigen.
[0136] Various techniques known to persons of ordinary skill in the
art can be used to determine whether an antigen-binding domain of
an antibody "interacts with one or more amino acids" within a
polypeptide or protein. Exemplary techniques include, e.g., routine
cross-blocking assay such as that described Antibodies, Harlow and
Lane (Cold Spring Harbor Press, Cold Spring Harb., NY), alanine
scanning mutational analysis, peptide blots analysis (Reineke,
2004, Methods Mol Biol 248:443-463), and peptide cleavage analysis.
In addition, methods such as epitope excision, epitope extraction
and chemical modification of antigens can be employed (Tomer, 2000,
Protein Science 9:487-496). Another method that can be used to
identify the amino acids within a polypeptide with which an
antigen-binding domain of an antibody interacts is
hydrogen/deuterium exchange detected by mass spectrometry. In
general terms, the hydrogen/deuterium exchange method involves
deuterium-labeling the protein of interest, followed by binding the
antibody to the deuterium-labeled protein. Next, the
protein/antibody complex is transferred to water to allow
hydrogen-deuterium exchange to occur at all residues except for the
residues protected by the antibody (which remain
deuterium-labeled). After dissociation of the antibody, the target
protein is subjected to protease cleavage and mass spectrometry
analysis, thereby revealing the deuterium-labeled residues which
correspond to the specific amino acids with which the antibody
interacts. See, e.g., Ehring (1999) Analytical Biochemistry
267(2):252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A.
X-ray crystallography of the antigen/antibody complex may also be
used for epitope mapping purposes.
[0137] The present invention further includes anti-PSMA antibodies
that bind to the same epitope as any of the specific exemplary
antibodies described herein (e.g. antibodies comprising any of the
amino acid sequences as set forth in Table 6 herein). Likewise, the
present invention also includes anti-PSMA antibodies that compete
for binding to PSMA with any of the specific exemplary antibodies
described herein (e.g. antibodies comprising any of the amino acid
sequences as set forth in Table 6 herein). Anti-PSMA antibodies
disclosed in U.S. application Ser. No. 15/223,434 are herein
incorporated by reference into this application.
[0138] The present invention also includes bispecific
antigen-binding molecules comprising a first antigen-binding domain
that specifically binds human CD3 and/or cynomolgus CD3 with low or
detectable binding affinity, and a second antigen binding domain
that specifically binds human tumor-associated antigen (TAA),
wherein the first antigen-binding domain binds to the same epitope
on CD3 as any of the specific exemplary CD3-specific
antigen-binding domains described herein.
[0139] Likewise, the present invention also includes bispecific
antigen-binding molecules comprising a first antigen-binding domain
that specifically binds human CD3 and/or cynomolgus CD3 with low or
detectable binding affinity, and a second antigen binding domain
that specifically binds human tumor-associated antigen (TAA),
wherein the first antigen-binding domain competes for binding to
CD3 with any of the specific exemplary CD3-specific antigen-binding
domains described herein.
[0140] One can easily determine whether a particular
antigen-binding molecule (e.g., antibody) or antigen-binding domain
thereof binds to the same epitope as, or competes for binding with,
a reference antigen-binding molecule of the present invention by
using routine methods known in the art. For example, to determine
if a test antibody binds to the same epitope on CD3 (or TAA) as a
reference bispecific antigen-binding molecule of the present
invention, the reference bispecific molecule is first allowed to
bind to a CD3 protein (or TAA protein). Next, the ability of a test
antibody to bind to the CD3 molecule is assessed. If the test
antibody is able to bind to CD3 (or TAA) following saturation
binding with the reference bispecific antigen-binding molecule, it
can be concluded that the test antibody binds to a different
epitope of CD3 (or TAA) than the reference bispecific
antigen-binding molecule. On the other hand, if the test antibody
is not able to bind to the CD3 (or TAA) molecule following
saturation binding with the reference bispecific antigen-binding
molecule, then the test antibody may bind to the same epitope of
CD3 (or TAA) as the epitope bound by the reference bispecific
antigen-binding molecule of the invention. Additional routine
experimentation (e.g., peptide mutation and binding analyses) can
then be carried out to confirm whether the observed lack of binding
of the test antibody is in fact due to binding to the same epitope
as the reference bispecific antigen-binding molecule or if steric
blocking (or another phenomenon) is responsible for the lack of
observed binding. If the reference antibody is one that has no
measurable binding as exemplified herein, then the reference
antibody may be mutated back to germline sequence in order to
determine binding to the CD3 for purpose of comparing epitope
interaction, or comparing its binding properties to the test
antibody as described herein. Experiments of this sort can be
performed using ELISA, RIA, Biacore, flow cytometry or any other
quantitative or qualitative antibody-binding assay available in the
art. In accordance with certain embodiments of the present
invention, two antigen-binding proteins bind to the same (or
overlapping) epitope if, e.g., a 1-, 5-, 10-, 20- or 100-fold
excess of one antigen-binding protein inhibits binding of the other
by at least 50% but preferably 75%, 90% or even 99% as measured in
a competitive binding assay (see, e.g., Junghans et al., Cancer
Res. 1990:50:1495-1502). Alternatively, two antigen-binding
proteins are deemed to bind to the same epitope if essentially all
amino acid mutations in the antigen that reduce or eliminate
binding of one antigen-binding protein reduce or eliminate binding
of the other. Two antigen-binding proteins are deemed to have
"overlapping epitopes" if only a subset of the amino acid mutations
that reduce or eliminate binding of one antigen-binding protein
reduce or eliminate binding of the other.
[0141] To determine if an antibody or antigen-binding domain
thereof competes for binding with a reference antigen-binding
molecule, the above-described binding methodology is performed in
two orientations: In a first orientation, the reference
antigen-binding molecule is allowed to bind to a CD3 protein (or
TAA protein) under saturating conditions followed by assessment of
binding of the test antibody to the CD3 (or TAA) molecule. In a
second orientation, the test antibody is allowed to bind to a CD3
(or TAA) molecule under saturating conditions followed by
assessment of binding of the reference antigen-binding molecule to
the CD3 (or TAA) molecule. If, in both orientations, only the first
(saturating) antigen-binding molecule is capable of binding to the
CD3 (or TAA) molecule, then it is concluded that the test antibody
and the reference antigen-binding molecule compete for binding to
CD3 (or TAA). As will be appreciated by a person of ordinary skill
in the art, an antibody that competes for binding with a reference
antigen-binding molecule may not necessarily bind to the same
epitope as the reference antibody, but may sterically block binding
of the reference antibody by binding an overlapping or adjacent
epitope. If the reference antibody is one that has no measurable
binding as exemplified herein, then the reference antibody may be
mutated back to germline sequence in order to determine binding to
the CD3 for purpose of comparing epitope interaction, or comparing
its binding properties or blocking interaction with the test
antibody as described herein.
Preparation of Antigen-Binding Domains and Construction of
Bispecific Molecules
[0142] Antigen-binding domains specific for particular antigens can
be prepared by any antibody generating technology known in the art.
Once obtained, two different antigen-binding domains, specific for
two different antigens (e.g., CD3 and TAA), can be appropriately
arranged relative to one another to produce a bispecific
antigen-binding molecule of the present invention using routine
methods. (A discussion of exemplary bispecific antibody formats
that can be used to construct the bispecific antigen-binding
molecules of the present invention is provided elsewhere herein).
In certain embodiments, one or more of the individual components
(e.g., heavy and light chains) of the multispecific antigen-binding
molecules of the invention are derived from chimeric, humanized or
fully human antibodies. Methods for making such antibodies are well
known in the art. For example, one or more of the heavy and/or
light chains of the bispecific antigen-binding molecules of the
present invention can be prepared using VELOCIMMUNE.TM. technology.
Using VELOCIMMUNE.TM. technology (or any other human antibody
generating technology), high affinity chimeric antibodies to a
particular antigen (e.g., CD3 or TAA) are initially isolated having
a human variable region and a mouse constant region. The antibodies
are characterized and selected for desirable characteristics,
including affinity, selectivity, epitope, etc. The mouse constant
regions are replaced with a desired human constant region to
generate fully human heavy and/or light chains that can be
incorporated into the bispecific antigen-binding molecules of the
present invention.
[0143] Genetically engineered animals may be used to make human
bispecific antigen-binding molecules. For example, a genetically
modified mouse can be used which is incapable of rearranging and
expressing an endogenous mouse immunoglobulin light chain variable
sequence, wherein the mouse expresses only one or two human light
chain variable domains encoded by human immunoglobulin sequences
operably linked to the mouse kappa (.kappa.) constant gene at the
endogenous mouse kappa (.kappa.) locus. Such genetically modified
mice can be used to produce fully human bispecific antigen-binding
molecules comprising two different heavy chains that associate with
an identical light chain that comprises a variable domain derived
from one of two different human light chain variable region gene
segments. (See, e.g., US 2011/0195454 for a detailed discussion of
such engineered mice and the use thereof to produce bispecific
antigen-binding molecules). Antibodies of the invention may
comprise immunoglobulin heavy chains associated with a common light
chain. The common light chain may be derived from a cognate light
chain of the anti-TAA heavy chain, or derived from a known or
public domain light chain variable region derived from a light
chain exhibiting promiscuity or ability to pair with a wide variety
of non-cognate heavy chains, i.e. a universal or common light
chain. Antibodies of the invention may comprise immunoglobulin
heavy chains associated with a single rearranged light chain. In
some embodiments, the light chain a variable domain derived from a
human V.kappa.1-39 gene segment or a V.kappa.3-20 gene segment. In
other embodiments, the light chain comprises a variable domain
derived from a human V.kappa.1-39 gene segment rearranged with a
human J.kappa.5 or a human J.kappa.1 gene segment, or a
V.kappa.3-20 gene segment rearranged with a human J.kappa.1 gene
segment, or a V.kappa.1-39 gene segment rearranged with a human
J.kappa.1 gene segment.
Bioequivalents
[0144] The present invention encompasses antigen-binding molecules
having amino acid sequences that vary from those of the exemplary
molecules disclosed herein but that retain the ability to bind or
interact with CD3 and/or TAA. Such variant molecules may comprise
one or more additions, deletions, or substitutions of amino acids
when compared to parent sequence, but exhibit biological activity
that is essentially equivalent to that of the described bispecific
antigen-binding molecules.
[0145] The present invention includes antigen-binding molecules
that are bioequivalent to any of the exemplary antigen-binding
molecules set forth herein. Two antigen-binding proteins, or
antibodies, are considered bioequivalent if, for example, they are
pharmaceutical equivalents or pharmaceutical alternatives whose
rate and extent of absorption do not show a significant difference
when administered at the same molar dose under similar experimental
conditions, either single does or multiple dose. Some
antigen-binding proteins will be considered equivalents or
pharmaceutical alternatives if they are equivalent in the extent of
their absorption but not in their rate of absorption and yet may be
considered bioequivalent because such differences in the rate of
absorption are intentional and are reflected in the labeling, are
not essential to the attainment of effective body drug
concentrations on, e.g., chronic use, and are considered medically
insignificant for the particular drug product studied.
[0146] In one embodiment, two antigen-binding proteins are
bioequivalent if there are no clinically meaningful differences in
their safety, purity, and potency.
[0147] In one embodiment, two antigen-binding proteins are
bioequivalent if a patient can be switched one or more times
between the reference product and the biological product without an
expected increase in the risk of adverse effects, including a
clinically significant change in immunogenicity, or diminished
effectiveness, as compared to continued therapy without such
switching.
[0148] In one embodiment, two antigen-binding proteins are
bioequivalent if they both act by a common mechanism or mechanisms
of action for the condition or conditions of use, to the extent
that such mechanisms are known.
[0149] Bioequivalence may be demonstrated by in vivo and in vitro
methods. Bioequivalence measures include, e.g., (a) an in vivo test
in humans or other mammals, in which the concentration of the
antibody or its metabolites is measured in blood, plasma, serum, or
other biological fluid as a function of time; (b) an in vitro test
that has been correlated with and is reasonably predictive of human
in vivo bioavailability data; (c) an in vivo test in humans or
other mammals in which the appropriate acute pharmacological effect
of the antibody (or its target) is measured as a function of time;
and (d) in a well-controlled clinical trial that establishes
safety, efficacy, or bioavailability or bioequivalence of an
antigen-binding protein.
[0150] Bioequivalent variants of the exemplary bispecific
antigen-binding molecules set forth herein may be constructed by,
for example, making various substitutions of residues or sequences
or deleting terminal or internal residues or sequences not needed
for biological activity. For example, cysteine residues not
essential for biological activity can be deleted or replaced with
other amino acids to prevent formation of unnecessary or incorrect
intramolecular disulfide bridges upon renaturation. In other
contexts, bioequivalent antigen-binding proteins may include
variants of the exemplary bispecific antigen-binding molecules set
forth herein comprising amino acid changes which modify the
glycosylation characteristics of the molecules, e.g., mutations
which eliminate or remove glycosylation.
Species Selectivity and Species Cross-Reactivity
[0151] According to certain embodiments of the invention,
antigen-binding molecules are provided which display weak or no
interaction with human CD3 and weak or no interaction with CD3 from
other species, such as cynomolgous monkey CD3. Also provided are
antigen-binding molecules which bind to human TAA but not to TAA
from other species. The present invention also includes
antigen-binding molecules that bind to human CD3 and to CD3 from
one or more non-human species; and/or antigen-binding molecules
that bind to human TAA and to TAA from one or more non-human
species.
[0152] According to certain exemplary embodiments of the invention,
antigen-binding molecules are provided which bind weakly to human
CD3 and/or human TAA and may bind or not bind, as the case may be,
to one or more of mouse, rat, guinea pig, hamster, gerbil, pig,
cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus,
marmoset, rhesus or chimpanzee CD3 and/or TAA. For example, in
certain exemplary embodiments of the present invention bispecific
antigen-binding molecules are provided comprising a first
antigen-binding domain that weakly binds human CD3 and cynomolgus
CD3, and a second antigen-binding domain that specifically binds
human PSMA, MUC16, EGFRvIII or STEAP2.
Immunoconjugates
[0153] The present invention encompasses antigen-binding molecules
conjugated to a therapeutic moiety ("immunoconjugate"), such as a
cytotoxin, a chemotherapeutic drug, an immunosuppressant or a
radioisotope. Cytotoxic agents include any agent that is
detrimental to cells. Examples of suitable cytotoxic agents and
chemotherapeutic agents for forming immunoconjugates are known in
the art, (see for example, WO 05/103081).
Therapeutic Formulation and Administration
[0154] The present invention provides pharmaceutical compositions
comprising the antigen-binding molecules of the present invention.
The pharmaceutical compositions of the invention are formulated
with suitable carriers, excipients, and other agents that provide
improved transfer, delivery, tolerance, and the like. A multitude
of appropriate formulations can be found in the formulary known to
all pharmaceutical chemists: Remington's Pharmaceutical Sciences,
Mack Publishing Company, Easton, Pa. These formulations include,
for example, powders, pastes, ointments, jellies, waxes, oils,
lipids, lipid (cationic or anionic) containing vesicles (such as
LIPOFECTIN.TM., Life Technologies, Carlsbad, Calif.), DNA
conjugates, anhydrous absorption pastes, oil-in-water and
water-in-oil emulsions, emulsions carbowax (polyethylene glycols of
various molecular weights), semi-solid gels, and semi-solid
mixtures containing carbowax. See also Powell et al. "Compendium of
excipients for parenteral formulations" PDA (1998) J Pharm Sci
Technol 52:238-311.
[0155] The dose of antigen-binding molecule administered to a
patient may vary depending upon the age and the size of the
patient, target disease, conditions, route of administration, and
the like. The preferred dose is typically calculated according to
body weight or body surface area. When a bispecific antigen-binding
molecule of the present invention is used for therapeutic purposes
in an adult patient, it may be advantageous to intravenously
administer the bispecific antigen-binding molecule of the present
invention normally at a single dose of about 0.01 to about 20 mg/kg
body weight, more preferably about 0.02 to about 7, about 0.03 to
about 5, or about 0.05 to about 3 mg/kg body weight. Depending on
the severity of the condition, the frequency and the duration of
the treatment can be adjusted. Effective dosages and schedules for
administering a bispecific antigen-binding molecule may be
determined empirically; for example, patient progress can be
monitored by periodic assessment, and the dose adjusted
accordingly. Moreover, interspecies scaling of dosages can be
performed using well-known methods in the art (e.g., Mordenti et
al., 1991, Pharmaceut. Res. 8:1351).
[0156] Various delivery systems are known and can be used to
administer the pharmaceutical composition of the invention, e.g.,
encapsulation in liposomes, microparticles, microcapsules,
recombinant cells capable of expressing the mutant viruses,
receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol.
Chem. 262:4429-4432). Methods of introduction include, but are not
limited to, intradermal, intramuscular, intraperitoneal,
intravenous, subcutaneous, intranasal, epidural, and oral routes.
The composition may be administered by any convenient route, for
example by infusion or bolus injection, by absorption through
epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and
intestinal mucosa, etc.) and may be administered together with
other biologically active agents. Administration can be systemic or
local.
[0157] A pharmaceutical composition of the present invention can be
delivered subcutaneously or intravenously with a standard needle
and syringe. In addition, with respect to subcutaneous delivery, a
pen delivery device readily has applications in delivering a
pharmaceutical composition of the present invention. Such a pen
delivery device can be reusable or disposable. A reusable pen
delivery device generally utilizes a replaceable cartridge that
contains a pharmaceutical composition. Once all of the
pharmaceutical composition within the cartridge has been
administered and the cartridge is empty, the empty cartridge can
readily be discarded and replaced with a new cartridge that
contains the pharmaceutical composition. The pen delivery device
can then be reused. In a disposable pen delivery device, there is
no replaceable cartridge. Rather, the disposable pen delivery
device comes prefilled with the pharmaceutical composition held in
a reservoir within the device. Once the reservoir is emptied of the
pharmaceutical composition, the entire device is discarded.
[0158] Numerous reusable pen and autoinjector delivery devices have
applications in the subcutaneous delivery of a pharmaceutical
composition of the present invention. Examples include, but are not
limited to AUTOPEN.TM. (Owen Mumford, Inc., Woodstock, UK),
DISETRONIC.TM. pen (Disetronic Medical Systems, Bergdorf,
Switzerland), HUMALOG MIX 75/25.TM. pen, HUMALOG.TM. pen, HUMALIN
70/30.TM. pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN.TM.
I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN
JUNIOR.TM. (Novo Nordisk, Copenhagen, Denmark), BD.TM. pen (Becton
Dickinson, Franklin Lakes, N.J.), OPTIPEN.TM., OPTIPEN PRO.TM.,
OPTIPEN STARLET.TM., and OPTICLIK.TM. (sanofi-aventis, Frankfurt,
Germany), to name only a few. Examples of disposable pen delivery
devices having applications in subcutaneous delivery of a
pharmaceutical composition of the present invention include, but
are not limited to the SOLOSTAR.TM. pen (sanofi-aventis), the
FLEXPEN.TM. (Novo Nordisk), and the KWIKPEN.TM. (Eli Lilly), the
SURECLICK.TM. Autoinjector (Amgen, Thousand Oaks, Calif.), the
PENLET.TM. (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey,
L.P.), and the HUMIRA.TM. Pen (Abbott Labs, Abbott Park Ill.), to
name only a few.
[0159] In certain situations, the pharmaceutical composition can be
delivered in a controlled release system. In one embodiment, a pump
may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref.
Biomed. Eng. 14:201). In another embodiment, polymeric materials
can be used; see, Medical Applications of Controlled Release,
Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla. In yet
another embodiment, a controlled release system can be placed in
proximity of the composition's target, thus requiring only a
fraction of the systemic dose (see, e.g., Goodson, 1984, in Medical
Applications of Controlled Release, supra, vol. 2, pp. 115-138).
Other controlled release systems are discussed in the review by
Langer, 1990, Science 249:1527-1533.
[0160] The injectable preparations may include dosage forms for
intravenous, subcutaneous, intracutaneous and intramuscular
injections, drip infusions, etc. These injectable preparations may
be prepared by methods publicly known. For example, the injectable
preparations may be prepared, e.g., by dissolving, suspending or
emulsifying the antibody or its salt described above in a sterile
aqueous medium or an oily medium conventionally used for
injections. As the aqueous medium for injections, there are, for
example, physiological saline, an isotonic solution containing
glucose and other auxiliary agents, etc., which may be used in
combination with an appropriate solubilizing agent such as an
alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol,
polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80,
HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor
oil)], etc. As the oily medium, there are employed, e.g., sesame
oil, soybean oil, etc., which may be used in combination with a
solubilizing agent such as benzyl benzoate, benzyl alcohol, etc.
The injection thus prepared is preferably filled in an appropriate
ampoule.
[0161] Advantageously, the pharmaceutical compositions for oral or
parenteral use described above are prepared into dosage forms in a
unit dose suited to fit a dose of the active ingredients. Such
dosage forms in a unit dose include, for example, tablets, pills,
capsules, injections (ampoules), suppositories, etc. The amount of
the aforesaid antibody contained is generally about 5 to about 500
mg per dosage form in a unit dose; especially in the form of
injection, it is preferred that the aforesaid antibody is contained
in about 5 to about 100 mg and in about 10 to about 250 mg for the
other dosage forms.
Therapeutic Uses of the Antigen-Binding Molecules
[0162] The present invention includes methods comprising
administering to a subject in need thereof a therapeutic
composition comprising an anti-tumor antibody or antigen-binding
fragment thereof, or a bispecific antigen-binding molecule that
specifically binds weakly or has no detectable binding to CD3 and
binds a tumor-associated antigen. The therapeutic composition can
comprise any of the antibodies or bispecific antigen-binding
molecules as disclosed herein and a pharmaceutically acceptable
carrier or diluent. As used herein, the expression "a subject in
need thereof" means a human or non-human animal that exhibits one
or more symptoms or indicia of cancer (e.g., a subject expressing a
tumor or suffering from any of the cancers mentioned herein below),
or who otherwise would benefit from an inhibition or reduction in
tumor activity or a depletion of tumor cells (e.g., PSMA++ prostate
cancer cells).
[0163] The antibodies and bispecific antigen-binding molecules of
the invention (and therapeutic compositions comprising the same)
are useful, inter alia, for treating any disease or disorder in
which stimulation, activation and/or targeting of an immune
response would be beneficial. In particular, the bispecific
antigen-binding molecules of the present invention may be used for
the treatment, prevention and/or amelioration of any disease or
disorder associated with or mediated by a cell expressing a TAA,
e.g. PSMA expression or activity or the proliferation of PSMA+
cells. The mechanism of action by which the therapeutic methods of
the invention are achieved include killing of the cells expressing
tumor-associated antigens, in the presence of effector cells, for
example, by CDC, apoptosis, ADCC, phagocytosis, or by a combination
of two or more of these mechanisms. Cells expressing
tumor-associated antigens, such as PSMA, MUC16, STEAP2 or EGFRvIII,
which can be inhibited or killed using the bispecific
antigen-binding molecules of the invention include, for example,
prostate tumor cells.
[0164] The antigen-binding molecules of the present invention may
be used to treat, e.g., primary and/or metastatic tumors arising in
the brain and meninges, head and neck, oropharynx, lung and
bronchial tree, gastrointestinal tract, male and female
reproductive tract, muscle, bone, skin and appendages, connective
tissue, spleen, immune system, blood forming cells and bone marrow,
liver and urinary tract, kidney, bladder and/or special sensory
organs such as the eye. In certain embodiments, the bispecific
antigen-binding molecules of the invention are used to treat one or
more of, but not limited to, the following cancers: pancreatic
carcinoma, head and neck cancer, prostate cancer, malignant
gliomas, osteosarcoma, colorectal cancer, gastric cancer (e.g.,
gastric cancer with MET amplification), malignant mesothelioma,
multiple myeloma, ovarian cancer, small cell lung cancer, non-small
cell lung cancer, synovial sarcoma, thyroid cancer, breast cancer,
melanomaglioma, breast cancer (e.g. ductal or intraductal breast
carcinoma, squamous cell carcinoma, esophageal cancer, clear cell
renal cell carcinoma, chromophobe renal cell carcinoma, (renal)
oncocytoma, (renal) transitional cell carcinoma, urothelial
carcinoma, (bladder) adenocarcinoma, or (bladder) small cell
carcinoma. According to certain embodiments of the present
invention, the bispecific antibodies are useful for treating a
patient afflicted with a refractory or treatment-resistant cancer,
e.g. castrate-resistant prostate cancer. According to exemplary
embodiments of the invention, methods are provided comprising
administering an anti-CD3/anti-PSMA bispecific antigen-binding
molecule as disclosed herein to a patient who is afflicted with a
castrate-resistant prostate cancer. Analytic/diagnostic methods
known in the art, such as tumor scanning, etc., may be used to
ascertain whether a patient harbors a tumor that is
castrate-resistant.
[0165] The present invention also includes methods for treating
residual cancer in a subject. As used herein, the term "residual
cancer" means the existence or persistence of one or more cancerous
cells in a subject following treatment with an anti-cancer therapy,
such as a first-line or standard therapy.
[0166] According to certain aspects, the present invention provides
methods for treating a cancer associated with TAA expression (e.g.,
prostate cancer associated with PSMA expression or STEAP2
expression, glioblastoma associated with EGFRvIII expression, or
ovarian cancer associated with MUC16 expression) comprising
administering one or more of the bispecific antigen-binding
molecules described elsewhere herein to a subject after the subject
has been determined to have the cancer. For example, the present
invention includes methods for treating prostate cancer comprising
administering an anti-CD3/anti-TAA bispecific antigen-binding
molecule to a patient 1 day, 2 days, 3 days, 4 days, 5 days, 6
days, 1 week, 2 weeks, 3 weeks or 4 weeks, 2 months, 4 months, 6
months, 8 months, 1 year, or more after the subject has received a
previous therapy.
Combination Therapies and Formulations
[0167] The present invention provides methods which comprise
administering a pharmaceutical composition comprising any of the
exemplary antibodies and bispecific antigen-binding molecules
described herein in combination with one or more additional
therapeutic agents. Exemplary additional therapeutic agents that
may be combined with or administered in combination with an
antigen-binding molecule of the present invention include, e.g., an
anti-Programmed Cell Death 1 antibody (e.g. an anti-PD1 antibody as
described in U.S. Pat. Appln. Pub. No. US2015/0203579A1), an
anti-Programmed Cell Death Ligand-1 (e.g. an anti-PD-L1 antibody as
described in U.S. Pat. Appln. Pub. No. US2015/0203580A1), an EGFR
antagonist (e.g., an anti-EGFR antibody [e.g., cetuximab or
panitumumab] or small molecule inhibitor of EGFR [e.g., gefitinib
or erlotinib]), an antagonist of another EGFR family member such as
Her2/ErbB2, ErbB3 or ErbB4 (e.g., anti-ErbB2, anti-ErbB3 or
anti-ErbB4 antibody or small molecule inhibitor of ErbB2, ErbB3 or
ErbB4 activity), an antagonist of EGFRvIII (e.g., an antibody that
specifically binds EGFRvIII), a cMET anagonist (e.g., an anti-cMET
antibody), an IGF1R antagonist (e.g., an anti-IGF1R antibody), a
B-raf inhibitor (e.g., vemurafenib, sorafenib, GDC-0879, PLX-4720),
a PDGFR-.alpha. inhibitor (e.g., an anti-PDGFR-.alpha. antibody), a
PDGFR-.beta. inhibitor (e.g., an anti-PDGFR-.beta. antibody), a
VEGF antagonist (e.g., a VEGF-Trap, see, e.g., U.S. Pat. No.
7,087,411 (also referred to herein as a "VEGF-inhibiting fusion
protein"), anti-VEGF antibody (e.g., bevacizumab), a small molecule
kinase inhibitor of VEGF receptor (e.g., sunitinib, sorafenib or
pazopanib)), a DLL4 antagonist (e.g., an anti-DLL4 antibody
disclosed in US 2009/0142354 such as REGN421), an Ang2 antagonist
(e.g., an anti-Ang2 antibody disclosed in US 2011/0027286 such as
H1H685P), a FOLH1 (PSMA) antagonist, a PRLR antagonist (e.g., an
anti-PRLR antibody), a STEAP1 or STEAP2 antagonist (e.g., an
anti-STEAP1 antibody or an anti-STEAP2 antibody), a TMPRSS2
antagonist (e.g., an anti-TMPRSS2 antibody), a MSLN antagonist
(e.g., an anti-MSLN antibody), a CA9 antagonist (e.g., an anti-CA9
antibody), a uroplakin antagonist (e.g., an anti-uroplakin
antibody), etc. Other agents that may be beneficially administered
in combination with the antigen-binding molecules of the invention
include cytokine inhibitors, including small-molecule cytokine
inhibitors and antibodies that bind to cytokines such as IL-1,
IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13,
IL-17, IL-18, or to their respective receptors. The pharmaceutical
compositions of the present invention (e.g., pharmaceutical
compositions comprising an anti-CD3/anti-PSMA bispecific
antigen-binding molecule as disclosed herein) may also be
administered as part of a therapeutic regimen comprising one or
more therapeutic combinations selected from "ICE": ifosfamide
(e.g., Ifex.RTM.), carboplatin (e.g., Paraplatin.RTM.), etoposide
(e.g., Etopophos.RTM., Toposar.RTM., VePesid.RTM., VP-16); "DHAP":
dexamethasone (e.g., Decadron.RTM.), cytarabine (e.g.,
Cytosar-U.RTM., cytosine arabinoside, ara-C), cisplatin (e.g.,
Platinol.RTM.-AQ); and "ESHAP": etoposide (e.g., Etopophos.RTM.,
Toposar.RTM., VePesid.RTM., VP-16), methylprednisolone (e.g.,
Medrol.RTM.), high-dose cytarabine, cisplatin (e.g.,
Platinol.RTM.-AQ).
[0168] The present invention also includes therapeutic combinations
comprising any of the antigen-binding molecules mentioned herein
and an inhibitor of one or more of VEGF, Ang2, DLL4, EGFR, ErbB2,
ErbB3, ErbB4, EGFRvIII, cMet, IGF1R, B-raf, PDGFR-.alpha.,
PDGFR-.beta., FOLH1 (PSMA), PRLR, STEAP1, STEAP2, TMPRSS2, MSLN,
CA9, uroplakin, or any of the aforementioned cytokines, wherein the
inhibitor is an aptamer, an antisense molecule, a ribozyme, an
siRNA, a peptibody, a nanobody or an antibody fragment (e.g., Fab
fragment; F(ab')2 fragment; Fd fragment; Fv fragment; scFv; dAb
fragment; or other engineered molecules, such as diabodies,
triabodies, tetrabodies, minibodies and minimal recognition units).
The antigen-binding molecules of the invention may also be
administered and/or co-formulated in combination with antivirals,
antibiotics, analgesics, corticosteroids and/or NSAIDs. The
antigen-binding molecules of the invention may also be administered
as part of a treatment regimen that also includes radiation
treatment and/or conventional chemotherapy.
[0169] The additional therapeutically active component(s) may be
administered just prior to, concurrent with, or shortly after the
administration of an antigen-binding molecule of the present
invention; (for purposes of the present disclosure, such
administration regimens are considered the administration of an
antigen-binding molecule "in combination with" an additional
therapeutically active component).
[0170] The present invention includes pharmaceutical compositions
in which an antigen-binding molecule of the present invention is
co-formulated with one or more of the additional therapeutically
active component(s) as described elsewhere herein.
Administration Regimens
[0171] According to certain embodiments of the present invention,
multiple doses of the bispecifc antigen-binding molecule (e.g., an
anti-TAA bispecific antigen-binding molecule) may be administered
to a subject over a defined time course. The methods according to
this aspect of the invention comprise sequentially administering to
a subject multiple doses of an antigen-binding molecule of the
invention. As used herein, "sequentially administering" means that
each dose of an antigen-binding molecule is administered to the
subject at a different point in time, e.g., on different days
separated by a predetermined interval (e.g., hours, days, weeks or
months). The present invention includes methods which comprise
sequentially administering to the patient a single initial dose of
an antigen-binding molecule, followed by one or more secondary
doses of the antigen-binding molecule, and optionally followed by
one or more tertiary doses of the antigen-binding molecule.
[0172] The terms "initial dose," "secondary doses," and "tertiary
doses," refer to the temporal sequence of administration of the
antigen-binding molecule of the invention. Thus, the "initial dose"
is the dose which is administered at the beginning of the treatment
regimen (also referred to as the "baseline dose"); the "secondary
doses" are the doses which are administered after the initial dose;
and the "tertiary doses" are the doses which are administered after
the secondary doses. The initial, secondary, and tertiary doses may
all contain the same amount of the antigen-binding molecule, but
generally may differ from one another in terms of frequency of
administration. In certain embodiments, however, the amount of an
antigen-binding molecule contained in the initial, secondary and/or
tertiary doses varies from one another (e.g., adjusted up or down
as appropriate) during the course of treatment. In certain
embodiments, two or more (e.g., 2, 3, 4, or 5) doses are
administered at the beginning of the treatment regimen as "loading
doses" followed by subsequent doses that are administered on a less
frequent basis (e.g., "maintenance doses").
[0173] In one exemplary embodiment of the present invention, each
secondary and/or tertiary dose is administered 1 to 26 (e.g., 1,
11/2, 2, 21/2, 3, 31/2, 4, 41/2, 5, 51/2, 6, 61/2, 7, 71/2, 8,
81/2, 9, 91/2, 10, 101/2, 11, 111/2, 12, 121/2, 13, 131/2, 14,
141/2, 15, 151/2, 16, 161/2, 17, 171/2, 18, 181/2, 19, 191/2, 20,
201/2, 21, 211/2, 22, 221/2, 23, 231/2, 24, 241/2, 25, 251/2, 26,
261/2, or more) weeks after the immediately preceding dose. The
phrase "the immediately preceding dose," as used herein, means, in
a sequence of multiple administrations, the dose of antigen-binding
molecule which is administered to a patient prior to the
administration of the very next dose in the sequence with no
intervening doses.
[0174] The methods according to this aspect of the invention may
comprise administering to a patient any number of secondary and/or
tertiary doses of an antigen-binding molecule (e.g., an anti-TAA
bispecific antigen-binding molecule). For example, in certain
embodiments, only a single secondary dose is administered to the
patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7,
8, or more) secondary doses are administered to the patient.
Likewise, in certain embodiments, only a single tertiary dose is
administered to the patient. In other embodiments, two or more
(e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are
administered to the patient.
[0175] In embodiments involving multiple secondary doses, each
secondary dose may be administered at the same frequency as the
other secondary doses. For example, each secondary dose may be
administered to the patient 1 to 2 weeks after the immediately
preceding dose. Similarly, in embodiments involving multiple
tertiary doses, each tertiary dose may be administered at the same
frequency as the other tertiary doses. For example, each tertiary
dose may be administered to the patient 2 to 4 weeks after the
immediately preceding dose. Alternatively, the frequency at which
the secondary and/or tertiary doses are administered to a patient
can vary over the course of the treatment regimen. The frequency of
administration may also be adjusted during the course of treatment
by a physician depending on the needs of the individual patient
following clinical examination.
EXAMPLES
[0176] The following examples are put forth so as to provide those
of ordinary skill in the art with a complete disclosure and
description of how to make and use the methods and compositions of
the invention, and are not intended to limit the scope of what the
inventors regard as their invention. Efforts have been made to
ensure accuracy with respect to numbers used (e.g., amounts,
temperature, etc.) but some experimental errors and deviations
should be accounted for. Unless indicated otherwise, parts are
parts by weight, molecular weight is average molecular weight,
temperature is in degrees Centigrade, and pressure is at or near
atmospheric.
Example 1: Generation of Anti-CD3 Antibodies
[0177] The following procedures were aimed at identifying
antibodies that specifically recognized CD3 (T cell co-receptor) as
an antigen.
[0178] A pool of anti-CD3 antibodies were derived by immunizing
genetically modified mice. Briefly, mice genetically engineered to
express reverse chimeric (human variable, mouse constant) and
immunoglobulin heavy chains associated with a single rearranged
light chain (e.g., a V.sub.K1-39/J or a V.sub.K3-20/J), were
immunized with a CD3 antigen and generated B cells that comprised a
diversity of human VH rearrangements in order to express a diverse
repertoire of high-affinity antigen-specific antibodies. Certain
exemplified antibodies described in the subject application have
been made recombinantly and express the same light chain sequence
of V.sub.K1-39J.kappa.5 (LCVR set forth in SEQ ID NO: 162), while
other antibodies made recombinantly express a cognate light chain
of one of the heavy chain arms (e.g. the tumor target arm).
[0179] Generated antibodies were tested for affinity to human and
cynomolgus monkey CD3 antigen in an in vitro binding assay, and
e.g. one CD3 antibody: designated CD3-VH-P (HCVR set forth in SEQ
ID NO: 154) was identified, amongst a few others, that were found
to bind to both human and cyno CD3 having an EC.sub.50 between 1
and 40 nM affinity (+++), as determined in a FACS titration of
Jurkat cells and cynomolgus T cells, respectively. See, e.g. FACS
binding experiments outlined in Example 4 herein below.
[0180] The germline amino acid residues of CD3-VH-P were
subsequently identified and an antibody designated "CD3-VH-G" was
engineered to contain only germline frameworks. Other antibody
derivatives were engineered by well-known molecular cloning
techniques to replace amino acid residues in a stepwise manner
based on differences between the germline sequence and the CD3-VH-P
sequence. Each antibody derivative is given a "CD3-VH-G" number
designation. See Table 1 and FIG. 1.
[0181] Bispecific antibodies, comprising a first binding arm
derived from the engineered anti-CD3 antibodies with the
designations and descriptions shown in Table 1, and a second
binding arm derived from anti-TAA antibodies, were prepared and
tested for monovalent affinity to CD3-bearing cells in a FACS assay
(as described in Example 4). The monovalent binding affinity
results of these bispecific antibodies are shown in the two right
columns of Table 1. In specific examples, bispecific antibodies
having a TAA-binding arm and a CD3-binding arm with designations
"CD3-VH-G," "CD3-VH-G5," and "CD3-VH-G20," respectively, bound
Jurkat cells with an EC.sub.50 of 2.7E-08, no detectable binding,
and 5.5E-07, respectively.
TABLE-US-00001 TABLE 1 Mutations to CDRs Based on the Germline
Sequence and Corresponding FACS Binding Affinity for Each
Engineered Antibody Antibody CD3-VH Description of Mutations
compared cyno T Designation to antibody CD3-VH-G* JURKAT cells
CD3-VH-G Germline (GL) only framework (+ + +) (+ + +) regions
(FRs); CD3-VHP CDRs CD3-VH-G2 All GL (FRs and CDRs). (-) (-)
CD3-VH-G3 All GL (FRs and CDRs). (-) (-) Add back A33S. CD3-VH-G4
All GL (FRs and CDRs). (-) (-) Add back Y105K CD3-VH-G5 All GL (FRs
and CDRs). (-) (-) Add back A33S and Y105K. CD3-VH-G8 Germline
frameworks. (+ + +) (+) Add back K58I CD3-VH-G9 Germline
frameworks. (+) (-) Add backY99D CD3-VH-G10 Germline frameworks.
(+) (-) Add back H108Y CD3-VH-G11 Germline frameworks. (+ + +) (+)
Add back L111M CD3-VH-G12 Germline frameworks. (+ +) (+/-) Add back
K58I, Y99D CD3-VH-G13 Germline frameworks. (+ +) (+) Add back K58I,
H108Y CD3-VH-G14 Germline frameworks. (+ + +) (+ +) Add back K58I,
L111M CD3-VH-G15 Germline frameworks. (+) (-) Add back Y99D, -H108Y
CD3-VH-G16 Germline frameworks. (+ +) (+/-) Add back Y99D, L111M
CD3-VH-G17 Germline frameworks. (+/-) (+/-) Add back H108Y, L111M
CD3-VH-G18 Germline frameworks. (+/-) (-) Add back K58I, Y99D,
H108Y CD3-VH-G19 Germline frameworks. (+/-) (-) Add back K58I,
Y99D, L111M CD3-VH-G20 Germline frameworks. (+/-) (+/-) Add back
K58I, H108Y, L111M CD3-VH-G21 Germline frameworks. (+/-) (-) Add
back Y99D, H108Y, -L111M *Sequential numbering based on 7221G
(CD3-VH-G) mature protein
[0182] While CD3-VH-G and some other engineered antibodies retained
their binding affinity as seen in the FACS assays, several anti-CD3
antibodies bound to human or cyno CD3 in vitro with weak (+/-) to
no (-) measurable affinity. Binding affinities, binding kinetics,
and other biological properties to elucidate toxicity and
pharmacokinetic (pK) profiles were subsequently investigated for
bispecific antibodies comprising the exemplary anti-CD3 antibodies
generated in accordance with the methods of this Example, and are
described in detail in the Examples set forth below.
Example 2: Heavy and Light Chain Variable Regions (Amino Acid and
Nucleic Acid Sequences of the CDRs)
[0183] Amino acid and nucleic acid sequences were determined for
each antibody heavy chain sequence. Each antibody heavy chain, as a
derivative of the germline sequence IGHV3-9*01/D5-12*01/J6*02 (SEQ
ID NO: 181) was assigned a "G" number designation for consistent
nomenclature. Table 2 sets forth the amino acid sequence
identifiers of the heavy chain variable regions and CDRs of the
engineered anti-CD3 antibodies of the invention. The corresponding
nucleic acid sequence identifiers are set forth in Table 3. The
amino acid and nucleic acid sequence identifiers of the light chain
variable region and CDRs to construct each recombinant antibody are
also identified below in Tables 4 and 5, respectively.
TABLE-US-00002 TABLE 2 Heavy Chain Amino Acid Sequence Identifiers
Antibody CD3-VH SEQ ID NOs: Designation HCVR CDR1 CDR2 CDR3
CD3-VH-G 2 4 6 8 CD3-VH-G2 10 12 14 16 CD3-VH-G3 18 20 22 24
CD3-VH-G4 26 28 30 32 CD3-VH-G5 34 36 38 40 CD3-VH-G8 42 44 46 48
CD3-VH-G9 50 52 54 56 CD3-VH-G10 58 60 62 64 CD3-VH-G11 66 68 70 72
CD3-VH-G12 74 76 78 80 CD3-VH-G13 82 84 86 88 CD3-VH-G14 90 92 94
96 CD3-VH-G15 98 100 102 104 CD3-VH-G16 106 108 110 112 CD3-VH-G17
114 116 118 120 CD3-VH-G18 122 124 126 128 CD3-VH-G19 130 132 134
136 CD3-VH-G20 138 140 142 144 CD3-VH-G21 146 148 150 152 CD3-VH-P
154 156 158 160
TABLE-US-00003 TABLE 3 Heavy Chain Nucleic Acid Sequence
Identifiers Antibody CD3-VH SEQ ID NOs: Designation HCVR CDR1 CDR2
CDR3 CD3-VH-G 1 3 5 7 CD3-VH-G2 9 11 13 15 CD3-VH-G3 17 19 21 23
CD3-VH-G4 25 27 29 31 CD3-VH-G5 33 35 37 39 CD3-VH-G8 41 43 45 47
CD3-VH-G9 49 51 53 55 CD3-VH-G10 57 59 61 63 CD3-VH-G11 65 67 69 71
CD3-VH-G12 73 75 77 79 CD3-VH-G13 81 83 85 87 CD3-VH-G14 89 91 93
95 CD3-VH-G15 97 99 101 103 CD3-VH-G16 105 107 109 111 CD3-VH-G17
113 115 117 119 CD3-VH-G18 121 123 125 127 CD3-VH-G19 129 131 133
135 CD3-VH-G20 137 139 141 143 CD3-VH-G21 145 147 149 151 CD3-VH-P
153 155 157 159
TABLE-US-00004 TABLE 4 Light Chain Amino Acid Sequence Identifiers
Antibody ULC SEQ ID NOs: Designation LCVR CDR1 CDR2 CDR3 VK1-39JK5
162 164 166 168
TABLE-US-00005 TABLE 5 Light Chain Nucleic Acid Sequence
Identifiers Antibody ULC SEQ ID NOs: Designation LCVR CDR1 CDR2
CDR3 VK1-39JK5 161 163 165 167
[0184] Control 1 antibody designated "CD3-L2K" was constructed
based on a known anti-CD3 antibody (i.e., the anti-CD3 antibody
"L2K" as set forth in WO2004/106380).
[0185] Isotype Control Antibody, referred to in the Examples
hereinbelow, is an isotype matched (modified IgG4) antibody that
interacts with an irrelevant antigen, i.e. FelD1 antigen.
Example 3: Generation of ULC Bispecific Antibodies that Bind CD3
and Tumor-Associated Antigens (TAA)
[0186] Bispecific antibodies comprising an anti-CD3-specific
binding domain and an anti-TAA-specific binding domain, such as
PSMA, EGFRvIII, MUC16, or STEAP2, were constructed using standard
molecular biology methodologies utilizing a heavy chain from an
anti-CD3 antibody described herein, a heavy chain from an anti-TAA
antibody and a common light chain or a universal light chain (ULC).
The anti-TAA antibodies used to construct the bispecific antibodies
of this invention were obtained by immunizing genetically modified
mice.
[0187] A summary of the component parts of the antigen-binding
domains of the various bispecific antibodies made in accordance
with this Example is set forth below in Tables 6, 7 and 8. All
bispecific antibodies were manufactured having a modified
(chimeric) IgG4 Fc domain as set forth in US Patent Application
Publication No. US20140243504A1, published on Aug. 28, 2014.
Exemplary EGFRvIIIxCD3 bispecific antibodies can be prepared using
any of the heavy chain and light chain variable regions (or CDRs)
of any of the EGFRvIII antibodies discussed in US Patent
Application Publication NO. US20150259423, which is hereby
incorporated by reference in its entirety, in combination with the
variable regions or CDRs of any of the anti-CD3 antibodies
discussed herein.
TABLE-US-00006 TABLE 6 Construction of PSMAxCD3 Bispecific
Antibodies Anti-PSMA Antigen- Binding Anti-CD3 Common Domain
Antigen-Binding Light Heavy Chain Domain Chain Bispecific Antibody
Variable Heavy Chain Variable Identifier Region Variable Region
Region BSPSMA/CD3-003 PSMA-VH-B CD3-VH-G VK1-39JK5 BSPSMA/CD3-200
CD3-VH-G2 BSPSMA/CD3-300 CD3-VH-G3 BSPSMA/CD3-400 CD3-VH-G4
BSPSMA/CD3-004 CD3-VH-G5 BSPSMA/CD3-800 CD3-VH-G8 BSPSMA/CD3-900
CD3-VH-G9 BSPSMA/CD3-1000 CD3-VH-G10 BSPSMA/CD3-1100 CD3-VH-G11
BSPSMA/CD3-1200 CD3-VH-G12 BSPSMA/CD3-1300 CD3-VH-G13
BSPSMA/CD3-1400 CD3-VH-G14 BSPSMA/CD3-1500 CD3-VH-G15
BSPSMA/CD3-1600 CD3-VH-G16 BSPSMA/CD3-1700 CD3-VH-G17
BSPSMA/CD3-1800 CD3-VH-G18 BSPSMA/CD3-1900 CD3-VH-G19
BSPSMA/CD3-005 CD3-VH-G20 BSPSMA/CD3-2100 CD3-VH-G21
TABLE-US-00007 TABLE 7 Construction of EGFRvIII xCD3 Bispecific
Antibodies Anti-EGFRvIII Anti-CD3 Antigen-Binding Antigen-Binding
Bispecific Domain Domain Common Light Antibody Heavy Chain Heavy
Chain Chain Variable Identifier Variable Region Variable Region
Region BSV3/CD3-001 EGFRvIII-VH-A CD3-VH-G EGFRvIII- BSV3/CD3-002
CD3-VH-G5 VL-A BSV3/CD3-003 CD3-VH-G9 BSV3/CD3-004 CD3-VH-G10
TABLE-US-00008 TABLE 8 Construction of MUC16xCD3 Bispecific
Antibodies Anti-MUC16 Anti-CD3 Common Antigen-Binding
Antigen-Binding Light Domain Domain Chain Bispecific Antibody Heavy
Chain Heavy Chain Variable Identifier Variable Region Variable
Region Region BSMUC16/CD3-001 MUC16-VH-A CD3-VH-G MUC16-
BSMUC16/CD3-002 CD3-VH-G5 VL-A BSMUC16/CD3-003 CD3-VH-G9
BSMUC16/CD3-004 CD3-VH-G10 BSMUC16/CD3-005 CD3-VH-G20
TABLE-US-00009 TABLE 9 Construction of STEAP2xCD3 Bispecific
Antibodies Anti-STEAP2 Anti-CD3 Common Antigen-Binding
Antigen-Binding Light Domain Domain Chain Bispecific Heavy Chain
Heavy Chain Variable Antibody Identifier Variable Region Variable
Region Region BSSTEAP2/CD3-001 STEAP2-VH-A CD3-VH-G STEAP2-
BSSTEAP2/CD3-002 CD3-VH-G5 VL-A BSSTEAP2/CD3-003 CD3-VH-G20
[0188] Each of the exemplary bispecific antibodies were tested in
various bioassays as described herein below.
Example 4: Binding Affinities of Exemplified Bispecific Antibodies
as Measured by FACS Analysis
[0189] In this example, the ability of CD3.times.TAA bispecific
antibodies to bind to human and cynomolgus CD3-expressing cell
lines via FACS was determined. Additionally, the ability of these
bispecific antibodies to bind to target-specific (TAA-specific)
cell lines was also confirmed. As described above, the various
bispecific antibodies of this invention utilized a single
TAA-specific binding arm (PSMA, EGFRvIII, MUC16, or STEAP2; see
Example 3, Tables 6, 7 and 8) paired with one of a panel of
anti-CD3 binding arms (see Examples 1 and 2 hereinabove) and a
common light chain. As is also shown in Example 5, the
CD3.times.TAA bispecific antibodies displayed a range of affinities
to human soluble heterodimeric hCD3.epsilon./.delta..mFc protein
via surface plasmon resonance.
[0190] Briefly, 2.times.10.sup.5 cells/well of human CD3-expressing
Jurkat, cynomolgus T or TAA-specific expressing cells were
incubated with a serial dilution of bispecific antibodies for 30
min at 4.degree. C. After incubation, cells were washed and a goat
F(ab').sub.2 anti-human Fc.gamma. PE labeled secondary (Jackson
Immunolabs) was added to the cells for an additional 30 min. Next,
cells were washed, re-suspended in cold PBS+1% BSA and analyzed via
flow cytometry on a BD FACS Canto II.
[0191] For FACS analysis, cells were gated by forward scatter
height vs. forward scatter area for single events selection,
followed by side and forward scatters. The EC.sub.50 for cell
binding titration was determined using PRISM.TM. software (GraphPad
Software, Inc., La Jolla, Calif.). Values were calculated using
4-parameter non-linear regression analysis.
TABLE-US-00010 TABLE 10A FACS Binding on CD3 and PSMA-Specific Cell
lines Anti-CD3- Bispecific Binding Jurkat Cyno T-cells
B16F10.9/PSMA Antibody Identifier Arm EC.sub.50 [M] EC.sub.50 [M]
EC.sub.50 [M] BSPSMA/CD3-003 CD3-VH-G 1.65E-08 1.42E-08 2.26E-09
BSPSMA/CD3-200 CD3-VH-G2 NB NB 1.88E-09 BSPSMA/CD3-300 CD3-VH-G3 NB
NB 1.90E-09 BSPSMA/CD3-400 CD3-VH-G4 NB NB 1.72E-09 BSPSMA/CD3-004
CD3-VH-G5 Very weak NB 1.31E-09 BSPSMA/CD3-800 CD3-VH-G8 1.93E-08
1.96E-08 1.31E-09 BSPSMA/CD3-900 CD3-VH-G9 2.74E-07 NB 1.43E-09
BSPSMA/CD3-1000 CD3-VH-G10 2.77E-07 NB 1.19E-09 BSPSMA/CD3-1100
CD3-VH-G11 1.83E-08 8.90E-07 1.03E-09 BSPSMA/CD3-1200 CD3-VH-G12
4.72E-08 NB 1.16E-09 BSPSMA/CD3-1300 CD3-VH-G13 1.02E-07 2.17E-06
1.25E-09 BSPSMA/CD3-1400 CD3-VH-G14 3.19E-08 1.70E-07 1.30E-09
BSPSMA/CD3-1500 CD3-VH-G15 9.30E-08 NB 1.21E-09 BSPSMA/CD3-1600
CD3-VH-G16 5.68E-08 NB 1.03E-09 BSPSMA/CD3-1700 CD3-VH-G17 2.00E-07
3.35E-06 1.34E-09 BSPSMA/CD3-1800 CD3-VH-G18 1.26E-07 NB 2.16E-09
BSPSMA/CD3-1900 CD3-VH-G19 6.07E-08 NB 1.35E-09 BSPSMA/CD3-005
CD3-VH-G20 2.10E-07 6.14E-06 2.09E-09 BSPSMA/CD3-2100 CD3-VH-G21
1.06E-07 NB 1.14E-09
TABLE-US-00011 TABLE 10B FACS Binding on CD3 and EGFRvIII-Specific
Cell lines Anti-CD3 Cyno T- U87/ Bispecific Antibody Binding Jurkat
Cells EGFRvIII Identifier Arm EC.sub.50 [M] EC.sub.50 [M] EC.sub.50
[M] BSV3/CD3-001 CD3-VH-G 1.46E-09 NT 2.40E-09 BSV3/CD3-002
CD3-VH-G5 Very weak NT 5.60E-09
TABLE-US-00012 TABLE 10C FACS Binding on CD3 and MUC16-Specific
Cell lines Cyno T- OVCAR3 Bispecific Antibody Anti-CD3 Jurkat cells
(MUC16+) Identifier Binding Arm EC.sub.50 [M] EC.sub.50 [M]
EC.sub.50 [M] BSMUC16/ CD3-VH-G 3.21E-09 NT 1.20E-09 CD3-001
BSMUC16/ CD3-VH-G5 Very weak NT 2.69E-09 CD3-002
[0192] As shown in Table 10A, the CD3 binding arms of each
CD3.times.PSMA bispecific antibody displayed a range of cell
binding affinity to human CD3 expressing Jurkat cells (15 to 300 nM
EC.sub.50 range). Importantly, the CD3 arms that showed weak-to-no
binding to human CD3 heterodimeric protein via surface plasmon
resonance (see Table 11 hereinbelow) also correlated with weak to
no observable binding on Jurkat cells (i.e. CD3-VH-G2, CD3-VH-G3,
CD3-VH-G5). Non-detectable binding, or no detectable binding, in
the FACS assay or equivalent assay means that the affinity between
the antibody and its target antigen is beyond the detection limit
of the assay (e.g. >1 .mu.M). Several CD3-binding arms also
displayed cross reactivity to cynomolgus T-cells. All tested
bispecific antibodies displayed similar cell binding on respective
PSMA, EGFRvIII and MUC16-expressing cell lines, confirming that
bispecific pairing with individual CD3 arms did not affect or
diminish TAA-specific binding (TAA-specific binding was less than
or equal to 5.6 nM (high affinity) in all examples tested).
[0193] Antibodies exhibiting weak-to-no detectable binding to human
CD3, and also exhibiting weak-to-no binding to cynomolgus CD3, are
considered advantageous for avidity-driven bispecific pairing in
accordance with the present invention, and were further tested for
cytotoxicity in in vitro and in vivo assays.
Example 5: Binding Affinities of Exemplified Antibodies as Measured
by a Surface Plasmon Resonance Binding Assay
[0194] Binding affinities and kinetic constants of
anti-TAA.times.anti-CD3 bispecific antibodies to soluble
heterodimeric hCD3.epsilon./.delta..mFc protein
(hCD3E=UniProtKB/Swiss-Prot: P07766.2; SEQ_ID NO: 169;
hCD3.delta.=UniProtKB/Swiss-Prot: P04234.1, SEQ ID NO: 170) were
determined by surface plasmon resonance at 37.degree. C. using
either an antigen-capture format (Table 11) or an antibody-capture
format (data not shown). In this example, BSPSMA/CD3 bispecific
antibodies were utilized as these pairings represented the use of a
wider panel of antibodies for the CD3 binding arm. Measurements
were conducted on a Sierra Sensors MASS-1 instrument.
[0195] In the antigen-capture format, the MASS-1 high-density amine
sensor surface was derivatized with a goat anti-mouse IgG2a
polyclonal antibody (Southern Biotech). Soluble heterodimeric CD3
protein was captured and the respective antibodies were injected
over the captured antigen.
[0196] Kinetic association (k.sub.a) and dissociation (k.sub.d)
rate constants were determined by processing and fitting the data
to a 1:1 binding model using MASS-1 AnalyserR2 curve fitting
software. Binding dissociation equilibrium constants (K.sub.D) and
dissociative half-lives (t.sub.1/2) were calculated from the
kinetic rate constants as: K.sub.D (M)=k.sub.d/k.sub.a; and
t.sub.1/2 (min)=(In2/(60*k.sub.d).
TABLE-US-00013 TABLE 11 Affinities of anti-CD3 Bispecific
Antibodies to Soluble Human CD3 Binding at 37.degree.
C./Antigen-Capture Format Corresponding anti-CD3 Antigen-
Bispecific Binding HCVR Antibody Identifier Identifier ka
(Ms.sup.-1) kd (s.sup.-1) K.sub.D (M) T1/2 (min) BSPSMA/CD3-003
CD3-VH-G 1.32E+05 7.62E-04 5.78E-09 15.2 BSPSMA/CD3-200 CD3-VH-G2
NB NB NB NB BSPSMA/CD3-300 CD3-VH-G3 NB NB NB NB BSPSMA/CD3-400
CD3-VH-G4 NB NB NB NB BSPSMA/CD3-004 CD3-VH-G5 NB NB NB NB
BSPSMA/CD3-800 CD3-VH-G8 5.95E+04 1.15E-03 1.94E-08 10.0
BSPSMA/CD3-900 CD3-VH-G9 4.38E+04 4.95E-03 1.13E-07 2.3
BSPSMA/CD3-1000 CD3-VH-G10 3.44E+04 6.37E-03 1.85E-07 1.8
BSPSMA/CD3-1100 CD3-VH-G11 9.21E+04 1.02E-03 1.11E-08 11.3
BSPSMA/CD3-1200 CD3-VH-G12 3.85E+04 2.47E-03 6.42E-08 4.7
BSPSMA/CD3-1300 CD3-VH-G13 2.03E+04 2.48E-03 1.22E-07 4.7
BSPSMA/CD3-1400 CD3-VH-G14 6.21E+04 3.31E-03 5.33E-08 3.5
BSPSMA/CD3-1500 CD3-VH-G15 7.36E+04 6.11E-03 8.29E-08 1.9
BSPSMA/CD3-1600 CD3-VH-G16 6.43E+04 2.43E-03 3.78E-08 4.7
BSPSMA/CD3-1700 CD3-VH-G17 4.70E+04 3.07E-03 6.52E-08 3.8
BSPSMA/CD3-1800 CD3-VH-G18 NB NB NB NB BSPSMA/CD3-1900 CD3-VH-G19
4.43E+04 5.09E-03 1.15E-07 2.3 BSPSMA/CD3-005 CD3-VH-G20 1.73E+04
5.77E-03 3.34E-07 2.0 BSPSMA/CD3-2100 CD3-VH-G21 3.02E+04 2.34E-03
7.75E-08 4.9 Control 1 CD3-L2K 3.68E+05 2.66E-03 7.22E-09 4.3 NB:
No binding detected
[0197] As shown in Table 11, all of the derived
anti-CD3.times.anti-PSMA bispecific antibodies maintained very weak
binding to soluble CD3 in the surface plasmon resonance binding
assay, e.g. having a K.sub.D value greater than 11 nM up to 334 nM
which is weaker than that of the bispecific anti-CD3 arm derived
from germline frameworks, CD3-VH-G.
[0198] Several bispecific antibodies exhibited greater than 50 nM
K.sub.D values, and some were greater than 100 nM
(>1.times.10.sup.-7) K.sub.D values (i.e. BSPSMA/CD3-900,
BSPSMA/CD3-1000, BSPSMA/CD3-1900), greater than 300 nM
(>3.times.10.sup.-7) K.sub.D values (i.e. BSPSMA/CD3-005) and
even beyond the detection limit of the assay (>500 nM;
>5.times.10.sup.-7), i.e. showed no detectable binding to
soluble human CD3 (i.e. BSPSMA/CD3-200, BSPSMA/CD3-300,
BSPSMA/CD3-400, BSPSMA/CD3-004 and BSPSMA/CD3-1800).
Example 6: T Cell Activation and Tumor-Specific Cytotoxicity
Exhibited by Bispecific Antibodies of the Invention as Measured In
Vitro
[0199] In this example, the specific killing of PSMA, EGFRvIII or
MUC16-expressing TAA target cells in the presence of CD3-based
bispecific antibodies was monitored via flow cytometry. As reported
previously, the bispecific antibodies displayed a range of affinity
to CD3 protein and CD3-expressing cell lines (i.e. weak, moderate
and strong binding). This same panel of bispecific antibodies was
tested for the ability to induce naive human T-cells to re-direct
killing toward target-expressing cells.
[0200] Briefly, PSMA-expressing (C4-2, 22Rv1 and TRAMPC2_PSMA),
EGFRvIII-expressing (U87/EGFRvIII) or MUC16-expressing (OVCAR3)
cell lines were labeled with 1 .mu.M of the fluorescent tracking
dye Violet Cell Tracker. After labeling, cells were plated
overnight at 37.degree. C. Separately, human PBMCs were plated in
supplemented RPMI media at 1.times.10.sup.6 cells/mL and incubated
overnight at 37.degree. C. in order to enrich for lymphocytes by
depleting adherent macrophages, dendritic cells, and some
monocytes. The next day, target cells were co-incubated with
adherent cell-depleted naive PBMC (Effector/Target cell 4:1 ratio)
and a serial dilution of relevant bispecific antibodies or Isotype
control (concentration range: 66.7 nM to 0.25 pM) for 48 hours at
37.degree. C. Cells were removed from cell culture plates using an
enzyme-free cell dissociation buffer, and analyzed by FACS.
[0201] For FACS analysis, cells were stained with a dead/live far
red cell tracker (Invitrogen). 5.times.10.sup.5 counting beads were
added to each well immediately before FACS analysis.
1.times.10.sup.4 beads were collected for each sample. For the
assessment of specificity of killing, cells were gated on live
Violet labeled populations. Percent of live population was recorded
and used for the calculation of normalized survival.
[0202] T cell activation was assessed by incubating cells with
directly conjugated antibodies to CD2 and CD69, and by reporting
the percent of activated (CD69+) T cells out of total T cells
(CD2+).
[0203] As the results in Tables 12A-12C show, depletion of
TAA-expressing cells was observed with anti-PSMA, EGFRvIII or
MUC16.times.CD3 bispecifics. Most of the tested bispecific
antibodies activated and directed human T cells to deplete the
target cells with EC.sub.50s in picomolar range. Additionally, the
observed target-cell lysis (depletion) was associated with an
up-regulation of CD69 cells on CD2+ T cells, with picomolar (pM)
EC.sub.50s.
[0204] Importantly, the results of this example demonstrate that
several bispecifics which utilized a CD3 binding arm that displayed
weak-to-non-observable binding to CD3 protein or CD3-expressing
cells (i.e. CD3-VH-G5) still retained the ability to activate
T-cells and exhibited potent cytotoxicity of tumor
antigen-expressing cells.
TABLE-US-00014 TABLE 12A Cytotoxicity and T-cell activation
properties of selected PSMAxCD3 Bispecific Antibodies Bispecific
Anti-CD3 C4-2 Cell 22RV1 TrampC2.PSMA T cell Antibody Binding
depletion Cell depletion Cell depletion activation Identifier Arm
EC.sub.50 [M] EC.sub.50 [M] EC.sub.50 [M] EC.sub.50 [M] BSPSMA/
CD3-VH-G 1.03E-11 NT 6.43E-12 1.23E-12 CD3-003 BSPSMA/ CD3-VH-G2 NT
No activity NT No activity CD3-200 BSPSMA/ CD3-VH-G3 NT Very weak
NT 1.85E-11 CD3-300 BSPSMA/ CD3-VH-G4 NT Very weak NT Very weak
CD3-400 BSPSMA/ CD3-VH-G5 2.15E-11 6.31E-12 1.15E-11 1.34E-11
CD3-004 BSPSMA/ CD3-VH-G8 NT NT 9.27E-12 1.76E-12 CD3-800 BSPSMA/
CD3-VH-G9 NT NT 3.50E-12 1.12E-12 CD3-900 BSPSMA/ CD3-VH- NT NT
5.97E-12 1.28E-12 CD3-1000 G10 BSPSMA/ CD3-VH- NT NT 3.86E-12
1.11E-12 CD3-1100 G11 BSPSMA/ CD3-VH- 8.74E-12 NT NT 2.31E-12
CD3-1300 G13 BSPSMA/ CD3-VH- 7.37E-12 2.07E-12 NT 3.89E-12 CD3-1700
G17 BSPSMA/ CD3-VH- 1.39E-11 8.32E-12 NT 6.11E-12 CD3-005 G20 NT =
not tested
TABLE-US-00015 TABLE 12B Cytotoxicity and T-cell activation
properties of selected EGFRvIIIxCD3 Bispecific Antibodies
U87_EGFRvIII T cell Bispecific Antibody Anti-CD3 Binding cell
depletion activation Identifier Arm EC.sub.50 [M] EC.sub.50 [M]
BSV3/CD3-001 CD3-VH-G 3.64E-10 3.33E-11 BSV3/CD3-002 CD3-VH-G5
1.30E-09 1.13E-10
TABLE-US-00016 TABLE 12C Cytotoxicity and T-cell activation
properties of selected MUC16xCD3 Bispecific Antibodies OVCAR3 T
cell Bispecific Antibody Anti-CD3 Binding cell depletion activation
Identifier Arm EC.sub.50 [M] EC.sub.50 [M] BSV3/CD3-001 CD3-VH-G
2.24E-11 5.88E-12 BSV3/CD3-002 CD3-VH-G5 3.06E-11 1.01E-11
Example 7: Anti-PSMA/Anti-CD3 Bispecific Antibodies Display Potent
Anti-Tumor Efficacy In Vivo
[0205] To determine the in vivo efficacy of exemplary
anti-PSMA/anti-CD3 bispecific antibodies identified as having weak
or no detectable binding affinity to human and cynomolgus CD3,
studies were performed in immunocompromised mice bearing human
prostate cancer xenografts. Additional studies were also carried
out in immunocompetent mice bearing mouse prostate cancer
xenografts engineered to express human PSMA.
Efficacy of Anti-PSMA/Anti-CD3 Bispecific Antibodies in Human Tumor
Xenograft Models
[0206] To assess the in vivo efficacy of the anti-PSMA/anti-CD3
bispecifics in human tumor xenograft studies, NOD scid gamma (NSG)
mice (Jackson Laboratories, Bar Harbor, Me.) were co-implanted with
human peripheral blood mononuclear cells (PBMCs) along with 22Rv1
or C4-2 human prostate tumor cells which endogenously express
PSMA.
[0207] Briefly, 4.times.10.sup.6 22 Rv1 or 5.times.10.sup.6 C4-2
cells (MD Anderson, TX) cells were co-implanted s.c. with
1.times.10.sup.6 human PBMCs (ReachBio, LLC., Seattle, Wash.) in a
50:50 mix of matrigel matrix (BD Biosciences) into the right flank
of male NSG mice. In the C4-2 study, mice were treated i.p. on days
0, 4, and 7 post tumor implantation with 0.1 mg/kg BSPSMA/CD3-003
or BSPSMA/CD3-005.
[0208] In an additional xenogenic model, anti-PSMA/anti-CD3
bispecifics were tested in mice engrafted with human hematopoietic
CD34+ stem cells. Briefly, newborn SIRP.alpha.
BALB/c-Rag2-IL2r.gamma.-(BRG) pups were engrafted with hCD34+ fetal
liver cells. 3-6 months later hCD34-engrafted SIRP.alpha. BRG mice
were then implanted with C4-2 cells (5.times.10.sup.6 s.c. in
matrigel). 8 days later, mice were treated with 10 .mu.g of
BSPSMA/CD3-004 or an isotype control antibody, followed by
2.times./week doses throughout the study.
[0209] In all studies, tumor size was measured 2.times./week using
calipers and tumor volume calculated as
Volume=(length.times.width.sup.2)/2.
[0210] As the results in Table 13 show, the bispecific antibodies
tested in the xenogenic models described above were all effective
at suppressing tumor growth compared to treatment with the isotype
control.
Efficacy of Anti-PSMA/Anti-CD3 Bispecific Antibodies in
Immune-Competent Tumor Model
[0211] Additionally, anti-PSMA/anti-CD3 bispecifics were assessed
for anti-tumor activity in an immune-competent model (U.S.
Provisional Application No. 62/083,653, filed Nov. 24, 2014). Mice
humanized for the three chains (Sys) of CD3 were also humanized for
PSMA and implanted with a variant murine prostate cancer cell line
TRAMP-C2 transfected with human PSMA.
[0212] Prior to study initiation, the tumorigenic cell line variant
TRAMP-C2_hPSMAv#1 was generated. Briefly, 7.5.times.10.sup.6
TRAMP-C2_hPSMA cells were implanted s.c. into the right flank of
male mice humanized for CD3 and PSMA. A tumor was excised and cut
into 3 mm fragments and subsequently implanted into the right flank
of new male humanized mice. A tumor arising from the implanted
tumor fragments was then harvested and disaggregated into a single
cell suspension. These cells (TRAMP-C2_hPSMAv#1) were then cultured
in vitro under G418 selection. 4.times.10.sup.6 cells of this
variant cell line were then implanted into the right flank of male
PSMA/CD3 humanized mice for the bispecific antibody efficacy
studies.
[0213] Humanized PSMA/CD3 mice implanted with TRAMPC2_hPSMAv#1 were
treated with 100 .mu.g or 10 .mu.g of anti-PSMA/anti-CD3 bispecific
antibody BSPSMA/CD3-004 or an isotype control 2.times./week
starting from the day of tumor implantation. Serum cytokine levels
4 h post-injection were also examined, as well as spleen T-cell
levels. Study was terminated at Day 27.
[0214] As the results in Table 14 show, the anti-PSMA/anti-CD3
bispecific molecule tested, BSPSMA/CD3-004, showed efficacy in
significantly delaying tumor growth across treatment groups.
Minimal cytokine release was observed after administration of
BSPSMA/CD3-004, possibly due to the weak binding of the anti-CD3.
Both antibodies tested showed anti-tumor efficacy without depleting
T cells in the spleen.
[0215] In summary, the anti-PSMA/anti-CD3 bispecific antibodies of
this invention display potent anti-tumor efficacy in both
immune-compromised and immune-competent tumor models, despite
having low to no detectable binding to CD3 antigen.
Example 8: Anti-MUC16/Anti-CD3 Bispecific Antibodies Display Potent
Anti-Tumor Efficacy In Vivo
[0216] To determine the in vivo efficacy of exemplary
anti-MUC16/anti-CD3 bispecific antibodies identified as having weak
or no detectable binding affinity to human and cynomolgus CD3,
studies were performed in immunocompromised mice bearing human
prostate cancer xenografts. The efficacy of selected bispecific
antibodies was tested in both immediate treatment and therapeutic
treatment dosing models.
Efficacy of Anti-MUC16/Anti-CD3 Bispecific Antibodies in Human
Tumor Xenograft Models
[0217] To assess the in vivo efficacy of the anti-MUC16/anti-CD3
bispecifics in human tumor xenograft studies, NOD scid gamma (NSG)
mice (Jackson Laboratories, Bar Harbor, Me.) were pre-implanted
with human peripheral blood mononuclear cells (PBMCs; ReachBio
LLC., Seattle, Wash.) and then given ascites cells from the human
ovarian cancer cell line OVCAR-3 (American Type Tissue Culture,
Manassas, Va.) transduced with luciferase (OVCAR-3/Luc). OVCAR-3
cells endogenously express MUC-16.
[0218] Briefly, NSG mice were injected intraperitoneally (i.p.)
with 5.0.times.10.sup.6 human PBMCs. 8d later, 1.5.times.10.sup.6
ascites cells from the OVCAR-3/Luc cell line, previously passaged
in vivo, were administered i.p. to the NSG mice engrafted with
PBMCs. In the immediate treatment group, mice were treated i.p. on
the day of OVCAR-3/Luc cell implantation with MUC16/CD3 Bispecific
antibodies BSMUC16/CD3-001 or BSMUC16/CD3-005, or an isotype
control, at a dose of 10 ug/mouse (N=5 mice/treatment group). In
the therapeutic dose model, mice were treated i.p. 7d post tumor
implantation with the MUC16/CD3 Bispecific or control antibodies
described above, at a dose of 10 ug/mouse (N=5/treatment
group).
[0219] In all studies, tumor growth was monitored via
bioluminescent imaging (BLI). Mice were injected i.p. with the
luciferase substrate D-luciferin suspended in PBS (150 mg/kg) and
imaged under isoflurane anesthesia after 10 min. BLI was performed
using the Xenogen IVIS system (Perkin Elmer, Hopkinton, Mass.) and
BLI signals were extracted using Living Image software
(Xenogen/Perkin Elmer). Regions of interest were drawn around each
cell mass and photon intensities were recorded as
photons(p)/sec(s)/cm.sup.2/steradian(sr). For the
immediate-treatment group, data is shown as BLI levels 26d post
tumor implantation (Table 15). For the therapeutic-treatment group,
data is shown as fold-change in BLI between day 6 (1 d before
treatment) and at study endpoint (26d post tumor implantation;
Table 16).
[0220] As the results show, both BSMUC16/CD3-001 and
BSMUC16/CD3-005 showed similar efficacy in suppressing tumor growth
compared to the isotype control when BLI was measured at Day 26 in
the immediate dosing model. Both anti-MUC16/anti-CD3 bispecific
antibodies also suppressed the growth of established tumors when
administered 7d post tumor implantation, compared to the control.
In summary, the bispecific anti-MUC16/anti-CD3 antibodies of this
invention display potent anti-tumor efficacy in several models.
TABLE-US-00017 TABLE 15 Efficacy of anti-MUC16/anti-CD3 Bispecific
Antibodies in Immune- Compromised Xenograft Model: Immediate Dosing
Avg Bioluminescent Radiance Tumor Model/ (photons/sec/cm.sup.2/
Mouse Strain/ Bispecific steradian) Day 26 Dose Antibody Identifier
N (mean .+-. SD) OVCAR-3/Luc/ BSMUC16/CD3-001 5 1.4 .times.
10.sup.3 .+-. 3.5 .times. 10.sup.2 NSG/ BSMUC16/CD3-005 5 1.5
.times. 10.sup.3 .+-. 9.7 .times. 10.sup.2 10 ug/mouse Isotype
Control 5 2.0 .times. 10.sup.7 .+-. 1.0 .times. 10.sup.6
TABLE-US-00018 TABLE 16 Efficacy of anti-Muc16/anti-CD3 Bispecific
Antibodies in Immune-Compromised Xenograft Model: Therapeutic
Treatment Fold change in Avg Bioluminescent Tumor Model/ Radiance
[p/s/cm.sup.2/sr] Mouse Strain/ Bispecific Antibody at Day 26
relative to Day 6 Dose Identifier N (mean .+-. SD) OVCAR-3/
BSMUC16/CD3-001 5 2.0 .+-. 5.0 Luc/NSG/ BSMUC16/CD3-005 5 0.01 .+-.
0.02 10 ug/mouse Isotype Control 5 21.0 .+-. 8.0
Example 9: Pharmacokinetic Assessment of Anti-MUC16.times.CD3
Bispecific Antibodies
[0221] Assessment of the pharmacokinetics of anti-MUC16.times.CD3
bispecific antibodies BSMUC16/CD3-001 and BSMUC16/CD3-005 and an
isotype control were conducted in humanized MUC16.times. CD3 mice
(mice homozygous for human MUC16 and CD3 expression,
MUC16.sup.hu/hu.times. CD3.sup.hu/hu), CD3 humanized mice (mice
homozygous for human CD3 expression, C.sub.D3 hu/hu)) and
strain-matched (75% C57BL, 25%129Sv) wild-type (WT) mice. Cohorts
contained 4-5 mice per tested antibody and per mouse strain. All
mice received a single intra-peritoneal (i.p.) 0.4 mg/kg dose.
Blood samples were collected at 3 and 6 hours, 1, 3, 7, 14 and 28
days post dosing. Blood was processed into serum and frozen at
-80.degree. C. until analyzed.
[0222] Circulating antibody concentrations were determined by total
human IgG antibody analysis using the GyroLab xPlore.TM. (Gyros,
Uppsala, Sweden). Briefly, a biotinylated goat anti-human IgG
polyclonal antibody (Jackson ImmunoResearch, West Grove, Pa.) was
captured onto streptavidin coated beads on a Gyrolab Bioaffy 200 CD
(Gyros) in order to capture the human IgG present in the sera.
After affinity column capture, bound human IgG antibody in samples
was detected with Alexa-647 labeled goat anti-human IgG (Jackson
ImmunoResearch). Fluorescent signal on the column allowed for the
detection of bound IgG and response units (RU) were read by the
instrument. Sample concentrations were determined by interpolation
from a standard curve that was fit using a 5-parameter logistic
curve fit using the Gyrolab Evaluator Software.
[0223] PK parameters were determined by non-compartmental analysis
(NCA) using Phoenix.RTM.WinNonlin.RTM. software Version 6.3
(Certara, L. P., Princeton, N.J.) and an extravascular dosing
model. Using the respective mean concentration values for each
antibody, all PK parameters including observed maximum
concentration in serum (C.sub.max), estimated half-life observed
(t.sub.1/2), and area under the concentration curve versus time up
to the last measureable concentration (AUC.sub.last) were
determined using a linear trapezoidal rule with linear
interpolation and uniform weighting
[0224] Following i.p. administration of antibodies in WT mice, the
total IgG concentration-time profiles of BSMUC16/CD3-001,
BSMUC16/CD3-005 and the isotype control were all similar,
characterized first by a brief drug distribution followed by a
single drug elimination phase throughout the remainder of the
study. Maximum serum concentrations (C.sub.max) and calculated drug
exposure (AUC.sub.last) of the three antibodies were comparable
(within 1.3-fold of each other). Following i.p. administration of
antibodies in CD3.sup.hu/hu mice, BSMUC16/CD3-001, BSMUC16/CD3-005
and isotype control had comparable C.sub.max concentrations (4.6,
3.6 and 4.1 .mu.g/mL, respectively). BSMUC16/CD3-005 and the
isotype control exhibited similar drug elimination curves, while
BSMUC16/CD3-001 exhibited steeper drug elimination than both,
suggesting that human CD3 target binding drives clearance. Terminal
antibody concentration for BSMUC16/CD3-001 was 0.03 .mu.g/mL, which
is about 28-fold less than terminal antibody concentrations
determined for the isotype control (0.85 .mu.g/mL) and 22-fold less
than BSMUC16/CD3-005 (0.66 .mu.g/mL) serum concentrations.
[0225] In MUC16.sup.hu/hu.times.CD3.sup.hu/hu double-humanized
mice, the Muc16.times.CD3 bispecific and isotype control antibodies
had comparable C.sub.max concentrations (C.sub.max range: 4.5-6.9
.mu.g/mL). Both bispecific antibodies exhibited steeper drug
elimination than the isotype control suggesting a target-mediated
effect. Terminal antibody concentrations for BSMUC16/CD3-001 and
BSMUC16/CD3-005 were about 29-fold and 2.9-fold less, respectively,
than terminal antibody concentrations determined for the isotype
control (0.86 .mu.g/mL).
[0226] A summary of the data for total anti-MUC16.times.CD3
bispecific antibodies and isotype control antibody concentrations
are summarized in Table 17. Mean PK parameters are described in
Tables 18A and 18B. Mean total antibody concentrations versus time
are shown in FIGS. 2A, 2B and 2C. In conclusion, MUC16.times.CD3
bispecific antibodies exhibited similar C.sub.max and drug
elimination curves in WT mice, but BSMUC16/CD3-001 displayed
steeper elimination rates than BSMUC16/CD3-005 and the isotype
control in CD3 single-humanized mice and MUC16/CD3 double humanized
mice. Since the bispecific antibodies administered in this PK study
are comprised of the same anti-MUC16 binding arm, the results
suggest that the strength of binding of the CD3 targeting arm may
play a role in drug exposure levels (AUC.sub.last) and drug
elimination rates. Neither BSMUC16/CD3-001 or BSMUC16/CD3-005 bind
mouse MUC16 or mouse CD3.
TABLE-US-00019 TABLE 17 Mean Concentrations of Total IgG in Serum
Following a Single 0.4 mg/kg Intra- peritoneal Injection of
BSMUC16/CD3-001, BSMUC16/CD3-005 and Isotype Control Antibodies in
WT Mice, Humanized CD3 Mice and Humanized MUC16 .times. CD3 mice
Total mAb Concentration In Mouse Serum MUC16.sup.hu/hu .times. WT
CD3.sup.hu/hu CD3.sup.hu/hu Mean Mean Mean Antibody Time (d)
(.mu.g/mL) +/-SD (.mu.g/mL) +/-SD (.mu.g/mL) +/-SD BSMUC16/CD3-
0.13 5.39 0.34 4.30 0.29 6.77 1.52 001 0.25 5.80 0.36 4.26 1.07
6.63 1.06 1.00 4.13 0.43 2.87 0.71 4.89 0.53 3.00 3.19 0.53 1.44
0.27 2.50 0.22 7.00 2.61 0.73 0.72 0.13 1.20 0.22 14.00 1.44 0.69
0.18 0.05 0.28 0.08 21.00 0.93 ND 0.07 0.02 0.06 0.05 28.00 0.60 ND
0.04 0.01 0.03 0.02 BSMUC16/CD3- 0.13 4.23 0.62 3.35 1.15 4.35 0.24
005 0.25 4.53 0.55 3.40 0.96 4.45 0.49 1.00 3.47 0.32 2.72 0.42
3.00 0.61 3.00 2.51 0.13 1.95 0.37 1.98 0.41 7.00 2.02 0.24 2.31
0.67 1.58 0.36 14.00 1.19 0.17 1.01 0.23 0.78 0.26 21.00 1.19 0.29
1.19 0.11 0.66 0.29 28.00 0.71 0.20 0.66 0.28 0.30 0.22 Isotype
Control 0.13 5.07 1.16 5.43 1.30 6.56 0.70 0.25 5.91 1.10 5.67 1.91
6.48 0.90 1.00 2.64 0.24 2.98 1.14 2.82 0.30 3.00 2.05 0.06 2.29
0.83 1.57 0.37 7.00 1.80 0.25 2.14 0.85 1.96 0.37 14.00 1.22 0.28
1.48 0.66 1.34 0.37 21.00 1.20 0.58 1.43 0.72 1.24 0.44 28.00 0.73
0.24 0.85 0.29 0.86 0.41 Time: (h, when noted) = time in hours post
single-dose injection; D = Day of study; SD = Standard deviation;
ND = Not determined due to exclusion of mice with drug clearing
anti-drug titers
TABLE-US-00020 TABLE 18A Summary of Pharmacokinetic Parameters:
CD3.sup.hu/hu humanized mice WT mice CD3.sup.hu/hu mice Isotype
BSMUC16/ BSMUC16/CD3- Isotype BSMUC16/ BSMUC16/ Parameter Units
Control CD3-001 005 Control CD3-001 CD3-005 C.sub.max .mu.g/mL 5
.+-. 3 6 .+-. 0.4 5 .+-. 0.5 4.1 .+-. 3 4.6 .+-. 0.8 3.5 .+-. 1
T.sub.1/2 d 11 .+-. 4 7 .+-. 3 12 .+-. 2 14 .+-. 0.5 3.9 .+-. 0.6
11 .+-. 5 AUC.sub.last d .mu.g/mL 35 .+-. 18 40 .+-. 11 45 .+-. 5
49 .+-. 20 16 .+-. 3 36 .+-. 13 C.sub.max = Peak concentration; AUC
= Area under the concentration-time curve; AUC.sub.last = AUC
computed from time zero to the time of the last positive
concentration; T.sub.1/2 = Estimated half-life observed; d =
day
TABLE-US-00021 TABLE 18B Summary of Pharmacokinetic Parameters:
MUC16.sup.hu/hu .times. CD3.sup.hu/hu double- humanized mice WT
mice MUC16.sup.hu/hu .times. CD3.sup.hu/hu mice Isotype BSMUC16/
BSMUC16/ Isotype BSMUC16/ BSMUC16/ Parameter Units Control CD3-001
CD3-005 Control CD3-001 CD3-005 C.sub.max .mu.g/mL 5 .+-. 3 6 .+-.
0.4 5 .+-. 0.5 6.7 .+-. 0.7 6.9 .+-. 1 4.5 .+-. 4 T.sub.1/2 d 11
.+-. 4 7 .+-. 3 12 .+-. 2 12.9 .+-. 4 3.3 .+-. 0.8 8.2 .+-. 4
AUC.sub.last d .mu.g/mL 35 .+-. 18 40 .+-. 11 45 .+-. 5 46 .+-. 10
27 .+-. 3 34 .+-. 11 C.sub.max = Peak concentration; AUC = Area
under the concentration-time curve; AUC.sub.last = AUC computed
from time zero to the time of the last positive concentration;
T.sub.1/2 = Estimated half-life observed; d = day
Example 10: Anti-STEAP2/Anti-CD3 Bispecific Antibodies Display
Potent Anti-Tumor Efficacy In Vivo
[0227] To determine the in vivo efficacy of exemplary
anti-STEAP2/anti-CD3 bispecific antibodies identified as having
weak or no detectable binding affinity to human and cynomolgus CD3,
studies were performed in immunocompromised mice bearing human
prostate cancer xenografts.
[0228] To assess the in vivo efficacy of the anti-STEAP2/anti-CD3
bispecifics in human tumor xenograft studies, NOD scid gamma (NSG)
mice (Jackson Laboratories, Bar Harbor, Me.) were co-implanted with
human peripheral blood mononuclear cells (PBMCs; ReachBio LLC.,
Seattle, Wash.) along with human prostate cancer C4-2 cells (MD
Anderson Cancer Center, Houston Tex.) which endogenously express
STEAP2.
[0229] Briefly, 5.0.times.10.sup.6 C4-2 cells were co-implanted
subcutaneously (s.c.) with 1.25.times.10.sup.6 human PBMCs in a
50:50 mix of matrigel matrix (BD Biosciences, San Jose, Calif.)
into the right flank of male NSG mice. Mice were treated
intraperitoneally (i.p.) on the day of implantation (immediate
treatment model) with anti-STEAP2/anti-CD3 bispecifics
BSSTEAP2/CD3-001, BSSTEAP2/CD3-002 or BSSTEAP2/CD3-003, or an
isotype control (that dos not bind C4-2 tumor cells), at a dose of
0.1 or 0.01 mg/kg (N=5 mice/group).
[0230] Tumor size was measured 2.times./week using calipers and
tumor volume calculated as Volume=(length.times.width.sup.2)/2.
Data is shown as tumor size (mm.sup.3) at study endpoint, 46d
post-tumor implantation (Table 19).
[0231] As the results in Table 19 show, BSSTEAP2/CD3-001,
BSSTEAP2/CD3-002 and BSSTEAP2/CD3-003 significantly suppressed
tumor growth compared to an isotype control when tumor sizes were
measured at study endpoint. Importantly, the
anti-STEAP.sup.2/anti-CD3 bispecific antibodies were efficacious in
inhibiting C4-2 tumor growth even at the lowest dose of 0.1
mg/kg.
TABLE-US-00022 TABLE 19 Efficacy of anti-STEAP2/anti-CD3 Bispecific
Antibodies in Immune- Compromised Xenograft Model: Immediate Dosing
Tumor Tumor Size (mm.sup.3) Model/ 46 d post-tumor Mouse Bispecific
Antibody Dose implantation Strain Identifier (mg/kg) N (mean .+-.
SD) C4-2/ BSSTEAP2/CD3-001 0.1 5 18.0 .+-. 14.0 NSG 0.01 5 23.0
.+-. 220 BSSTEAP2/CD3-002 0.1 5 15.0 .+-. 12.0 0.01 5 17.0 .+-. 8.0
BSSTEAP2/CD3-003 0.1 5 19.0 .+-. 12.0 0.01 5 25.0 .+-. 21.0 Control
Bispecific 0.1 5 1020.0 .+-. 922.0 The present invention is not to
be limited in scope by the specific embodiments
[0232] The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become apparent to those skilled in the art from the
foregoing description and the accompanying figures. Such
modifications are intended to fall within the scope of the appended
claims.
Sequence CWU 1
1
2011372DNAArtificial Sequencesynthetic 1gaagtacagc ttgtagaatc
cggcggagga ctggtacaac ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt
tacattcgac gattacagca tgcattgggt gaggcaagct 120cctggtaaag
gattggaatg ggttagcggg atatcatgga actcaggaag caagggatac
180gccgacagcg tgaaaggccg atttacaata tctagggaca acgcaaaaaa
ctctctctac 240cttcaaatga actctcttag ggcagaagac acagcattgt
attattgcgc aaaatacggc 300agtggttatg gcaagtttta tcattatgga
ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
3722124PRTArtificial Sequencesynthetic 2Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met His
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser
Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50 55
60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr
Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr His
Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val
Ser Ser 115 120 324DNAArtificial Sequencesynthetic 3gggtttacat
tcgacgatta cagc 2448PRTArtificial Sequencesynthetic 4Gly Phe Thr
Phe Asp Asp Tyr Ser 1 5 524DNAArtificial Sequencesynthetic
5atatcatgga actcaggaag caag 2468PRTArtificial Sequencesynthetic
6Ile Ser Trp Asn Ser Gly Ser Lys 1 5 751DNAArtificial
Sequencesynthetic 7gcaaaatacg gcagtggtta tggcaagttt tatcattatg
gactggacgt g 51817PRTArtificial Sequencesynthetic 8Ala Lys Tyr Gly
Ser Gly Tyr Gly Lys Phe Tyr His Tyr Gly Leu Asp 1 5 10 15 Val
9372DNAArtificial Sequencesynthetic 9gaagtacagt tggtagaatc
tggaggagga ctcgtgcaac caggacgatc attgcggttg 60agttgtgctg ctagtggatt
cacattcgac gactatgcta tgcattgggt aagacaggct 120ccaggaaaag
gactcgaatg ggtgtcagga ataagttgga actccggaag cattgggtac
180gcagattcag tcaaagggcg attcaccata tcccgagata acgctaagaa
ctcactttac 240cttcaaatga actctcttcg agcagaggac actgcacttt
attattgcgc taaggacggc 300tccggttatg gatattttta ttattatgga
atggacgtat ggggacaagg cactactgtt 360accgttagtt cc
37210124PRTArtificial Sequencesynthetic 10Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Tyr Phe Tyr
Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 1124DNAArtificial Sequencesynthetic
11ggattcacat tcgacgacta tgct 24128PRTArtificial Sequencesynthetic
12Gly Phe Thr Phe Asp Asp Tyr Ala 1 5 1324DNAArtificial
Sequencesynthetic 13ataagttgga actccggaag catt 24148PRTArtificial
Sequencesynthetic 14Ile Ser Trp Asn Ser Gly Ser Ile 1 5
1551DNAArtificial Sequencesynthetic 15gctaaggacg gctccggtta
tggatatttt tattattatg gaatggacgt a 511617PRTArtificial
Sequencesynthetic 16Ala Lys Asp Gly Ser Gly Tyr Gly Tyr Phe Tyr Tyr
Tyr Gly Met Asp 1 5 10 15 Val 17372DNAArtificial Sequencesynthetic
17gaagtacaac tggtcgaatc tggaggaggt cttgttcaac ctggtcgatc acttcgcctt
60tcttgtgccg cttctggttt cactttcgac gattatagca tgcattgggt acgacaggct
120cccggaaaag ggctggaatg ggtgtcagga attagttgga actcaggaag
tattggatac 180gctgattcag tcaaaggacg cttcacaatc tcaagggaca
acgctaaaaa ctcactttat 240ttgcaaatga actctctccg cgctgaagat
accgctctct attattgcgc caaagatggg 300tctggttacg gttattttta
ctactatgga atggacgttt ggggccaagg aacaactgtc 360acagtatcat cc
37218124PRTArtificial Sequencesynthetic 18Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Tyr Phe Tyr
Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 1924DNAArtificial Sequencesynthetic
19ggtttcactt tcgacgatta tagc 24208PRTArtificial Sequencesynthetic
20Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 2124DNAArtificial
Sequencesynthetic 21attagttgga actcaggaag tatt 24228PRTArtificial
Sequencesynthetic 22Ile Ser Trp Asn Ser Gly Ser Ile 1 5
2351DNAArtificial Sequencesynthetic 23gccaaagatg ggtctggtta
cggttatttt tactactatg gaatggacgt t 512417PRTArtificial
Sequencesynthetic 24Ala Lys Asp Gly Ser Gly Tyr Gly Tyr Phe Tyr Tyr
Tyr Gly Met Asp 1 5 10 15 Val 25372DNAArtificial Sequencesynthetic
25gaagttcaac ttgtggaaag tggcggagga ttggttcaac caggacgttc attgaggctt
60tcatgcgcag cttccggatt tacatttgac gattacgcaa tgcactgggt tagacaggca
120ccaggaaaag gactggagtg ggtgagcggg atttcatgga acagcggcag
tatcggttat 180gcagactcag ttaaaggaag attcaccatc agtagagaca
acgcaaaaaa ttccctttat 240ctccaaatga actctcttag ggccgaagat
acagcattgt actactgcgc aaaagacgga 300tcaggttacg gaaaatttta
ctactatggt atggatgtat ggggtcaggg aaccacagta 360actgtatcaa gc
37226124PRTArtificial Sequencesynthetic 26Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 2724DNAArtificial Sequencesynthetic
27ggatttacat ttgacgatta cgca 24288PRTArtificial Sequencesynthetic
28Gly Phe Thr Phe Asp Asp Tyr Ala 1 5 2924DNAArtificial
Sequencesynthetic 29atttcatgga acagcggcag tatc 24308PRTArtificial
Sequencesynthetic 30Ile Ser Trp Asn Ser Gly Ser Ile 1 5
3151DNAArtificial Sequencesynthetic 31gcaaaagacg gatcaggtta
cggaaaattt tactactatg gtatggatgt a 513217PRTArtificial
Sequencesynthetic 32Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr Tyr
Tyr Gly Met Asp 1 5 10 15 Val 33372DNAArtificial Sequencesynthetic
33gaagtgcaac tcgttgaaag cggaggagga ctggtccagc ccggcagatc tctcagattg
60tcttgcgctg catccggatt tacatttgac gactattcaa tgcactgggt acggcaagcc
120ccaggtaaag gactcgaatg ggtaagcggc atatcttgga actcaggcag
tattggctac 180gcagattcag taaaaggaag attcactatt tcaagggata
atgctaagaa cagtctctac 240ttgcaaatga atagcttgcg cgcagaagat
acagcacttt attattgtgc aaaagatgga 300agcggttatg ggaaatttta
ttattatggt atggatgtat ggggtcaagg tacaacagtt 360actgtgtcaa gt
37234124PRTArtificial Sequencesynthetic 34Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 3524DNAArtificial Sequencesynthetic
35ggatttacat ttgacgacta ttca 24368PRTArtificial Sequencesynthetic
36Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 3724DNAArtificial
Sequencesynthetic 37atatcttgga actcaggcag tatt 24388PRTArtificial
Sequencesynthetic 38Ile Ser Trp Asn Ser Gly Ser Ile 1 5
3951DNAArtificial Sequencesynthetic 39gcaaaagatg gaagcggtta
tgggaaattt tattattatg gtatggatgt a 514017PRTArtificial
Sequencesynthetic 40Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr Tyr
Tyr Gly Met Asp 1 5 10 15 Val 41372DNAArtificial Sequencesynthetic
41gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
catcggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaatacggc 300agtggttatg gcaagtttta
tcattatgga ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37242124PRTArtificial Sequencesynthetic 42Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 4324DNAArtificial Sequencesynthetic
43gggtttacat tcgacgatta cagc 24448PRTArtificial Sequencesynthetic
44Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 4524DNAArtificial
Sequencesynthetic 45atatcatgga actcaggaag catc 24468PRTArtificial
Sequencesynthetic 46Ile Ser Trp Asn Ser Gly Ser Ile 1 5
4751DNAArtificial Sequencesynthetic 47gcaaaatacg gcagtggtta
tggcaagttt tatcattatg gactggacgt g 514817PRTArtificial
Sequencesynthetic 48Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr His
Tyr Gly Leu Asp 1 5 10 15 Val 49372DNAArtificial Sequencesynthetic
49gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
caagggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaagacggc 300agtggttatg gcaagtttta
tcattatgga ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37250124PRTArtificial Sequencesynthetic 50Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 5124DNAArtificial Sequencesynthetic
51gggtttacat tcgacgatta cagc 24528PRTArtificial Sequencesynthetic
52Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 5324DNAArtificial
Sequencesynthetic 53atatcatgga actcaggaag caag 24548PRTArtificial
Sequencesynthetic 54Ile Ser Trp Asn Ser Gly Ser Lys 1 5
5551DNAArtificial Sequencesynthetic 55gcaaaagacg gcagtggtta
tggcaagttt tatcattatg gactggacgt g 515617PRTArtificial
Sequencesynthetic 56Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr His
Tyr Gly Leu Asp 1 5 10 15 Val 57372DNAArtificial Sequencesynthetic
57gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
caagggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaatacggc 300agtggttatg gcaagtttta
ttattatgga ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37258124PRTArtificial Sequencesynthetic 58Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 5924DNAArtificial Sequencesynthetic
59gggtttacat tcgacgatta cagc 24608PRTArtificial Sequencesynthetic
60Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 6124DNAArtificial
Sequencesynthetic 61atatcatgga actcaggaag caag 24628PRTArtificial
Sequencesynthetic 62Ile Ser Trp Asn Ser Gly Ser Lys 1 5
6351DNAArtificial Sequencesynthetic 63gcaaaatacg gcagtggtta
tggcaagttt tattattatg gactggacgt g 516417PRTArtificial
Sequencesynthetic 64Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr Tyr
Tyr Gly Leu Asp 1 5 10 15 Val 65372DNAArtificial Sequencesynthetic
65gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
caagggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaatacggc 300agtggttatg gcaagtttta
tcattatgga atggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37266124PRTArtificial Sequencesynthetic 66Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 6724DNAArtificial Sequencesynthetic
67gggtttacat tcgacgatta cagc 24688PRTArtificial Sequencesynthetic
68Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 6924DNAArtificial
Sequencesynthetic 69atatcatgga actcaggaag caag 24708PRTArtificial
Sequencesynthetic 70Ile Ser Trp Asn Ser Gly Ser Lys 1 5
7151DNAArtificial Sequencesynthetic 71gcaaaatacg gcagtggtta
tggcaagttt tatcattatg gaatggacgt g 517217PRTArtificial
Sequencesynthetic 72Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr His
Tyr Gly Met Asp 1 5 10 15 Val 73372DNAArtificial Sequencesynthetic
73gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
catcggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaagacggc 300agtggttatg gcaagtttta
tcattatgga ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37274124PRTArtificial Sequencesynthetic 74Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 7524DNAArtificial Sequencesynthetic
75gggtttacat tcgacgatta cagc 24768PRTArtificial Sequencesynthetic
76Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 7724DNAArtificial
Sequencesynthetic 77atatcatgga actcaggaag catc 24788PRTArtificial
Sequencesynthetic 78Ile Ser Trp Asn Ser Gly Ser Ile 1 5
7951DNAArtificial Sequencesynthetic 79gcaaaagacg gcagtggtta
tggcaagttt tatcattatg gactggacgt g 518017PRTArtificial
Sequencesynthetic 80Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr His
Tyr Gly Leu Asp 1 5 10 15 Val 81372DNAArtificial Sequencesynthetic
81gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
catcggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaatacggc 300agtggttatg gcaagtttta
ttattatgga ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37282124PRTArtificial Sequencesynthetic 82Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 8324DNAArtificial Sequencesynthetic
83gggtttacat tcgacgatta cagc 24848PRTArtificial Sequencesynthetic
84Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 8524DNAArtificial
Sequencesynthetic 85atatcatgga actcaggaag catc 24868PRTArtificial
Sequencesynthetic 86Ile Ser Trp Asn Ser Gly Ser Ile 1 5
8751DNAArtificial Sequencesynthetic 87gcaaaatacg gcagtggtta
tggcaagttt tattattatg gactggacgt g 518817PRTArtificial
Sequencesynthetic 88Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr Tyr
Tyr Gly Leu Asp 1 5 10 15 Val 89372DNAArtificial Sequencesynthetic
89gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
catcggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaatacggc 300agtggttatg gcaagtttta
tcattatgga atggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37290124PRTArtificial Sequencesynthetic 90Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 9124DNAArtificial Sequencesynthetic
91gggtttacat tcgacgatta cagc 24928PRTArtificial Sequencesynthetic
92Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 9324DNAArtificial
Sequencesynthetic 93atatcatgga actcaggaag catc 24948PRTArtificial
Sequencesynthetic 94Ile Ser Trp Asn Ser Gly Ser Ile 1 5
9551DNAArtificial Sequencesynthetic 95gcaaaatacg gcagtggtta
tggcaagttt tatcattatg gaatggacgt g 519617PRTArtificial
Sequencesynthetic 96Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr His
Tyr Gly Met Asp 1 5 10 15 Val 97372DNAArtificial Sequencesynthetic
97gaagtacagc ttgtagaatc cggcggagga ctggtacaac ctggaagaag tcttagactg
60agttgcgcag ctagtgggtt tacattcgac gattacagca tgcattgggt gaggcaagct
120cctggtaaag gattggaatg ggttagcggg atatcatgga actcaggaag
caagggatac 180gccgacagcg tgaaaggccg atttacaata tctagggaca
acgcaaaaaa ctctctctac 240cttcaaatga actctcttag ggcagaagac
acagcattgt attattgcgc aaaagacggc 300agtggttatg gcaagtttta
ttattatgga ctggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
37298124PRTArtificial Sequencesynthetic 98Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Leu Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 9924DNAArtificial Sequencesynthetic
99gggtttacat tcgacgatta cagc 241008PRTArtificial Sequencesynthetic
100Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 10124DNAArtificial
Sequencesynthetic 101atatcatgga actcaggaag caag 241028PRTArtificial
Sequencesynthetic 102Ile Ser Trp Asn Ser Gly Ser Lys 1 5
10351DNAArtificial Sequencesynthetic 103gcaaaagacg gcagtggtta
tggcaagttt tattattatg gactggacgt g 5110417PRTArtificial
Sequencesynthetic 104Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Leu Asp 1 5 10 15 Val 105372DNAArtificial
Sequencesynthetic 105gaagtacagc ttgtagaatc cggcggagga ctggtacaac
ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt tacattcgac gattacagca
tgcattgggt gaggcaagct 120cctggtaaag gattggaatg ggttagcggg
atatcatgga actcaggaag caagggatac 180gccgacagcg tgaaaggccg
atttacaata tctagggaca acgcaaaaaa ctctctctac 240cttcaaatga
actctcttag ggcagaagac acagcattgt attattgcgc aaaagacggc
300agtggttatg gcaagtttta tcattatgga atggacgtgt ggggacaagg
gacaacagtg 360acagtgagta gc 372106124PRTArtificial
Sequencesynthetic 106Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp
Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90
95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr His Tyr Gly Met Asp
100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
10724DNAArtificial Sequencesynthetic 107gggtttacat tcgacgatta cagc
241088PRTArtificial Sequencesynthetic 108Gly Phe Thr Phe Asp Asp
Tyr Ser 1 5 10924DNAArtificial Sequencesynthetic 109atatcatgga
actcaggaag caag 241108PRTArtificial Sequencesynthetic 110Ile Ser
Trp Asn Ser Gly Ser Lys 1 5 11151DNAArtificial Sequencesynthetic
111gcaaaagacg gcagtggtta tggcaagttt tatcattatg gaatggacgt g
5111217PRTArtificial Sequencesynthetic 112Ala Lys Asp Gly Ser Gly
Tyr Gly Lys Phe Tyr His Tyr Gly Met Asp 1 5 10 15 Val
113372DNAArtificial Sequencesynthetic 113gaagtacagc ttgtagaatc
cggcggagga ctggtacaac ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt
tacattcgac gattacagca tgcattgggt gaggcaagct 120cctggtaaag
gattggaatg ggttagcggg atatcatgga actcaggaag caagggatac
180gccgacagcg tgaaaggccg atttacaata tctagggaca acgcaaaaaa
ctctctctac 240cttcaaatga actctcttag ggcagaagac acagcattgt
attattgcgc aaaatacggc 300agtggttatg gcaagtttta ttattatgga
atggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
372114124PRTArtificial Sequencesynthetic 114Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 11524DNAArtificial Sequencesynthetic
115gggtttacat tcgacgatta cagc 241168PRTArtificial Sequencesynthetic
116Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 11724DNAArtificial
Sequencesynthetic 117atatcatgga actcaggaag caag 241188PRTArtificial
Sequencesynthetic 118Ile Ser Trp Asn Ser Gly Ser Lys 1 5
11951DNAArtificial Sequencesynthetic 119gcaaaatacg gcagtggtta
tggcaagttt tattattatg gaatggacgt g 5112017PRTArtificial
Sequencesynthetic 120Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Met Asp 1 5 10 15 Val 121372DNAArtificial
Sequencesynthetic 121gaagtacagc ttgtagaatc cggcggagga ctggtacaac
ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt tacattcgac gattacagca
tgcattgggt gaggcaagct 120cctggtaaag gattggaatg ggttagcggg
atatcatgga actcaggaag catcggatac 180gccgacagcg tgaaaggccg
atttacaata tctagggaca acgcaaaaaa ctctctctac 240cttcaaatga
actctcttag ggcagaagac acagcattgt attattgcgc aaaagacggc
300agtggttatg gcaagtttta ttattatgga ctggacgtgt ggggacaagg
gacaacagtg 360acagtgagta gc 372122124PRTArtificial
Sequencesynthetic 122Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp
Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90
95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr Tyr Tyr Gly Leu Asp
100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
12324DNAArtificial Sequencesynthetic 123gggtttacat tcgacgatta
cagc
241248PRTArtificial Sequencesynthetic 124Gly Phe Thr Phe Asp Asp
Tyr Ser 1 5 12524DNAArtificial Sequencesynthetic 125atatcatgga
actcaggaag catc 241268PRTArtificial Sequencesynthetic 126Ile Ser
Trp Asn Ser Gly Ser Ile 1 5 12751DNAArtificial Sequencesynthetic
127gcaaaagacg gcagtggtta tggcaagttt tattattatg gactggacgt g
5112817PRTArtificial Sequencesynthetic 128Ala Lys Asp Gly Ser Gly
Tyr Gly Lys Phe Tyr Tyr Tyr Gly Leu Asp 1 5 10 15 Val
129372DNAArtificial Sequencesynthetic 129gaagtacagc ttgtagaatc
cggcggagga ctggtacaac ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt
tacattcgac gattacagca tgcattgggt gaggcaagct 120cctggtaaag
gattggaatg ggttagcggg atatcatgga actcaggaag catcggatac
180gccgacagcg tgaaaggccg atttacaata tctagggaca acgcaaaaaa
ctctctctac 240cttcaaatga actctcttag ggcagaagac acagcattgt
attattgcgc aaaagacggc 300agtggttatg gcaagtttta tcattatgga
atggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
372130124PRTArtificial Sequencesynthetic 130Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 13124DNAArtificial Sequencesynthetic
131gggtttacat tcgacgatta cagc 241328PRTArtificial Sequencesynthetic
132Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 13324DNAArtificial
Sequencesynthetic 133atatcatgga actcaggaag catc 241348PRTArtificial
Sequencesynthetic 134Ile Ser Trp Asn Ser Gly Ser Ile 1 5
13551DNAArtificial Sequencesynthetic 135gcaaaagacg gcagtggtta
tggcaagttt tatcattatg gaatggacgt g 5113617PRTArtificial
Sequencesynthetic 136Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
His Tyr Gly Met Asp 1 5 10 15 Val 137372DNAArtificial
Sequencesynthetic 137gaagtacagc ttgtagaatc cggcggagga ctggtacaac
ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt tacattcgac gattacagca
tgcattgggt gaggcaagct 120cctggtaaag gattggaatg ggttagcggg
atatcatgga actcaggaag catcggatac 180gccgacagcg tgaaaggccg
atttacaata tctagggaca acgcaaaaaa ctctctctac 240cttcaaatga
actctcttag ggcagaagac acagcattgt attattgcgc aaaatacggc
300agtggttatg gcaagtttta ttattatgga atggacgtgt ggggacaagg
gacaacagtg 360acagtgagta gc 372138124PRTArtificial
Sequencesynthetic 138Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp
Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90
95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr Tyr Tyr Gly Met Asp
100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
13924DNAArtificial Sequencesynthetic 139gggtttacat tcgacgatta cagc
241408PRTArtificial Sequencesynthetic 140Gly Phe Thr Phe Asp Asp
Tyr Ser 1 5 14124DNAArtificial Sequencesynthetic 141atatcatgga
actcaggaag catc 241428PRTArtificial Sequencesynthetic 142Ile Ser
Trp Asn Ser Gly Ser Ile 1 5 14351DNAArtificial Sequencesynthetic
143gcaaaatacg gcagtggtta tggcaagttt tattattatg gaatggacgt g
5114417PRTArtificial Sequencesynthetic 144Ala Lys Tyr Gly Ser Gly
Tyr Gly Lys Phe Tyr Tyr Tyr Gly Met Asp 1 5 10 15 Val
145372DNAArtificial Sequencesynthetic 145gaagtacagc ttgtagaatc
cggcggagga ctggtacaac ctggaagaag tcttagactg 60agttgcgcag ctagtgggtt
tacattcgac gattacagca tgcattgggt gaggcaagct 120cctggtaaag
gattggaatg ggttagcggg atatcatgga actcaggaag caagggatac
180gccgacagcg tgaaaggccg atttacaata tctagggaca acgcaaaaaa
ctctctctac 240cttcaaatga actctcttag ggcagaagac acagcattgt
attattgcgc aaaagacggc 300agtggttatg gcaagtttta ttattatgga
atggacgtgt ggggacaagg gacaacagtg 360acagtgagta gc
372146124PRTArtificial Sequencesynthetic 146Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Lys Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr
Val Ser Ser 115 120 14724DNAArtificial Sequencesynthetic
147gggtttacat tcgacgatta cagc 241488PRTArtificial Sequencesynthetic
148Gly Phe Thr Phe Asp Asp Tyr Ser 1 5 14924DNAArtificial
Sequencesynthetic 149atatcatgga actcaggaag caag 241508PRTArtificial
Sequencesynthetic 150Ile Ser Trp Asn Ser Gly Ser Lys 1 5
15151DNAArtificial Sequencesynthetic 151gcaaaagacg gcagtggtta
tggcaagttt tattattatg gaatggacgt g 5115217PRTArtificial
Sequencesynthetic 152Ala Lys Asp Gly Ser Gly Tyr Gly Lys Phe Tyr
Tyr Tyr Gly Met Asp 1 5 10 15 Val 153372DNAArtificial
Sequencesynthetic 153gaagtgcagc tggtggagtc tgggggaggc ttggtacagc
ctggcaggtc cctgagactc 60tcctgtgtag cctctggatt cacctttgat gattattcca
tgcactgggt ccggcaagct 120ccagggaagg gcctggagtg ggtctcaggt
attagttgga atagtggtag caaagactat 180gcggactctg tgaagggccg
attcaccatc tccagagaca acgccaagaa ctccctgtat 240ctgcaaatga
acagtctgag agctgaagac acggccttgt attactgtgc aaaatatgga
300agtggctacg ggaagttcta ccactacggt ttggacgtct ggggccaagg
gaccacggtc 360accgtctcct ca 372154124PRTArtificial
Sequencesynthetic 154Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser
Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ser Met His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp
Asn Ser Gly Ser Lys Asp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90
95 Ala Lys Tyr Gly Ser Gly Tyr Gly Lys Phe Tyr His Tyr Gly Leu Asp
100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
15524DNAArtificial Sequencesynthetic 155ggattcacct ttgatgatta ttcc
241568PRTArtificial Sequencesynthetic 156Gly Phe Thr Phe Asp Asp
Tyr Ser 1 5 15724DNAArtificial Sequencesynthetic 157attagttgga
atagtggtag caaa 241588PRTArtificial Sequencesynthetic 158Ile Ser
Trp Asn Ser Gly Ser Lys 1 5 15951DNAArtificial Sequencesynthetic
159gcaaaatatg gaagtggcta cgggaagttc taccactacg gtttggacgt c
5116017PRTArtificial Sequencesynthetic 160Ala Lys Tyr Gly Ser Gly
Tyr Gly Lys Phe Tyr His Tyr Gly Leu Asp 1 5 10 15 Val
161324DNAArtificial Sequencesynthetic 161gacatccaga tgacccagtc
tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca
gagcattagc agctatttaa attggtatca gcagaaacca 120gggaaagccc
ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccgtca
180aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag
tctgcaacct 240gaagattttg caacttacta ctgtcaacag agttacagta
cccctccgat caccttcggc 300caagggacac gactggagat taaa
324162108PRTArtificial Sequencesynthetic 162Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser
Thr Pro Pro 85 90 95 Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
Lys 100 105 16318DNAArtificial Sequencesynthetic 163cagagcatta
gcagctat 181646PRTArtificial Sequencesynthetic 164Gln Ser Ile Ser
Ser Tyr 1 5 1659DNAArtificial Sequencesynthetic 165gctgcatcc 9
1663PRTArtificial Sequencesynthetic 166Ala Ala Ser 1
16730DNAArtificial Sequencesynthetic 167caacagagtt acagtacccc
tccgatcacc 3016810PRTArtificial Sequencesynthetic 168Gln Gln Ser
Tyr Ser Thr Pro Pro Ile Thr 1 5 10 169207PRTArtificial
Sequencesynthetic 169Met Gln Ser Gly Thr His Trp Arg Val Leu Gly
Leu Cys Leu Leu Ser 1 5 10 15 Val Gly Val Trp Gly Gln Asp Gly Asn
Glu Glu Met Gly Gly Ile Thr 20 25 30 Gln Thr Pro Tyr Lys Val Ser
Ile Ser Gly Thr Thr Val Ile Leu Thr 35 40 45 Cys Pro Gln Tyr Pro
Gly Ser Glu Ile Leu Trp Gln His Asn Asp Lys 50 55 60 Asn Ile Gly
Gly Asp Glu Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp 65 70 75 80 His
Leu Ser Leu Lys Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr 85 90
95 Val Cys Tyr Pro Arg Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu
100 105 110 Tyr Leu Arg Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp
Val Met 115 120 125 Ser Val Ala Thr Ile Val Ile Val Asp Ile Cys Ile
Thr Gly Gly Leu 130 135 140 Leu Leu Leu Val Tyr Tyr Trp Ser Lys Asn
Arg Lys Ala Lys Ala Lys 145 150 155 160 Pro Val Thr Arg Gly Ala Gly
Ala Gly Gly Arg Gln Arg Gly Gln Asn 165 170 175 Lys Glu Arg Pro Pro
Pro Val Pro Asn Pro Asp Tyr Glu Pro Ile Arg 180 185 190 Lys Gly Gln
Arg Asp Leu Tyr Ser Gly Leu Asn Gln Arg Arg Ile 195 200 205
170171PRTArtificial Sequencesynthetic 170Met Glu His Ser Thr Phe
Leu Ser Gly Leu Val Leu Ala Thr Leu Leu 1 5 10 15 Ser Gln Val Ser
Pro Phe Lys Ile Pro Ile Glu Glu Leu Glu Asp Arg 20 25 30 Val Phe
Val Asn Cys Asn Thr Ser Ile Thr Trp Val Glu Gly Thr Val 35 40 45
Gly Thr Leu Leu Ser Asp Ile Thr Arg Leu Asp Leu Gly Lys Arg Ile 50
55 60 Leu Asp Pro Arg Gly Ile Tyr Arg Cys Asn Gly Thr Asp Ile Tyr
Lys 65 70 75 80 Asp Lys Glu Ser Thr Val Gln Val His Tyr Arg Met Cys
Gln Ser Cys 85 90 95 Val Glu Leu Asp Pro Ala Thr Val Ala Gly Ile
Ile Val Thr Asp Val 100 105 110 Ile Ala Thr Leu Leu Leu Ala Leu Gly
Val Phe Cys Phe Ala Gly His 115 120 125 Glu Thr Gly Arg Leu Ser Gly
Ala Ala Asp Thr Gln Ala Leu Leu Arg 130 135 140 Asn Asp Gln Val Tyr
Gln Pro Leu Arg Asp Arg Asp Asp Ala Gln Tyr 145 150 155 160 Ser His
Leu Gly Gly Asn Trp Ala Arg Asn Lys 165 170 171750PRTArtificial
Sequencesynthetic 171Met Trp Asn Leu Leu His Glu Thr Asp Ser Ala
Val Ala Thr Ala Arg 1 5 10 15 Arg Pro Arg Trp Leu Cys Ala Gly Ala
Leu Val Leu Ala Gly Gly Phe 20 25 30 Phe Leu Leu Gly Phe Leu Phe
Gly Trp Phe Ile Lys Ser Ser Asn Glu 35 40 45 Ala Thr Asn Ile Thr
Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu 50 55 60 Leu Lys Ala
Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile 65 70 75 80 Pro
His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile 85 90
95 Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
100 105 110 Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn
Tyr Ile 115 120 125 Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn
Thr Ser Leu Phe 130 135 140 Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val
Ser Asp Ile Val Pro Pro 145 150 155 160 Phe Ser Ala Phe Ser Pro Gln
Gly Met Pro Glu Gly Asp Leu Val Tyr 165 170 175 Val Asn Tyr Ala Arg
Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met 180 185 190 Lys Ile Asn
Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val 195 200 205 Phe
Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly 210 215
220 Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys
225 230 235 240 Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val
Gln Arg Gly 245 250 255 Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro
Leu Thr Pro Gly Tyr 260 265 270 Pro Ala Asn Glu Tyr Ala Tyr Arg Arg
Gly Ile Ala Glu Ala Val Gly 275 280 285 Leu Pro Ser Ile Pro Val His
Pro Ile Gly Tyr Tyr Asp Ala Gln Lys 290 295 300 Leu Leu Glu Lys Met
Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg 305 310 315 320 Gly Ser
Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn 325 330 335
Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val 340
345 350 Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu
Pro 355 360 365 Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp
Val Phe Gly 370 375 380 Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val
His Glu Ile Val Arg 385 390
395 400 Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr
Ile 405 410 415 Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu
Gly Ser Thr 420 425 430 Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln
Glu Arg Gly Val Ala 435 440 445 Tyr Ile Asn Ala Asp Ser Ser Ile Glu
Gly Asn Tyr Thr Leu Arg Val 450 455 460 Asp Cys Thr Pro Leu Met Tyr
Ser Leu Val His Asn Leu Thr Lys Glu 465 470 475 480 Leu Lys Ser Pro
Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser 485 490 495 Trp Thr
Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile 500 505 510
Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu 515
520 525 Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr
Asn 530 535 540 Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu
Thr Tyr Glu 545 550 555 560 Leu Val Glu Lys Phe Tyr Asp Pro Met Phe
Lys Tyr His Leu Thr Val 565 570 575 Ala Gln Val Arg Gly Gly Met Val
Phe Glu Leu Ala Asn Ser Ile Val 580 585 590 Leu Pro Phe Asp Cys Arg
Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala 595 600 605 Asp Lys Ile Tyr
Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr 610 615 620 Tyr Ser
Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr 625 630 635
640 Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
645 650 655 Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe
Leu Glu 660 665 670 Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg
Pro Phe Tyr Arg 675 680 685 His Val Ile Tyr Ala Pro Ser Ser His Asn
Lys Tyr Ala Gly Glu Ser 690 695 700 Phe Pro Gly Ile Tyr Asp Ala Leu
Phe Asp Ile Glu Ser Lys Val Asp 705 710 715 720 Pro Ser Lys Ala Trp
Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala 725 730 735 Phe Thr Val
Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala 740 745 750
172943PRTArtificial Sequencesynthetic 172Met Arg Pro Ser Gly Thr
Ala Gly Ala Ala Leu Leu Ala Leu Leu Ala 1 5 10 15 Ala Leu Cys Pro
Ala Ser Arg Ala Leu Glu Glu Lys Lys Gly Asn Tyr 20 25 30 Val Val
Thr Asp His Gly Ser Cys Val Arg Ala Cys Gly Ala Asp Ser 35 40 45
Tyr Glu Met Glu Glu Asp Gly Val Arg Lys Cys Lys Lys Cys Glu Gly 50
55 60 Pro Cys Arg Lys Val Cys Asn Gly Ile Gly Ile Gly Glu Phe Lys
Asp 65 70 75 80 Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe Lys
Asn Cys Thr 85 90 95 Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val
Ala Phe Arg Gly Asp 100 105 110 Ser Phe Thr His Thr Pro Pro Leu Asp
Pro Gln Glu Leu Asp Ile Leu 115 120 125 Lys Thr Val Lys Glu Ile Thr
Gly Phe Leu Leu Ile Gln Ala Trp Pro 130 135 140 Glu Asn Arg Thr Asp
Leu His Ala Phe Glu Asn Leu Glu Ile Ile Arg 145 150 155 160 Gly Arg
Thr Lys Gln His Gly Gln Phe Ser Leu Ala Val Val Ser Leu 165 170 175
Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu Ile Ser Asp Gly 180
185 190 Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr Ala Asn Thr
Ile 195 200 205 Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys Thr
Lys Ile Ile 210 215 220 Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr
Gly Gln Val Cys His 225 230 235 240 Ala Leu Cys Ser Pro Glu Gly Cys
Trp Gly Pro Glu Pro Arg Asp Cys 245 250 255 Val Ser Cys Arg Asn Val
Ser Arg Gly Arg Glu Cys Val Asp Lys Cys 260 265 270 Asn Leu Leu Glu
Gly Glu Pro Arg Glu Phe Val Glu Asn Ser Glu Cys 275 280 285 Ile Gln
Cys His Pro Glu Cys Leu Pro Gln Ala Met Asn Ile Thr Cys 290 295 300
Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala His Tyr Ile Asp 305
310 315 320 Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val Met Gly
Glu Asn 325 330 335 Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His
Val Cys His Leu 340 345 350 Cys His Pro Asn Cys Thr Tyr Gly Cys Thr
Gly Pro Gly Leu Glu Gly 355 360 365 Cys Pro Thr Asn Gly Pro Lys Ile
Pro Ser Ile Ala Thr Gly Met Val 370 375 380 Gly Ala Leu Leu Leu Leu
Leu Val Val Ala Leu Gly Ile Gly Leu Phe 385 390 395 400 Met Arg Arg
Arg His Ile Val Arg Lys Arg Thr Leu Arg Arg Leu Leu 405 410 415 Gln
Glu Arg Glu Leu Val Glu Pro Leu Thr Pro Ser Gly Glu Ala Pro 420 425
430 Asn Gln Ala Leu Leu Arg Ile Leu Lys Glu Thr Glu Phe Lys Lys Ile
435 440 445 Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys Gly
Leu Trp 450 455 460 Ile Pro Glu Gly Glu Lys Val Lys Ile Pro Val Ala
Ile Lys Glu Leu 465 470 475 480 Arg Glu Ala Thr Ser Pro Lys Ala Asn
Lys Glu Ile Leu Asp Glu Ala 485 490 495 Tyr Val Met Ala Ser Val Asp
Asn Pro His Val Cys Arg Leu Leu Gly 500 505 510 Ile Cys Leu Thr Ser
Thr Val Gln Leu Ile Thr Gln Leu Met Pro Phe 515 520 525 Gly Cys Leu
Leu Asp Tyr Val Arg Glu His Lys Asp Asn Ile Gly Ser 530 535 540 Gln
Tyr Leu Leu Asn Trp Cys Val Gln Ile Ala Lys Gly Met Asn Tyr 545 550
555 560 Leu Glu Asp Arg Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn
Val 565 570 575 Leu Val Lys Thr Pro Gln His Val Lys Ile Thr Asp Phe
Gly Leu Ala 580 585 590 Lys Leu Leu Gly Ala Glu Glu Lys Glu Tyr His
Ala Glu Gly Gly Lys 595 600 605 Val Pro Ile Lys Trp Met Ala Leu Glu
Ser Ile Leu His Arg Ile Tyr 610 615 620 Thr His Gln Ser Asp Val Trp
Ser Tyr Gly Val Thr Val Trp Glu Leu 625 630 635 640 Met Thr Phe Gly
Ser Lys Pro Tyr Asp Gly Ile Pro Ala Ser Glu Ile 645 650 655 Ser Ser
Ile Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro Pro Ile Cys 660 665 670
Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met Ile Asp Ala 675
680 685 Asp Ser Arg Pro Lys Phe Arg Glu Leu Ile Ile Glu Phe Ser Lys
Met 690 695 700 Ala Arg Asp Pro Gln Arg Tyr Leu Val Ile Gln Gly Asp
Glu Arg Met 705 710 715 720 His Leu Pro Ser Pro Thr Asp Ser Asn Phe
Tyr Arg Ala Leu Met Asp 725 730 735 Glu Glu Asp Met Asp Asp Val Val
Asp Ala Asp Glu Tyr Leu Ile Pro 740 745 750 Gln Gln Gly Phe Phe Ser
Ser Pro Ser Thr Ser Arg Thr Pro Leu Leu 755 760 765 Ser Ser Leu Ser
Ala Thr Ser Asn Asn Ser Thr Val Ala Cys Ile Asp 770 775 780 Arg Asn
Gly Leu Gln Ser Cys Pro Ile Lys Glu Asp Ser Phe Leu Gln 785 790 795
800 Arg Tyr Ser Ser Asp Pro Thr Gly Ala Leu Thr Glu Asp Ser Ile Asp
805 810 815 Asp Thr Phe Leu Pro Val Pro Glu Tyr Ile Asn Gln Ser Val
Pro Lys 820 825 830 Arg Pro Ala Gly Ser Val Gln Asn Pro Val Tyr His
Asn Gln Pro Leu 835 840 845 Asn Pro Ala Pro Ser Arg Asp Pro His Tyr
Gln Asp Pro His Ser Thr 850 855 860 Ala Val Gly Asn Pro Glu Tyr Leu
Asn Thr Val Gln Pro Thr Cys Val 865 870 875 880 Asn Ser Thr Phe Asp
Ser Pro Ala His Trp Ala Gln Lys Gly Ser His 885 890 895 Gln Ile Ser
Leu Asp Asn Pro Asp Tyr Gln Gln Asp Phe Phe Pro Lys 900 905 910 Glu
Ala Lys Pro Asn Gly Ile Phe Lys Gly Ser Thr Ala Glu Asn Ala 915 920
925 Glu Tyr Leu Arg Val Ala Pro Gln Ser Ser Glu Phe Ile Gly Ala 930
935 940 17314507PRTArtificial Sequencesynthetic 173Met Leu Lys Pro
Ser Gly Leu Pro Gly Ser Ser Ser Pro Thr Arg Ser 1 5 10 15 Leu Met
Thr Gly Ser Arg Ser Thr Lys Ala Thr Pro Glu Met Asp Ser 20 25 30
Gly Leu Thr Gly Ala Thr Leu Ser Pro Lys Thr Ser Thr Gly Ala Ile 35
40 45 Val Val Thr Glu His Thr Leu Pro Phe Thr Ser Pro Asp Lys Thr
Leu 50 55 60 Ala Ser Pro Thr Ser Ser Val Val Gly Arg Thr Thr Gln
Ser Leu Gly 65 70 75 80 Val Met Ser Ser Ala Leu Pro Glu Ser Thr Ser
Arg Gly Met Thr His 85 90 95 Ser Glu Gln Arg Thr Ser Pro Ser Leu
Ser Pro Gln Val Asn Gly Thr 100 105 110 Pro Ser Arg Asn Tyr Pro Ala
Thr Ser Met Val Ser Gly Leu Ser Ser 115 120 125 Pro Arg Thr Arg Thr
Ser Ser Thr Glu Gly Asn Phe Thr Lys Glu Ala 130 135 140 Ser Thr Tyr
Thr Leu Thr Val Glu Thr Thr Ser Gly Pro Val Thr Glu 145 150 155 160
Lys Tyr Thr Val Pro Thr Glu Thr Ser Thr Thr Glu Gly Asp Ser Thr 165
170 175 Glu Thr Pro Trp Asp Thr Arg Tyr Ile Pro Val Lys Ile Thr Ser
Pro 180 185 190 Met Lys Thr Phe Ala Asp Ser Thr Ala Ser Lys Glu Asn
Ala Pro Val 195 200 205 Ser Met Thr Pro Ala Glu Thr Thr Val Thr Asp
Ser His Thr Pro Gly 210 215 220 Arg Thr Asn Pro Ser Phe Gly Thr Leu
Tyr Ser Ser Phe Leu Asp Leu 225 230 235 240 Ser Pro Lys Gly Thr Pro
Asn Ser Arg Gly Glu Thr Ser Leu Glu Leu 245 250 255 Ile Leu Ser Thr
Thr Gly Tyr Pro Phe Ser Ser Pro Glu Pro Gly Ser 260 265 270 Ala Gly
His Ser Arg Ile Ser Thr Ser Ala Pro Leu Ser Ser Ser Ala 275 280 285
Ser Val Leu Asp Asn Lys Ile Ser Glu Thr Ser Ile Phe Ser Gly Gln 290
295 300 Ser Leu Thr Ser Pro Leu Ser Pro Gly Val Pro Glu Ala Arg Ala
Ser 305 310 315 320 Thr Met Pro Asn Ser Ala Ile Pro Phe Ser Met Thr
Leu Ser Asn Ala 325 330 335 Glu Thr Ser Ala Glu Arg Val Arg Ser Thr
Ile Ser Ser Leu Gly Thr 340 345 350 Pro Ser Ile Ser Thr Lys Gln Thr
Ala Glu Thr Ile Leu Thr Phe His 355 360 365 Ala Phe Ala Glu Thr Met
Asp Ile Pro Ser Thr His Ile Ala Lys Thr 370 375 380 Leu Ala Ser Glu
Trp Leu Gly Ser Pro Gly Thr Leu Gly Gly Thr Ser 385 390 395 400 Thr
Ser Ala Leu Thr Thr Thr Ser Pro Ser Thr Thr Leu Val Ser Glu 405 410
415 Glu Thr Asn Thr His His Ser Thr Ser Gly Lys Glu Thr Glu Gly Thr
420 425 430 Leu Asn Thr Ser Met Thr Pro Leu Glu Thr Ser Ala Pro Gly
Glu Glu 435 440 445 Ser Glu Met Thr Ala Thr Leu Val Pro Thr Leu Gly
Phe Thr Thr Leu 450 455 460 Asp Ser Lys Ile Arg Ser Pro Ser Gln Val
Ser Ser Ser His Pro Thr 465 470 475 480 Arg Glu Leu Arg Thr Thr Gly
Ser Thr Ser Gly Arg Gln Ser Ser Ser 485 490 495 Thr Ala Ala His Gly
Ser Ser Asp Ile Leu Arg Ala Thr Thr Ser Ser 500 505 510 Thr Ser Lys
Ala Ser Ser Trp Thr Ser Glu Ser Thr Ala Gln Gln Phe 515 520 525 Ser
Glu Pro Gln His Thr Gln Trp Val Glu Thr Ser Pro Ser Met Lys 530 535
540 Thr Glu Arg Pro Pro Ala Ser Thr Ser Val Ala Ala Pro Ile Thr Thr
545 550 555 560 Ser Val Pro Ser Val Val Ser Gly Phe Thr Thr Leu Lys
Thr Ser Ser 565 570 575 Thr Lys Gly Ile Trp Leu Glu Glu Thr Ser Ala
Asp Thr Leu Ile Gly 580 585 590 Glu Ser Thr Ala Gly Pro Thr Thr His
Gln Phe Ala Val Pro Thr Gly 595 600 605 Ile Ser Met Thr Gly Gly Ser
Ser Thr Arg Gly Ser Gln Gly Thr Thr 610 615 620 His Leu Leu Thr Arg
Ala Thr Ala Ser Ser Glu Thr Ser Ala Asp Leu 625 630 635 640 Thr Leu
Ala Thr Asn Gly Val Pro Val Ser Val Ser Pro Ala Val Ser 645 650 655
Lys Thr Ala Ala Gly Ser Ser Pro Pro Gly Gly Thr Lys Pro Ser Tyr 660
665 670 Thr Met Val Ser Ser Val Ile Pro Glu Thr Ser Ser Leu Gln Ser
Ser 675 680 685 Ala Phe Arg Glu Gly Thr Ser Leu Gly Leu Thr Pro Leu
Asn Thr Arg 690 695 700 His Pro Phe Ser Ser Pro Glu Pro Asp Ser Ala
Gly His Thr Lys Ile 705 710 715 720 Ser Thr Ser Ile Pro Leu Leu Ser
Ser Ala Ser Val Leu Glu Asp Lys 725 730 735 Val Ser Ala Thr Ser Thr
Phe Ser His His Lys Ala Thr Ser Ser Ile 740 745 750 Thr Thr Gly Thr
Pro Glu Ile Ser Thr Lys Thr Lys Pro Ser Ser Ala 755 760 765 Val Leu
Ser Ser Met Thr Leu Ser Asn Ala Ala Thr Ser Pro Glu Arg 770 775 780
Val Arg Asn Ala Thr Ser Pro Leu Thr His Pro Ser Pro Ser Gly Glu 785
790 795 800 Glu Thr Ala Gly Ser Val Leu Thr Leu Ser Thr Ser Ala Glu
Thr Thr 805 810 815 Asp Ser Pro Asn Ile His Pro Thr Gly Thr Leu Thr
Ser Glu Ser Ser 820 825 830 Glu Ser Pro Ser Thr Leu Ser Leu Pro Ser
Val Ser Gly Val Lys Thr 835 840 845 Thr Phe Ser Ser Ser Thr Pro Ser
Thr His Leu Phe Thr Ser Gly Glu 850 855 860 Glu Thr Glu Glu Thr Ser
Asn Pro Ser Val Ser Gln Pro Glu Thr Ser 865 870 875 880 Val Ser Arg
Val Arg Thr Thr Leu Ala Ser Thr Ser Val Pro Thr Pro 885 890 895 Val
Phe Pro Thr Met Asp Thr Trp Pro Thr Arg Ser Ala Gln Phe Ser 900 905
910 Ser Ser His Leu Val Ser Glu Leu Arg Ala Thr Ser Ser Thr Ser Val
915 920 925 Thr Asn Ser Thr Gly Ser Ala Leu Pro Lys Ile Ser His Leu
Thr Gly 930 935 940 Thr Ala Thr Met Ser Gln Thr Asn Arg Asp Thr Phe
Asn Asp Ser Ala 945 950 955 960 Ala Pro Gln Ser Thr Thr Trp Pro Glu
Thr Ser Pro Arg Phe Lys Thr 965 970 975 Gly Leu Pro Ser Ala Thr Thr
Thr Val Ser Thr Ser Ala Thr Ser Leu 980 985 990 Ser Ala Thr Val Met
Val Ser Lys Phe Thr Ser Pro Ala Thr
Ser Ser 995 1000 1005 Met Glu Ala Thr Ser Ile Arg Glu Pro Ser Thr
Thr Ile Leu Thr 1010 1015 1020 Thr Glu Thr Thr Asn Gly Pro Gly Ser
Met Ala Val Ala Ser Thr 1025 1030 1035 Asn Ile Pro Ile Gly Lys Gly
Tyr Ile Thr Glu Gly Arg Leu Asp 1040 1045 1050 Thr Ser His Leu Pro
Ile Gly Thr Thr Ala Ser Ser Glu Thr Ser 1055 1060 1065 Met Asp Phe
Thr Met Ala Lys Glu Ser Val Ser Met Ser Val Ser 1070 1075 1080 Pro
Ser Gln Ser Met Asp Ala Ala Gly Ser Ser Thr Pro Gly Arg 1085 1090
1095 Thr Ser Gln Phe Val Asp Thr Phe Ser Asp Asp Val Tyr His Leu
1100 1105 1110 Thr Ser Arg Glu Ile Thr Ile Pro Arg Asp Gly Thr Ser
Ser Ala 1115 1120 1125 Leu Thr Pro Gln Met Thr Ala Thr His Pro Pro
Ser Pro Asp Pro 1130 1135 1140 Gly Ser Ala Arg Ser Thr Trp Leu Gly
Ile Leu Ser Ser Ser Pro 1145 1150 1155 Ser Ser Pro Thr Pro Lys Val
Thr Met Ser Ser Thr Phe Ser Thr 1160 1165 1170 Gln Arg Val Thr Thr
Ser Met Ile Met Asp Thr Val Glu Thr Ser 1175 1180 1185 Arg Trp Asn
Met Pro Asn Leu Pro Ser Thr Thr Ser Leu Thr Pro 1190 1195 1200 Ser
Asn Ile Pro Thr Ser Gly Ala Ile Gly Lys Ser Thr Leu Val 1205 1210
1215 Pro Leu Asp Thr Pro Ser Pro Ala Thr Ser Leu Glu Ala Ser Glu
1220 1225 1230 Gly Gly Leu Pro Thr Leu Ser Thr Tyr Pro Glu Ser Thr
Asn Thr 1235 1240 1245 Pro Ser Ile His Leu Gly Ala His Ala Ser Ser
Glu Ser Pro Ser 1250 1255 1260 Thr Ile Lys Leu Thr Met Ala Ser Val
Val Lys Pro Gly Ser Tyr 1265 1270 1275 Thr Pro Leu Thr Phe Pro Ser
Ile Glu Thr His Ile His Val Ser 1280 1285 1290 Thr Ala Arg Met Ala
Tyr Ser Ser Gly Ser Ser Pro Glu Met Thr 1295 1300 1305 Ala Pro Gly
Glu Thr Asn Thr Gly Ser Thr Trp Asp Pro Thr Thr 1310 1315 1320 Tyr
Ile Thr Thr Thr Asp Pro Lys Asp Thr Ser Ser Ala Gln Val 1325 1330
1335 Ser Thr Pro His Ser Val Arg Thr Leu Arg Thr Thr Glu Asn His
1340 1345 1350 Pro Lys Thr Glu Ser Ala Thr Pro Ala Ala Tyr Ser Gly
Ser Pro 1355 1360 1365 Lys Ile Ser Ser Ser Pro Asn Leu Thr Ser Pro
Ala Thr Lys Ala 1370 1375 1380 Trp Thr Ile Thr Asp Thr Thr Glu His
Ser Thr Gln Leu His Tyr 1385 1390 1395 Thr Lys Leu Ala Glu Lys Ser
Ser Gly Phe Glu Thr Gln Ser Ala 1400 1405 1410 Pro Gly Pro Val Ser
Val Val Ile Pro Thr Ser Pro Thr Ile Gly 1415 1420 1425 Ser Ser Thr
Leu Glu Leu Thr Ser Asp Val Pro Gly Glu Pro Leu 1430 1435 1440 Val
Leu Ala Pro Ser Glu Gln Thr Thr Ile Thr Leu Pro Met Ala 1445 1450
1455 Thr Trp Leu Ser Thr Ser Leu Thr Glu Glu Met Ala Ser Thr Asp
1460 1465 1470 Leu Asp Ile Ser Ser Pro Ser Ser Pro Met Ser Thr Phe
Ala Ile 1475 1480 1485 Phe Pro Pro Met Ser Thr Pro Ser His Glu Leu
Ser Lys Ser Glu 1490 1495 1500 Ala Asp Thr Ser Ala Ile Arg Asn Thr
Asp Ser Thr Thr Leu Asp 1505 1510 1515 Gln His Leu Gly Ile Arg Ser
Leu Gly Arg Thr Gly Asp Leu Thr 1520 1525 1530 Thr Val Pro Ile Thr
Pro Leu Thr Thr Thr Trp Thr Ser Val Ile 1535 1540 1545 Glu His Ser
Thr Gln Ala Gln Asp Thr Leu Ser Ala Thr Met Ser 1550 1555 1560 Pro
Thr His Val Thr Gln Ser Leu Lys Asp Gln Thr Ser Ile Pro 1565 1570
1575 Ala Ser Ala Ser Pro Ser His Leu Thr Glu Val Tyr Pro Glu Leu
1580 1585 1590 Gly Thr Gln Gly Arg Ser Ser Ser Glu Ala Thr Thr Phe
Trp Lys 1595 1600 1605 Pro Ser Thr Asp Thr Leu Ser Arg Glu Ile Glu
Thr Gly Pro Thr 1610 1615 1620 Asn Ile Gln Ser Thr Pro Pro Met Asp
Asn Thr Thr Thr Gly Ser 1625 1630 1635 Ser Ser Ser Gly Val Thr Leu
Gly Ile Ala His Leu Pro Ile Gly 1640 1645 1650 Thr Ser Ser Pro Ala
Glu Thr Ser Thr Asn Met Ala Leu Glu Arg 1655 1660 1665 Arg Ser Ser
Thr Ala Thr Val Ser Met Ala Gly Thr Met Gly Leu 1670 1675 1680 Leu
Val Thr Ser Ala Pro Gly Arg Ser Ile Ser Gln Ser Leu Gly 1685 1690
1695 Arg Val Ser Ser Val Leu Ser Glu Ser Thr Thr Glu Gly Val Thr
1700 1705 1710 Asp Ser Ser Lys Gly Ser Ser Pro Arg Leu Asn Thr Gln
Gly Asn 1715 1720 1725 Thr Ala Leu Ser Ser Ser Leu Glu Pro Ser Tyr
Ala Glu Gly Ser 1730 1735 1740 Gln Met Ser Thr Ser Ile Pro Leu Thr
Ser Ser Pro Thr Thr Pro 1745 1750 1755 Asp Val Glu Phe Ile Gly Gly
Ser Thr Phe Trp Thr Lys Glu Val 1760 1765 1770 Thr Thr Val Met Thr
Ser Asp Ile Ser Lys Ser Ser Ala Arg Thr 1775 1780 1785 Glu Ser Ser
Ser Ala Thr Leu Met Ser Thr Ala Leu Gly Ser Thr 1790 1795 1800 Glu
Asn Thr Gly Lys Glu Lys Leu Arg Thr Ala Ser Met Asp Leu 1805 1810
1815 Pro Ser Pro Thr Pro Ser Met Glu Val Thr Pro Trp Ile Ser Leu
1820 1825 1830 Thr Leu Ser Asn Ala Pro Asn Thr Thr Asp Ser Leu Asp
Leu Ser 1835 1840 1845 His Gly Val His Thr Ser Ser Ala Gly Thr Leu
Ala Thr Asp Arg 1850 1855 1860 Ser Leu Asn Thr Gly Val Thr Arg Ala
Ser Arg Leu Glu Asn Gly 1865 1870 1875 Ser Asp Thr Ser Ser Lys Ser
Leu Ser Met Gly Asn Ser Thr His 1880 1885 1890 Thr Ser Met Thr Tyr
Thr Glu Lys Ser Glu Val Ser Ser Ser Ile 1895 1900 1905 His Pro Arg
Pro Glu Thr Ser Ala Pro Gly Ala Glu Thr Thr Leu 1910 1915 1920 Thr
Ser Thr Pro Gly Asn Arg Ala Ile Ser Leu Thr Leu Pro Phe 1925 1930
1935 Ser Ser Ile Pro Val Glu Glu Val Ile Ser Thr Gly Ile Thr Ser
1940 1945 1950 Gly Pro Asp Ile Asn Ser Ala Pro Met Thr His Ser Pro
Ile Thr 1955 1960 1965 Pro Pro Thr Ile Val Trp Thr Ser Thr Gly Thr
Ile Glu Gln Ser 1970 1975 1980 Thr Gln Pro Leu His Ala Val Ser Ser
Glu Lys Val Ser Val Gln 1985 1990 1995 Thr Gln Ser Thr Pro Tyr Val
Asn Ser Val Ala Val Ser Ala Ser 2000 2005 2010 Pro Thr His Glu Asn
Ser Val Ser Ser Gly Ser Ser Thr Ser Ser 2015 2020 2025 Pro Tyr Ser
Ser Ala Ser Leu Glu Ser Leu Asp Ser Thr Ile Ser 2030 2035 2040 Arg
Arg Asn Ala Ile Thr Ser Trp Leu Trp Asp Leu Thr Thr Ser 2045 2050
2055 Leu Pro Thr Thr Thr Trp Pro Ser Thr Ser Leu Ser Glu Ala Leu
2060 2065 2070 Ser Ser Gly His Ser Gly Val Ser Asn Pro Ser Ser Thr
Thr Thr 2075 2080 2085 Glu Phe Pro Leu Phe Ser Ala Ala Ser Thr Ser
Ala Ala Lys Gln 2090 2095 2100 Arg Asn Pro Glu Thr Glu Thr His Gly
Pro Gln Asn Thr Ala Ala 2105 2110 2115 Ser Thr Leu Asn Thr Asp Ala
Ser Ser Val Thr Gly Leu Ser Glu 2120 2125 2130 Thr Pro Val Gly Ala
Ser Ile Ser Ser Glu Val Pro Leu Pro Met 2135 2140 2145 Ala Ile Thr
Ser Arg Ser Asp Val Ser Gly Leu Thr Ser Glu Ser 2150 2155 2160 Thr
Ala Asn Pro Ser Leu Gly Thr Ala Ser Ser Ala Gly Thr Lys 2165 2170
2175 Leu Thr Arg Thr Ile Ser Leu Pro Thr Ser Glu Ser Leu Val Ser
2180 2185 2190 Phe Arg Met Asn Lys Asp Pro Trp Thr Val Ser Ile Pro
Leu Gly 2195 2200 2205 Ser His Pro Thr Thr Asn Thr Glu Thr Ser Ile
Pro Val Asn Ser 2210 2215 2220 Ala Gly Pro Pro Gly Leu Ser Thr Val
Ala Ser Asp Val Ile Asp 2225 2230 2235 Thr Pro Ser Asp Gly Ala Glu
Ser Ile Pro Thr Val Ser Phe Ser 2240 2245 2250 Pro Ser Pro Asp Thr
Glu Val Thr Thr Ile Ser His Phe Pro Glu 2255 2260 2265 Lys Thr Thr
His Ser Phe Arg Thr Ile Ser Ser Leu Thr His Glu 2270 2275 2280 Leu
Thr Ser Arg Val Thr Pro Ile Pro Gly Asp Trp Met Ser Ser 2285 2290
2295 Ala Met Ser Thr Lys Pro Thr Gly Ala Ser Pro Ser Ile Thr Leu
2300 2305 2310 Gly Glu Arg Arg Thr Ile Thr Ser Ala Ala Pro Thr Thr
Ser Pro 2315 2320 2325 Ile Val Leu Thr Ala Ser Phe Thr Glu Thr Ser
Thr Val Ser Leu 2330 2335 2340 Asp Asn Glu Thr Thr Val Lys Thr Ser
Asp Ile Leu Asp Ala Arg 2345 2350 2355 Lys Thr Asn Glu Leu Pro Ser
Asp Ser Ser Ser Ser Ser Asp Leu 2360 2365 2370 Ile Asn Thr Ser Ile
Ala Ser Ser Thr Met Asp Val Thr Lys Thr 2375 2380 2385 Ala Ser Ile
Ser Pro Thr Ser Ile Ser Gly Met Thr Ala Ser Ser 2390 2395 2400 Ser
Pro Ser Leu Phe Ser Ser Asp Arg Pro Gln Val Pro Thr Ser 2405 2410
2415 Thr Thr Glu Thr Asn Thr Ala Thr Ser Pro Ser Val Ser Ser Asn
2420 2425 2430 Thr Tyr Ser Leu Asp Gly Gly Ser Asn Val Gly Gly Thr
Pro Ser 2435 2440 2445 Thr Leu Pro Pro Phe Thr Ile Thr His Pro Val
Glu Thr Ser Ser 2450 2455 2460 Ala Leu Leu Ala Trp Ser Arg Pro Val
Arg Thr Phe Ser Thr Met 2465 2470 2475 Val Ser Thr Asp Thr Ala Ser
Gly Glu Asn Pro Thr Ser Ser Asn 2480 2485 2490 Ser Val Val Thr Ser
Val Pro Ala Pro Gly Thr Trp Thr Ser Val 2495 2500 2505 Gly Ser Thr
Thr Asp Leu Pro Ala Met Gly Phe Leu Lys Thr Ser 2510 2515 2520 Pro
Ala Gly Glu Ala His Ser Leu Leu Ala Ser Thr Ile Glu Pro 2525 2530
2535 Ala Thr Ala Phe Thr Pro His Leu Ser Ala Ala Val Val Thr Gly
2540 2545 2550 Ser Ser Ala Thr Ser Glu Ala Ser Leu Leu Thr Thr Ser
Glu Ser 2555 2560 2565 Lys Ala Ile His Ser Ser Pro Gln Thr Pro Thr
Thr Pro Thr Ser 2570 2575 2580 Gly Ala Asn Trp Glu Thr Ser Ala Thr
Pro Glu Ser Leu Leu Val 2585 2590 2595 Val Thr Glu Thr Ser Asp Thr
Thr Leu Thr Ser Lys Ile Leu Val 2600 2605 2610 Thr Asp Thr Ile Leu
Phe Ser Thr Val Ser Thr Pro Pro Ser Lys 2615 2620 2625 Phe Pro Ser
Thr Gly Thr Leu Ser Gly Ala Ser Phe Pro Thr Leu 2630 2635 2640 Leu
Pro Asp Thr Pro Ala Ile Pro Leu Thr Ala Thr Glu Pro Thr 2645 2650
2655 Ser Ser Leu Ala Thr Ser Phe Asp Ser Thr Pro Leu Val Thr Ile
2660 2665 2670 Ala Ser Asp Ser Leu Gly Thr Val Pro Glu Thr Thr Leu
Thr Met 2675 2680 2685 Ser Glu Thr Ser Asn Gly Asp Ala Leu Val Leu
Lys Thr Val Ser 2690 2695 2700 Asn Pro Asp Arg Ser Ile Pro Gly Ile
Thr Ile Gln Gly Val Thr 2705 2710 2715 Glu Ser Pro Leu His Pro Ser
Ser Thr Ser Pro Ser Lys Ile Val 2720 2725 2730 Ala Pro Arg Asn Thr
Thr Tyr Glu Gly Ser Ile Thr Val Ala Leu 2735 2740 2745 Ser Thr Leu
Pro Ala Gly Thr Thr Gly Ser Leu Val Phe Ser Gln 2750 2755 2760 Ser
Ser Glu Asn Ser Glu Thr Thr Ala Leu Val Asp Ser Ser Ala 2765 2770
2775 Gly Leu Glu Arg Ala Ser Val Met Pro Leu Thr Thr Gly Ser Gln
2780 2785 2790 Gly Met Ala Ser Ser Gly Gly Ile Arg Ser Gly Ser Thr
His Ser 2795 2800 2805 Thr Gly Thr Lys Thr Phe Ser Ser Leu Pro Leu
Thr Met Asn Pro 2810 2815 2820 Gly Glu Val Thr Ala Met Ser Glu Ile
Thr Thr Asn Arg Leu Thr 2825 2830 2835 Ala Thr Gln Ser Thr Ala Pro
Lys Gly Ile Pro Val Lys Pro Thr 2840 2845 2850 Ser Ala Glu Ser Gly
Leu Leu Thr Pro Val Ser Ala Ser Ser Ser 2855 2860 2865 Pro Ser Lys
Ala Phe Ala Ser Leu Thr Thr Ala Pro Pro Thr Trp 2870 2875 2880 Gly
Ile Pro Gln Ser Thr Leu Thr Phe Glu Phe Ser Glu Val Pro 2885 2890
2895 Ser Leu Asp Thr Lys Ser Ala Ser Leu Pro Thr Pro Gly Gln Ser
2900 2905 2910 Leu Asn Thr Ile Pro Asp Ser Asp Ala Ser Thr Ala Ser
Ser Ser 2915 2920 2925 Leu Ser Lys Ser Pro Glu Lys Asn Pro Arg Ala
Arg Met Met Thr 2930 2935 2940 Ser Thr Lys Ala Ile Ser Ala Ser Ser
Phe Gln Ser Thr Gly Phe 2945 2950 2955 Thr Glu Thr Pro Glu Gly Ser
Ala Ser Pro Ser Met Ala Gly His 2960 2965 2970 Glu Pro Arg Val Pro
Thr Ser Gly Thr Gly Asp Pro Arg Tyr Ala 2975 2980 2985 Ser Glu Ser
Met Ser Tyr Pro Asp Pro Ser Lys Ala Ser Ser Ala 2990 2995 3000 Met
Thr Ser Thr Ser Leu Ala Ser Lys Leu Thr Thr Leu Phe Ser 3005 3010
3015 Thr Gly Gln Ala Ala Arg Ser Gly Ser Ser Ser Ser Pro Ile Ser
3020 3025 3030 Leu Ser Thr Glu Lys Glu Thr Ser Phe Leu Ser Pro Thr
Ala Ser 3035 3040 3045 Thr Ser Arg Lys Thr Ser Leu Phe Leu Gly Pro
Ser Met Ala Arg 3050 3055 3060 Gln Pro Asn Ile Leu Val His Leu Gln
Thr Ser Ala Leu Thr Leu 3065 3070 3075 Ser Pro Thr Ser Thr Leu Asn
Met Ser Gln Glu Glu Pro Pro Glu 3080 3085 3090 Leu Thr Ser Ser Gln
Thr Ile Ala Glu Glu Glu Gly Thr Thr Ala 3095 3100 3105 Glu Thr Gln
Thr Leu Thr Phe Thr Pro Ser Glu Thr Pro Thr Ser 3110 3115 3120 Leu
Leu Pro Val Ser Ser Pro Thr Glu Pro Thr Ala Arg Arg Lys 3125 3130
3135 Ser Ser Pro Glu Thr Trp Ala Ser Ser Ile Ser Val Pro Ala Lys
3140 3145 3150 Thr Ser Leu Val Glu Thr Thr Asp Gly Thr Leu Val Thr
Thr Ile 3155 3160 3165 Lys Met Ser Ser Gln Ala Ala Gln Gly Asn Ser
Thr Trp Pro Ala 3170 3175 3180 Pro Ala Glu Glu Thr Gly Ser Ser Pro
Ala Gly Thr Ser Pro Gly 3185 3190
3195 Ser Pro Glu Met Ser Thr Thr Leu Lys Ile Met Ser Ser Lys Glu
3200 3205 3210 Pro Ser Ile Ser Pro Glu Ile Arg Ser Thr Val Arg Asn
Ser Pro 3215 3220 3225 Trp Lys Thr Pro Glu Thr Thr Val Pro Met Glu
Thr Thr Val Glu 3230 3235 3240 Pro Val Thr Leu Gln Ser Thr Ala Leu
Gly Ser Gly Ser Thr Ser 3245 3250 3255 Ile Ser His Leu Pro Thr Gly
Thr Thr Ser Pro Thr Lys Ser Pro 3260 3265 3270 Thr Glu Asn Met Leu
Ala Thr Glu Arg Val Ser Leu Ser Pro Ser 3275 3280 3285 Pro Pro Glu
Ala Trp Thr Asn Leu Tyr Ser Gly Thr Pro Gly Gly 3290 3295 3300 Thr
Arg Gln Ser Leu Ala Thr Met Ser Ser Val Ser Leu Glu Ser 3305 3310
3315 Pro Thr Ala Arg Ser Ile Thr Gly Thr Gly Gln Gln Ser Ser Pro
3320 3325 3330 Glu Leu Val Ser Lys Thr Thr Gly Met Glu Phe Ser Met
Trp His 3335 3340 3345 Gly Ser Thr Gly Gly Thr Thr Gly Asp Thr His
Val Ser Leu Ser 3350 3355 3360 Thr Ser Ser Asn Ile Leu Glu Asp Pro
Val Thr Ser Pro Asn Ser 3365 3370 3375 Val Ser Ser Leu Thr Asp Lys
Ser Lys His Lys Thr Glu Thr Trp 3380 3385 3390 Val Ser Thr Thr Ala
Ile Pro Ser Thr Val Leu Asn Asn Lys Ile 3395 3400 3405 Met Ala Ala
Glu Gln Gln Thr Ser Arg Ser Val Asp Glu Ala Tyr 3410 3415 3420 Ser
Ser Thr Ser Ser Trp Ser Asp Gln Thr Ser Gly Ser Asp Ile 3425 3430
3435 Thr Leu Gly Ala Ser Pro Asp Val Thr Asn Thr Leu Tyr Ile Thr
3440 3445 3450 Ser Thr Ala Gln Thr Thr Ser Leu Val Ser Leu Pro Ser
Gly Asp 3455 3460 3465 Gln Gly Ile Thr Ser Leu Thr Asn Pro Ser Gly
Gly Lys Thr Ser 3470 3475 3480 Ser Ala Ser Ser Val Thr Ser Pro Ser
Ile Gly Leu Glu Thr Leu 3485 3490 3495 Arg Ala Asn Val Ser Ala Val
Lys Ser Asp Ile Ala Pro Thr Ala 3500 3505 3510 Gly His Leu Ser Gln
Thr Ser Ser Pro Ala Glu Val Ser Ile Leu 3515 3520 3525 Asp Val Thr
Thr Ala Pro Thr Pro Gly Ile Ser Thr Thr Ile Thr 3530 3535 3540 Thr
Met Gly Thr Asn Ser Ile Ser Thr Thr Thr Pro Asn Pro Glu 3545 3550
3555 Val Gly Met Ser Thr Met Asp Ser Thr Pro Ala Thr Glu Arg Arg
3560 3565 3570 Thr Thr Ser Thr Glu His Pro Ser Thr Trp Ser Ser Thr
Ala Ala 3575 3580 3585 Ser Asp Ser Trp Thr Val Thr Asp Met Thr Ser
Asn Leu Lys Val 3590 3595 3600 Ala Arg Ser Pro Gly Thr Ile Ser Thr
Met His Thr Thr Ser Phe 3605 3610 3615 Leu Ala Ser Ser Thr Glu Leu
Asp Ser Met Ser Thr Pro His Gly 3620 3625 3630 Arg Ile Thr Val Ile
Gly Thr Ser Leu Val Thr Pro Ser Ser Asp 3635 3640 3645 Ala Ser Ala
Val Lys Thr Glu Thr Ser Thr Ser Glu Arg Thr Leu 3650 3655 3660 Ser
Pro Ser Asp Thr Thr Ala Ser Thr Pro Ile Ser Thr Phe Ser 3665 3670
3675 Arg Val Gln Arg Met Ser Ile Ser Val Pro Asp Ile Leu Ser Thr
3680 3685 3690 Ser Trp Thr Pro Ser Ser Thr Glu Ala Glu Asp Val Pro
Val Ser 3695 3700 3705 Met Val Ser Thr Asp His Ala Ser Thr Lys Thr
Asp Pro Asn Thr 3710 3715 3720 Pro Leu Ser Thr Phe Leu Phe Asp Ser
Leu Ser Thr Leu Asp Trp 3725 3730 3735 Asp Thr Gly Arg Ser Leu Ser
Ser Ala Thr Ala Thr Thr Ser Ala 3740 3745 3750 Pro Gln Gly Ala Thr
Thr Pro Gln Glu Leu Thr Leu Glu Thr Met 3755 3760 3765 Ile Ser Pro
Ala Thr Ser Gln Leu Pro Phe Ser Ile Gly His Ile 3770 3775 3780 Thr
Ser Ala Val Thr Pro Ala Ala Met Ala Arg Ser Ser Gly Val 3785 3790
3795 Thr Phe Ser Arg Pro Asp Pro Thr Ser Lys Lys Ala Glu Gln Thr
3800 3805 3810 Ser Thr Gln Leu Pro Thr Thr Thr Ser Ala His Pro Gly
Gln Val 3815 3820 3825 Pro Arg Ser Ala Ala Thr Thr Leu Asp Val Ile
Pro His Thr Ala 3830 3835 3840 Lys Thr Pro Asp Ala Thr Phe Gln Arg
Gln Gly Gln Thr Ala Leu 3845 3850 3855 Thr Thr Glu Ala Arg Ala Thr
Ser Asp Ser Trp Asn Glu Lys Glu 3860 3865 3870 Lys Ser Thr Pro Ser
Ala Pro Trp Ile Thr Glu Met Met Asn Ser 3875 3880 3885 Val Ser Glu
Asp Thr Ile Lys Glu Val Thr Ser Ser Ser Ser Val 3890 3895 3900 Leu
Arg Thr Leu Asn Thr Leu Asp Ile Asn Leu Glu Ser Gly Thr 3905 3910
3915 Thr Ser Ser Pro Ser Trp Lys Ser Ser Pro Tyr Glu Arg Ile Ala
3920 3925 3930 Pro Ser Glu Ser Thr Thr Asp Lys Glu Ala Ile His Pro
Ser Thr 3935 3940 3945 Asn Thr Val Glu Thr Thr Gly Trp Val Thr Ser
Ser Glu His Ala 3950 3955 3960 Ser His Ser Thr Ile Pro Ala His Ser
Ala Ser Ser Lys Leu Thr 3965 3970 3975 Ser Pro Val Val Thr Thr Ser
Thr Arg Glu Gln Ala Ile Val Ser 3980 3985 3990 Met Ser Thr Thr Thr
Trp Pro Glu Ser Thr Arg Ala Arg Thr Glu 3995 4000 4005 Pro Asn Ser
Phe Leu Thr Ile Glu Leu Arg Asp Val Ser Pro Tyr 4010 4015 4020 Met
Asp Thr Ser Ser Thr Thr Gln Thr Ser Ile Ile Ser Ser Pro 4025 4030
4035 Gly Ser Thr Ala Ile Thr Lys Gly Pro Arg Thr Glu Ile Thr Ser
4040 4045 4050 Ser Lys Arg Ile Ser Ser Ser Phe Leu Ala Gln Ser Met
Arg Ser 4055 4060 4065 Ser Asp Ser Pro Ser Glu Ala Ile Thr Arg Leu
Ser Asn Phe Pro 4070 4075 4080 Ala Met Thr Glu Ser Gly Gly Met Ile
Leu Ala Met Gln Thr Ser 4085 4090 4095 Pro Pro Gly Ala Thr Ser Leu
Ser Ala Pro Thr Leu Asp Thr Ser 4100 4105 4110 Ala Thr Ala Ser Trp
Thr Gly Thr Pro Leu Ala Thr Thr Gln Arg 4115 4120 4125 Phe Thr Tyr
Ser Glu Lys Thr Thr Leu Phe Ser Lys Gly Pro Glu 4130 4135 4140 Asp
Thr Ser Gln Pro Ser Pro Pro Ser Val Glu Glu Thr Ser Ser 4145 4150
4155 Ser Ser Ser Leu Val Pro Ile His Ala Thr Thr Ser Pro Ser Asn
4160 4165 4170 Ile Leu Leu Thr Ser Gln Gly His Ser Pro Ser Ser Thr
Pro Pro 4175 4180 4185 Val Thr Ser Val Phe Leu Ser Glu Thr Ser Gly
Leu Gly Lys Thr 4190 4195 4200 Thr Asp Met Ser Arg Ile Ser Leu Glu
Pro Gly Thr Ser Leu Pro 4205 4210 4215 Pro Asn Leu Ser Ser Thr Ala
Gly Glu Ala Leu Ser Thr Tyr Glu 4220 4225 4230 Ala Ser Arg Asp Thr
Lys Ala Ile His His Ser Ala Asp Thr Ala 4235 4240 4245 Val Thr Asn
Met Glu Ala Thr Ser Ser Glu Tyr Ser Pro Ile Pro 4250 4255 4260 Gly
His Thr Lys Pro Ser Lys Ala Thr Ser Pro Leu Val Thr Ser 4265 4270
4275 His Ile Met Gly Asp Ile Thr Ser Ser Thr Ser Val Phe Gly Ser
4280 4285 4290 Ser Glu Thr Thr Glu Ile Glu Thr Val Ser Ser Val Asn
Gln Gly 4295 4300 4305 Leu Gln Glu Arg Ser Thr Ser Gln Val Ala Ser
Ser Ala Thr Glu 4310 4315 4320 Thr Ser Thr Val Ile Thr His Val Ser
Ser Gly Asp Ala Thr Thr 4325 4330 4335 His Val Thr Lys Thr Gln Ala
Thr Phe Ser Ser Gly Thr Ser Ile 4340 4345 4350 Ser Ser Pro His Gln
Phe Ile Thr Ser Thr Asn Thr Phe Thr Asp 4355 4360 4365 Val Ser Thr
Asn Pro Ser Thr Ser Leu Ile Met Thr Glu Ser Ser 4370 4375 4380 Gly
Val Thr Ile Thr Thr Gln Thr Gly Pro Thr Gly Ala Ala Thr 4385 4390
4395 Gln Gly Pro Tyr Leu Leu Asp Thr Ser Thr Met Pro Tyr Leu Thr
4400 4405 4410 Glu Thr Pro Leu Ala Val Thr Pro Asp Phe Met Gln Ser
Glu Lys 4415 4420 4425 Thr Thr Leu Ile Ser Lys Gly Pro Lys Asp Val
Ser Trp Thr Ser 4430 4435 4440 Pro Pro Ser Val Ala Glu Thr Ser Tyr
Pro Ser Ser Leu Thr Pro 4445 4450 4455 Phe Leu Val Thr Thr Ile Pro
Pro Ala Thr Ser Thr Leu Gln Gly 4460 4465 4470 Gln His Thr Ser Ser
Pro Val Ser Ala Thr Ser Val Leu Thr Ser 4475 4480 4485 Gly Leu Val
Lys Thr Thr Asp Met Leu Asn Thr Ser Met Glu Pro 4490 4495 4500 Val
Thr Asn Ser Pro Gln Asn Leu Asn Asn Pro Ser Asn Glu Ile 4505 4510
4515 Leu Ala Thr Leu Ala Ala Thr Thr Asp Ile Glu Thr Ile His Pro
4520 4525 4530 Ser Ile Asn Lys Ala Val Thr Asn Met Gly Thr Ala Ser
Ser Ala 4535 4540 4545 His Val Leu His Ser Thr Leu Pro Val Ser Ser
Glu Pro Ser Thr 4550 4555 4560 Ala Thr Ser Pro Met Val Pro Ala Ser
Ser Met Gly Asp Ala Leu 4565 4570 4575 Ala Ser Ile Ser Ile Pro Gly
Ser Glu Thr Thr Asp Ile Glu Gly 4580 4585 4590 Glu Pro Thr Ser Ser
Leu Thr Ala Gly Arg Lys Glu Asn Ser Thr 4595 4600 4605 Leu Gln Glu
Met Asn Ser Thr Thr Glu Ser Asn Ile Ile Leu Ser 4610 4615 4620 Asn
Val Ser Val Gly Ala Ile Thr Glu Ala Thr Lys Met Glu Val 4625 4630
4635 Pro Ser Phe Asp Ala Thr Phe Ile Pro Thr Pro Ala Gln Ser Thr
4640 4645 4650 Lys Phe Pro Asp Ile Phe Ser Val Ala Ser Ser Arg Leu
Ser Asn 4655 4660 4665 Ser Pro Pro Met Thr Ile Ser Thr His Met Thr
Thr Thr Gln Thr 4670 4675 4680 Gly Ser Ser Gly Ala Thr Ser Lys Ile
Pro Leu Ala Leu Asp Thr 4685 4690 4695 Ser Thr Leu Glu Thr Ser Ala
Gly Thr Pro Ser Val Val Thr Glu 4700 4705 4710 Gly Phe Ala His Ser
Lys Ile Thr Thr Ala Met Asn Asn Asp Val 4715 4720 4725 Lys Asp Val
Ser Gln Thr Asn Pro Pro Phe Gln Asp Glu Ala Ser 4730 4735 4740 Ser
Pro Ser Ser Gln Ala Pro Val Leu Val Thr Thr Leu Pro Ser 4745 4750
4755 Ser Val Ala Phe Thr Pro Gln Trp His Ser Thr Ser Ser Pro Val
4760 4765 4770 Ser Met Ser Ser Val Leu Thr Ser Ser Leu Val Lys Thr
Ala Gly 4775 4780 4785 Lys Val Asp Thr Ser Leu Glu Thr Val Thr Ser
Ser Pro Gln Ser 4790 4795 4800 Met Ser Asn Thr Leu Asp Asp Ile Ser
Val Thr Ser Ala Ala Thr 4805 4810 4815 Thr Asp Ile Glu Thr Thr His
Pro Ser Ile Asn Thr Val Val Thr 4820 4825 4830 Asn Val Gly Thr Thr
Gly Ser Ala Phe Glu Ser His Ser Thr Val 4835 4840 4845 Ser Ala Tyr
Pro Glu Pro Ser Lys Val Thr Ser Pro Asn Val Thr 4850 4855 4860 Thr
Ser Thr Met Glu Asp Thr Thr Ile Ser Arg Ser Ile Pro Lys 4865 4870
4875 Ser Ser Lys Thr Thr Arg Thr Glu Thr Glu Thr Thr Ser Ser Leu
4880 4885 4890 Thr Pro Lys Leu Arg Glu Thr Ser Ile Ser Gln Glu Ile
Thr Ser 4895 4900 4905 Ser Thr Glu Thr Ser Thr Val Pro Tyr Lys Glu
Leu Thr Gly Ala 4910 4915 4920 Thr Thr Glu Val Ser Arg Thr Asp Val
Thr Ser Ser Ser Ser Thr 4925 4930 4935 Ser Phe Pro Gly Pro Asp Gln
Ser Thr Val Ser Leu Asp Ile Ser 4940 4945 4950 Thr Glu Thr Asn Thr
Arg Leu Ser Thr Ser Pro Ile Met Thr Glu 4955 4960 4965 Ser Ala Glu
Ile Thr Ile Thr Thr Gln Thr Gly Pro His Gly Ala 4970 4975 4980 Thr
Ser Gln Asp Thr Phe Thr Met Asp Pro Ser Asn Thr Thr Pro 4985 4990
4995 Gln Ala Gly Ile His Ser Ala Met Thr His Gly Phe Ser Gln Leu
5000 5005 5010 Asp Val Thr Thr Leu Met Ser Arg Ile Pro Gln Asp Val
Ser Trp 5015 5020 5025 Thr Ser Pro Pro Ser Val Asp Lys Thr Ser Ser
Pro Ser Ser Phe 5030 5035 5040 Leu Ser Ser Pro Ala Met Thr Thr Pro
Ser Leu Ile Ser Ser Thr 5045 5050 5055 Leu Pro Glu Asp Lys Leu Ser
Ser Pro Met Thr Ser Leu Leu Thr 5060 5065 5070 Ser Gly Leu Val Lys
Ile Thr Asp Ile Leu Arg Thr Arg Leu Glu 5075 5080 5085 Pro Val Thr
Ser Ser Leu Pro Asn Phe Ser Ser Thr Ser Asp Lys 5090 5095 5100 Ile
Leu Ala Thr Ser Lys Asp Ser Lys Asp Thr Lys Glu Ile Phe 5105 5110
5115 Pro Ser Ile Asn Thr Glu Glu Thr Asn Val Lys Ala Asn Asn Ser
5120 5125 5130 Gly His Glu Ser His Ser Pro Ala Leu Ala Asp Ser Glu
Thr Pro 5135 5140 5145 Lys Ala Thr Thr Gln Met Val Ile Thr Thr Thr
Val Gly Asp Pro 5150 5155 5160 Ala Pro Ser Thr Ser Met Pro Val His
Gly Ser Ser Glu Thr Thr 5165 5170 5175 Asn Ile Lys Arg Glu Pro Thr
Tyr Phe Leu Thr Pro Arg Leu Arg 5180 5185 5190 Glu Thr Ser Thr Ser
Gln Glu Ser Ser Phe Pro Thr Asp Thr Ser 5195 5200 5205 Phe Leu Leu
Ser Lys Val Pro Thr Gly Thr Ile Thr Glu Val Ser 5210 5215 5220 Ser
Thr Gly Val Asn Ser Ser Ser Lys Ile Ser Thr Pro Asp His 5225 5230
5235 Asp Lys Ser Thr Val Pro Pro Asp Thr Phe Thr Gly Glu Ile Pro
5240 5245 5250 Arg Val Phe Thr Ser Ser Ile Lys Thr Lys Ser Ala Glu
Met Thr 5255 5260 5265 Ile Thr Thr Gln Ala Ser Pro Pro Glu Ser Ala
Ser His Ser Thr 5270 5275 5280 Leu Pro Leu Asp Thr Ser Thr Thr Leu
Ser Gln Gly Gly Thr His 5285 5290 5295 Ser Thr Val Thr Gln Gly Phe
Pro Tyr Ser Glu Val Thr Thr Leu 5300 5305 5310 Met Gly Met Gly Pro
Gly Asn Val Ser Trp Met Thr Thr Pro Pro 5315 5320 5325 Val Glu Glu
Thr Ser Ser Val Ser Ser Leu Met Ser Ser Pro Ala 5330 5335 5340 Met
Thr Ser Pro Ser Pro Val Ser Ser Thr Ser Pro Gln Ser Ile 5345 5350
5355 Pro Ser Ser Pro Leu Pro Val Thr Ala Leu Pro Thr Ser Val Leu
5360 5365 5370 Val Thr Thr Thr Asp Val Leu Gly Thr Thr Ser Pro Glu
Ser Val 5375 5380 5385 Thr Ser Ser Pro Pro Asn Leu
Ser Ser Ile Thr His Glu Arg Pro 5390 5395 5400 Ala Thr Tyr Lys Asp
Thr Ala His Thr Glu Ala Ala Met His His 5405 5410 5415 Ser Thr Asn
Thr Ala Val Thr Asn Val Gly Thr Ser Gly Ser Gly 5420 5425 5430 His
Lys Ser Gln Ser Ser Val Leu Ala Asp Ser Glu Thr Ser Lys 5435 5440
5445 Ala Thr Pro Leu Met Ser Thr Thr Ser Thr Leu Gly Asp Thr Ser
5450 5455 5460 Val Ser Thr Ser Thr Pro Asn Ile Ser Gln Thr Asn Gln
Ile Gln 5465 5470 5475 Thr Glu Pro Thr Ala Ser Leu Ser Pro Arg Leu
Arg Glu Ser Ser 5480 5485 5490 Thr Ser Glu Lys Thr Ser Ser Thr Thr
Glu Thr Asn Thr Ala Phe 5495 5500 5505 Ser Tyr Val Pro Thr Gly Ala
Ile Thr Gln Ala Ser Arg Thr Glu 5510 5515 5520 Ile Ser Ser Ser Arg
Thr Ser Ile Ser Asp Leu Asp Arg Pro Thr 5525 5530 5535 Ile Ala Pro
Asp Ile Ser Thr Gly Met Ile Thr Arg Leu Phe Thr 5540 5545 5550 Ser
Pro Ile Met Thr Lys Ser Ala Glu Met Thr Val Thr Thr Gln 5555 5560
5565 Thr Thr Thr Pro Gly Ala Thr Ser Gln Gly Ile Leu Pro Trp Asp
5570 5575 5580 Thr Ser Thr Thr Leu Phe Gln Gly Gly Thr His Ser Thr
Val Ser 5585 5590 5595 Gln Gly Phe Pro His Ser Glu Ile Thr Thr Leu
Arg Ser Arg Thr 5600 5605 5610 Pro Gly Asp Val Ser Trp Met Thr Thr
Pro Pro Val Glu Glu Thr 5615 5620 5625 Ser Ser Gly Phe Ser Leu Met
Ser Pro Ser Met Thr Ser Pro Ser 5630 5635 5640 Pro Val Ser Ser Thr
Ser Pro Glu Ser Ile Pro Ser Ser Pro Leu 5645 5650 5655 Pro Val Thr
Ala Leu Leu Thr Ser Val Leu Val Thr Thr Thr Asn 5660 5665 5670 Val
Leu Gly Thr Thr Ser Pro Glu Pro Val Thr Ser Ser Pro Pro 5675 5680
5685 Asn Leu Ser Ser Pro Thr Gln Glu Arg Leu Thr Thr Tyr Lys Asp
5690 5695 5700 Thr Ala His Thr Glu Ala Met His Ala Ser Met His Thr
Asn Thr 5705 5710 5715 Ala Val Ala Asn Val Gly Thr Ser Ile Ser Gly
His Glu Ser Gln 5720 5725 5730 Ser Ser Val Pro Ala Asp Ser His Thr
Ser Lys Ala Thr Ser Pro 5735 5740 5745 Met Gly Ile Thr Phe Ala Met
Gly Asp Thr Ser Val Ser Thr Ser 5750 5755 5760 Thr Pro Ala Phe Phe
Glu Thr Arg Ile Gln Thr Glu Ser Thr Ser 5765 5770 5775 Ser Leu Ile
Pro Gly Leu Arg Asp Thr Arg Thr Ser Glu Glu Ile 5780 5785 5790 Asn
Thr Val Thr Glu Thr Ser Thr Val Leu Ser Glu Val Pro Thr 5795 5800
5805 Thr Thr Thr Thr Glu Val Ser Arg Thr Glu Val Ile Thr Ser Ser
5810 5815 5820 Arg Thr Thr Ile Ser Gly Pro Asp His Ser Lys Met Ser
Pro Tyr 5825 5830 5835 Ile Ser Thr Glu Thr Ile Thr Arg Leu Ser Thr
Phe Pro Phe Val 5840 5845 5850 Thr Gly Ser Thr Glu Met Ala Ile Thr
Asn Gln Thr Gly Pro Ile 5855 5860 5865 Gly Thr Ile Ser Gln Ala Thr
Leu Thr Leu Asp Thr Ser Ser Thr 5870 5875 5880 Ala Ser Trp Glu Gly
Thr His Ser Pro Val Thr Gln Arg Phe Pro 5885 5890 5895 His Ser Glu
Glu Thr Thr Thr Met Ser Arg Ser Thr Lys Gly Val 5900 5905 5910 Ser
Trp Gln Ser Pro Pro Ser Val Glu Glu Thr Ser Ser Pro Ser 5915 5920
5925 Ser Pro Val Pro Leu Pro Ala Ile Thr Ser His Ser Ser Leu Tyr
5930 5935 5940 Ser Ala Val Ser Gly Ser Ser Pro Thr Ser Ala Leu Pro
Val Thr 5945 5950 5955 Ser Leu Leu Thr Ser Gly Arg Arg Lys Thr Ile
Asp Met Leu Asp 5960 5965 5970 Thr His Ser Glu Leu Val Thr Ser Ser
Leu Pro Ser Ala Ser Ser 5975 5980 5985 Phe Ser Gly Glu Ile Leu Thr
Ser Glu Ala Ser Thr Asn Thr Glu 5990 5995 6000 Thr Ile His Phe Ser
Glu Asn Thr Ala Glu Thr Asn Met Gly Thr 6005 6010 6015 Thr Asn Ser
Met His Lys Leu His Ser Ser Val Ser Ile His Ser 6020 6025 6030 Gln
Pro Ser Gly His Thr Pro Pro Lys Val Thr Gly Ser Met Met 6035 6040
6045 Glu Asp Ala Ile Val Ser Thr Ser Thr Pro Gly Ser Pro Glu Thr
6050 6055 6060 Lys Asn Val Asp Arg Asp Ser Thr Ser Pro Leu Thr Pro
Glu Leu 6065 6070 6075 Lys Glu Asp Ser Thr Ala Leu Val Met Asn Ser
Thr Thr Glu Ser 6080 6085 6090 Asn Thr Val Phe Ser Ser Val Ser Leu
Asp Ala Ala Thr Glu Val 6095 6100 6105 Ser Arg Ala Glu Val Thr Tyr
Tyr Asp Pro Thr Phe Met Pro Ala 6110 6115 6120 Ser Ala Gln Ser Thr
Lys Ser Pro Asp Ile Ser Pro Glu Ala Ser 6125 6130 6135 Ser Ser His
Ser Asn Ser Pro Pro Leu Thr Ile Ser Thr His Lys 6140 6145 6150 Thr
Ile Ala Thr Gln Thr Gly Pro Ser Gly Val Thr Ser Leu Gly 6155 6160
6165 Gln Leu Thr Leu Asp Thr Ser Thr Ile Ala Thr Ser Ala Gly Thr
6170 6175 6180 Pro Ser Ala Arg Thr Gln Asp Phe Val Asp Ser Glu Thr
Thr Ser 6185 6190 6195 Val Met Asn Asn Asp Leu Asn Asp Val Leu Lys
Thr Ser Pro Phe 6200 6205 6210 Ser Ala Glu Glu Ala Asn Ser Leu Ser
Ser Gln Ala Pro Leu Leu 6215 6220 6225 Val Thr Thr Ser Pro Ser Pro
Val Thr Ser Thr Leu Gln Glu His 6230 6235 6240 Ser Thr Ser Ser Leu
Val Ser Val Thr Ser Val Pro Thr Pro Thr 6245 6250 6255 Leu Ala Lys
Ile Thr Asp Met Asp Thr Asn Leu Glu Pro Val Thr 6260 6265 6270 Arg
Ser Pro Gln Asn Leu Arg Asn Thr Leu Ala Thr Ser Glu Ala 6275 6280
6285 Thr Thr Asp Thr His Thr Met His Pro Ser Ile Asn Thr Ala Val
6290 6295 6300 Ala Asn Val Gly Thr Thr Ser Ser Pro Asn Glu Phe Tyr
Phe Thr 6305 6310 6315 Val Ser Pro Asp Ser Asp Pro Tyr Lys Ala Thr
Ser Ala Val Val 6320 6325 6330 Ile Thr Ser Thr Ser Gly Asp Ser Ile
Val Ser Thr Ser Met Pro 6335 6340 6345 Arg Ser Ser Ala Met Lys Lys
Ile Glu Ser Glu Thr Thr Phe Ser 6350 6355 6360 Leu Ile Phe Arg Leu
Arg Glu Thr Ser Thr Ser Gln Lys Ile Gly 6365 6370 6375 Ser Ser Ser
Asp Thr Ser Thr Val Phe Asp Lys Ala Phe Thr Ala 6380 6385 6390 Ala
Thr Thr Glu Val Ser Arg Thr Glu Leu Thr Ser Ser Ser Arg 6395 6400
6405 Thr Ser Ile Gln Gly Thr Glu Lys Pro Thr Met Ser Pro Asp Thr
6410 6415 6420 Ser Thr Arg Ser Val Thr Met Leu Ser Thr Phe Ala Gly
Leu Thr 6425 6430 6435 Lys Ser Glu Glu Arg Thr Ile Ala Thr Gln Thr
Gly Pro His Arg 6440 6445 6450 Ala Thr Ser Gln Gly Thr Leu Thr Trp
Asp Thr Ser Ile Thr Thr 6455 6460 6465 Ser Gln Ala Gly Thr His Ser
Ala Met Thr His Gly Phe Ser Gln 6470 6475 6480 Leu Asp Leu Ser Thr
Leu Thr Ser Arg Val Pro Glu Tyr Ile Ser 6485 6490 6495 Gly Thr Ser
Pro Pro Ser Val Glu Lys Thr Ser Ser Ser Ser Ser 6500 6505 6510 Leu
Leu Ser Leu Pro Ala Ile Thr Ser Pro Ser Pro Val Pro Thr 6515 6520
6525 Thr Leu Pro Glu Ser Arg Pro Ser Ser Pro Val His Leu Thr Ser
6530 6535 6540 Leu Pro Thr Ser Gly Leu Val Lys Thr Thr Asp Met Leu
Ala Ser 6545 6550 6555 Val Ala Ser Leu Pro Pro Asn Leu Gly Ser Thr
Ser His Lys Ile 6560 6565 6570 Pro Thr Thr Ser Glu Asp Ile Lys Asp
Thr Glu Lys Met Tyr Pro 6575 6580 6585 Ser Thr Asn Ile Ala Val Thr
Asn Val Gly Thr Thr Thr Ser Glu 6590 6595 6600 Lys Glu Ser Tyr Ser
Ser Val Pro Ala Tyr Ser Glu Pro Pro Lys 6605 6610 6615 Val Thr Ser
Pro Met Val Thr Ser Phe Asn Ile Arg Asp Thr Ile 6620 6625 6630 Val
Ser Thr Ser Met Pro Gly Ser Ser Glu Ile Thr Arg Ile Glu 6635 6640
6645 Met Glu Ser Thr Phe Ser Leu Ala His Gly Leu Lys Gly Thr Ser
6650 6655 6660 Thr Ser Gln Asp Pro Ile Val Ser Thr Glu Lys Ser Ala
Val Leu 6665 6670 6675 His Lys Leu Thr Thr Gly Ala Thr Glu Thr Ser
Arg Thr Glu Val 6680 6685 6690 Ala Ser Ser Arg Arg Thr Ser Ile Pro
Gly Pro Asp His Ser Thr 6695 6700 6705 Glu Ser Pro Asp Ile Ser Thr
Glu Val Ile Pro Ser Leu Pro Ile 6710 6715 6720 Ser Leu Gly Ile Thr
Glu Ser Ser Asn Met Thr Ile Ile Thr Arg 6725 6730 6735 Thr Gly Pro
Pro Leu Gly Ser Thr Ser Gln Gly Thr Phe Thr Leu 6740 6745 6750 Asp
Thr Pro Thr Thr Ser Ser Arg Ala Gly Thr His Ser Met Ala 6755 6760
6765 Thr Gln Glu Phe Pro His Ser Glu Met Thr Thr Val Met Asn Lys
6770 6775 6780 Asp Pro Glu Ile Leu Ser Trp Thr Ile Pro Pro Ser Ile
Glu Lys 6785 6790 6795 Thr Ser Phe Ser Ser Ser Leu Met Pro Ser Pro
Ala Met Thr Ser 6800 6805 6810 Pro Pro Val Ser Ser Thr Leu Pro Lys
Thr Ile His Thr Thr Pro 6815 6820 6825 Ser Pro Met Thr Ser Leu Leu
Thr Pro Ser Leu Val Met Thr Thr 6830 6835 6840 Asp Thr Leu Gly Thr
Ser Pro Glu Pro Thr Thr Ser Ser Pro Pro 6845 6850 6855 Asn Leu Ser
Ser Thr Ser His Glu Ile Leu Thr Thr Asp Glu Asp 6860 6865 6870 Thr
Thr Ala Ile Glu Ala Met His Pro Ser Thr Ser Thr Ala Ala 6875 6880
6885 Thr Asn Val Glu Thr Thr Ser Ser Gly His Gly Ser Gln Ser Ser
6890 6895 6900 Val Leu Ala Asp Ser Glu Lys Thr Lys Ala Thr Ala Pro
Met Asp 6905 6910 6915 Thr Thr Ser Thr Met Gly His Thr Thr Val Ser
Thr Ser Met Ser 6920 6925 6930 Val Ser Ser Glu Thr Thr Lys Ile Lys
Arg Glu Ser Thr Tyr Ser 6935 6940 6945 Leu Thr Pro Gly Leu Arg Glu
Thr Ser Ile Ser Gln Asn Ala Ser 6950 6955 6960 Phe Ser Thr Asp Thr
Ser Ile Val Leu Ser Glu Val Pro Thr Gly 6965 6970 6975 Thr Thr Ala
Glu Val Ser Arg Thr Glu Val Thr Ser Ser Gly Arg 6980 6985 6990 Thr
Ser Ile Pro Gly Pro Ser Gln Ser Thr Val Leu Pro Glu Ile 6995 7000
7005 Ser Thr Arg Thr Met Thr Arg Leu Phe Ala Ser Pro Thr Met Thr
7010 7015 7020 Glu Ser Ala Glu Met Thr Ile Pro Thr Gln Thr Gly Pro
Ser Gly 7025 7030 7035 Ser Thr Ser Gln Asp Thr Leu Thr Leu Asp Thr
Ser Thr Thr Lys 7040 7045 7050 Ser Gln Ala Lys Thr His Ser Thr Leu
Thr Gln Arg Phe Pro His 7055 7060 7065 Ser Glu Met Thr Thr Leu Met
Ser Arg Gly Pro Gly Asp Met Ser 7070 7075 7080 Trp Gln Ser Ser Pro
Ser Leu Glu Asn Pro Ser Ser Leu Pro Ser 7085 7090 7095 Leu Leu Ser
Leu Pro Ala Thr Thr Ser Pro Pro Pro Ile Ser Ser 7100 7105 7110 Thr
Leu Pro Val Thr Ile Ser Ser Ser Pro Leu Pro Val Thr Ser 7115 7120
7125 Leu Leu Thr Ser Ser Pro Val Thr Thr Thr Asp Met Leu His Thr
7130 7135 7140 Ser Pro Glu Leu Val Thr Ser Ser Pro Pro Lys Leu Ser
His Thr 7145 7150 7155 Ser Asp Glu Arg Leu Thr Thr Gly Lys Asp Thr
Thr Asn Thr Glu 7160 7165 7170 Ala Val His Pro Ser Thr Asn Thr Ala
Ala Ser Asn Val Glu Ile 7175 7180 7185 Pro Ser Ser Gly His Glu Ser
Pro Ser Ser Ala Leu Ala Asp Ser 7190 7195 7200 Glu Thr Ser Lys Ala
Thr Ser Pro Met Phe Ile Thr Ser Thr Gln 7205 7210 7215 Glu Asp Thr
Thr Val Ala Ile Ser Thr Pro His Phe Leu Glu Thr 7220 7225 7230 Ser
Arg Ile Gln Lys Glu Ser Ile Ser Ser Leu Ser Pro Lys Leu 7235 7240
7245 Arg Glu Thr Gly Ser Ser Val Glu Thr Ser Ser Ala Ile Glu Thr
7250 7255 7260 Ser Ala Val Leu Ser Glu Val Ser Ile Gly Ala Thr Thr
Glu Ile 7265 7270 7275 Ser Arg Thr Glu Val Thr Ser Ser Ser Arg Thr
Ser Ile Ser Gly 7280 7285 7290 Ser Ala Glu Ser Thr Met Leu Pro Glu
Ile Ser Thr Thr Arg Lys 7295 7300 7305 Ile Ile Lys Phe Pro Thr Ser
Pro Ile Leu Ala Glu Ser Ser Glu 7310 7315 7320 Met Thr Ile Lys Thr
Gln Thr Ser Pro Pro Gly Ser Thr Ser Glu 7325 7330 7335 Ser Thr Phe
Thr Leu Asp Thr Ser Thr Thr Pro Ser Leu Val Ile 7340 7345 7350 Thr
His Ser Thr Met Thr Gln Arg Leu Pro His Ser Glu Ile Thr 7355 7360
7365 Thr Leu Val Ser Arg Gly Ala Gly Asp Val Pro Arg Pro Ser Ser
7370 7375 7380 Leu Pro Val Glu Glu Thr Ser Pro Pro Ser Ser Gln Leu
Ser Leu 7385 7390 7395 Ser Ala Met Ile Ser Pro Ser Pro Val Ser Ser
Thr Leu Pro Ala 7400 7405 7410 Ser Ser His Ser Ser Ser Ala Ser Val
Thr Ser Leu Leu Thr Pro 7415 7420 7425 Gly Gln Val Lys Thr Thr Glu
Val Leu Asp Ala Ser Ala Glu Pro 7430 7435 7440 Glu Thr Ser Ser Pro
Pro Ser Leu Ser Ser Thr Ser Val Glu Ile 7445 7450 7455 Leu Ala Thr
Ser Glu Val Thr Thr Asp Thr Glu Lys Ile His Pro 7460 7465 7470 Phe
Ser Asn Thr Ala Val Thr Lys Val Gly Thr Ser Ser Ser Gly 7475 7480
7485 His Glu Ser Pro Ser Ser Val Leu Pro Asp Ser Glu Thr Thr Lys
7490 7495 7500 Ala Thr Ser Ala Met Gly Thr Ile Ser Ile Met Gly Asp
Thr Ser 7505 7510 7515 Val Ser Thr Leu Thr Pro Ala Leu Ser Asn Thr
Arg Lys Ile Gln 7520 7525 7530 Ser Glu Pro Ala Ser Ser Leu Thr Thr
Arg Leu Arg Glu Thr Ser 7535 7540 7545 Thr Ser Glu Glu Thr Ser Leu
Ala Thr Glu Ala Asn Thr Val Leu 7550 7555 7560 Ser Lys Val Ser Thr
Gly Ala Thr Thr Glu Val Ser Arg Thr Glu 7565 7570 7575 Ala Ile Ser
Phe Ser Arg Thr Ser Met Ser Gly Pro Glu Gln Ser 7580
7585 7590 Thr Met Ser Gln Asp Ile Ser Ile Gly Thr Ile Pro Arg Ile
Ser 7595 7600 7605 Ala Ser Ser Val Leu Thr Glu Ser Ala Lys Met Thr
Ile Thr Thr 7610 7615 7620 Gln Thr Gly Pro Ser Glu Ser Thr Leu Glu
Ser Thr Leu Asn Leu 7625 7630 7635 Asn Thr Ala Thr Thr Pro Ser Trp
Val Glu Thr His Ser Ile Val 7640 7645 7650 Ile Gln Gly Phe Pro His
Pro Glu Met Thr Thr Ser Met Gly Arg 7655 7660 7665 Gly Pro Gly Gly
Val Ser Trp Pro Ser Pro Pro Phe Val Lys Glu 7670 7675 7680 Thr Ser
Pro Pro Ser Ser Pro Leu Ser Leu Pro Ala Val Thr Ser 7685 7690 7695
Pro His Pro Val Ser Thr Thr Phe Leu Ala His Ile Pro Pro Ser 7700
7705 7710 Pro Leu Pro Val Thr Ser Leu Leu Thr Ser Gly Pro Ala Thr
Thr 7715 7720 7725 Thr Asp Ile Leu Gly Thr Ser Thr Glu Pro Gly Thr
Ser Ser Ser 7730 7735 7740 Ser Ser Leu Ser Thr Thr Ser His Glu Arg
Leu Thr Thr Tyr Lys 7745 7750 7755 Asp Thr Ala His Thr Glu Ala Val
His Pro Ser Thr Asn Thr Gly 7760 7765 7770 Gly Thr Asn Val Ala Thr
Thr Ser Ser Gly Tyr Lys Ser Gln Ser 7775 7780 7785 Ser Val Leu Ala
Asp Ser Ser Pro Met Cys Thr Thr Ser Thr Met 7790 7795 7800 Gly Asp
Thr Ser Val Leu Thr Ser Thr Pro Ala Phe Leu Glu Thr 7805 7810 7815
Arg Arg Ile Gln Thr Glu Leu Ala Ser Ser Leu Thr Pro Gly Leu 7820
7825 7830 Arg Glu Ser Ser Gly Ser Glu Gly Thr Ser Ser Gly Thr Lys
Met 7835 7840 7845 Ser Thr Val Leu Ser Lys Val Pro Thr Gly Ala Thr
Thr Glu Ile 7850 7855 7860 Ser Lys Glu Asp Val Thr Ser Ile Pro Gly
Pro Ala Gln Ser Thr 7865 7870 7875 Ile Ser Pro Asp Ile Ser Thr Arg
Thr Val Ser Trp Phe Ser Thr 7880 7885 7890 Ser Pro Val Met Thr Glu
Ser Ala Glu Ile Thr Met Asn Thr His 7895 7900 7905 Thr Ser Pro Leu
Gly Ala Thr Thr Gln Gly Thr Ser Thr Leu Asp 7910 7915 7920 Thr Ser
Ser Thr Thr Ser Leu Thr Met Thr His Ser Thr Ile Ser 7925 7930 7935
Gln Gly Phe Ser His Ser Gln Met Ser Thr Leu Met Arg Arg Gly 7940
7945 7950 Pro Glu Asp Val Ser Trp Met Ser Pro Pro Leu Leu Glu Lys
Thr 7955 7960 7965 Arg Pro Ser Phe Ser Leu Met Ser Ser Pro Ala Thr
Thr Ser Pro 7970 7975 7980 Ser Pro Val Ser Ser Thr Leu Pro Glu Ser
Ile Ser Ser Ser Pro 7985 7990 7995 Leu Pro Val Thr Ser Leu Leu Thr
Ser Gly Leu Ala Lys Thr Thr 8000 8005 8010 Asp Met Leu His Lys Ser
Ser Glu Pro Val Thr Asn Ser Pro Ala 8015 8020 8025 Asn Leu Ser Ser
Thr Ser Val Glu Ile Leu Ala Thr Ser Glu Val 8030 8035 8040 Thr Thr
Asp Thr Glu Lys Thr His Pro Ser Ser Asn Arg Thr Val 8045 8050 8055
Thr Asp Val Gly Thr Ser Ser Ser Gly His Glu Ser Thr Ser Phe 8060
8065 8070 Val Leu Ala Asp Ser Gln Thr Ser Lys Val Thr Ser Pro Met
Val 8075 8080 8085 Ile Thr Ser Thr Met Glu Asp Thr Ser Val Ser Thr
Ser Thr Pro 8090 8095 8100 Gly Phe Phe Glu Thr Ser Arg Ile Gln Thr
Glu Pro Thr Ser Ser 8105 8110 8115 Leu Thr Leu Gly Leu Arg Lys Thr
Ser Ser Ser Glu Gly Thr Ser 8120 8125 8130 Leu Ala Thr Glu Met Ser
Thr Val Leu Ser Gly Val Pro Thr Gly 8135 8140 8145 Ala Thr Ala Glu
Val Ser Arg Thr Glu Val Thr Ser Ser Ser Arg 8150 8155 8160 Thr Ser
Ile Ser Gly Phe Ala Gln Leu Thr Val Ser Pro Glu Thr 8165 8170 8175
Ser Thr Glu Thr Ile Thr Arg Leu Pro Thr Ser Ser Ile Met Thr 8180
8185 8190 Glu Ser Ala Glu Met Met Ile Lys Thr Gln Thr Asp Pro Pro
Gly 8195 8200 8205 Ser Thr Pro Glu Ser Thr His Thr Val Asp Ile Ser
Thr Thr Pro 8210 8215 8220 Asn Trp Val Glu Thr His Ser Thr Val Thr
Gln Arg Phe Ser His 8225 8230 8235 Ser Glu Met Thr Thr Leu Val Ser
Arg Ser Pro Gly Asp Met Leu 8240 8245 8250 Trp Pro Ser Gln Ser Ser
Val Glu Glu Thr Ser Ser Ala Ser Ser 8255 8260 8265 Leu Leu Ser Leu
Pro Ala Thr Thr Ser Pro Ser Pro Val Ser Ser 8270 8275 8280 Thr Leu
Val Glu Asp Phe Pro Ser Ala Ser Leu Pro Val Thr Ser 8285 8290 8295
Leu Leu Asn Pro Gly Leu Val Ile Thr Thr Asp Arg Met Gly Ile 8300
8305 8310 Ser Arg Glu Pro Gly Thr Ser Ser Thr Ser Asn Leu Ser Ser
Thr 8315 8320 8325 Ser His Glu Arg Leu Thr Thr Leu Glu Asp Thr Val
Asp Thr Glu 8330 8335 8340 Asp Met Gln Pro Ser Thr His Thr Ala Val
Thr Asn Val Arg Thr 8345 8350 8355 Ser Ile Ser Gly His Glu Ser Gln
Ser Ser Val Leu Ser Asp Ser 8360 8365 8370 Glu Thr Pro Lys Ala Thr
Ser Pro Met Gly Thr Thr Tyr Thr Met 8375 8380 8385 Gly Glu Thr Ser
Val Ser Ile Ser Thr Ser Asp Phe Phe Glu Thr 8390 8395 8400 Ser Arg
Ile Gln Ile Glu Pro Thr Ser Ser Leu Thr Ser Gly Leu 8405 8410 8415
Arg Glu Thr Ser Ser Ser Glu Arg Ile Ser Ser Ala Thr Glu Gly 8420
8425 8430 Ser Thr Val Leu Ser Glu Val Pro Ser Gly Ala Thr Thr Glu
Val 8435 8440 8445 Ser Arg Thr Glu Val Ile Ser Ser Arg Gly Thr Ser
Met Ser Gly 8450 8455 8460 Pro Asp Gln Phe Thr Ile Ser Pro Asp Ile
Ser Thr Glu Ala Ile 8465 8470 8475 Thr Arg Leu Ser Thr Ser Pro Ile
Met Thr Glu Ser Ala Glu Ser 8480 8485 8490 Ala Ile Thr Ile Glu Thr
Gly Ser Pro Gly Ala Thr Ser Glu Gly 8495 8500 8505 Thr Leu Thr Leu
Asp Thr Ser Thr Thr Thr Phe Trp Ser Gly Thr 8510 8515 8520 His Ser
Thr Ala Ser Pro Gly Phe Ser His Ser Glu Met Thr Thr 8525 8530 8535
Leu Met Ser Arg Thr Pro Gly Asp Val Pro Trp Pro Ser Leu Pro 8540
8545 8550 Ser Val Glu Glu Ala Ser Ser Val Ser Ser Ser Leu Ser Ser
Pro 8555 8560 8565 Ala Met Thr Ser Thr Ser Phe Phe Ser Thr Leu Pro
Glu Ser Ile 8570 8575 8580 Ser Ser Ser Pro His Pro Val Thr Ala Leu
Leu Thr Leu Gly Pro 8585 8590 8595 Val Lys Thr Thr Asp Met Leu Arg
Thr Ser Ser Glu Pro Glu Thr 8600 8605 8610 Ser Ser Pro Pro Asn Leu
Ser Ser Thr Ser Ala Glu Ile Leu Ala 8615 8620 8625 Thr Ser Glu Val
Thr Lys Asp Arg Glu Lys Ile His Pro Ser Ser 8630 8635 8640 Asn Thr
Pro Val Val Asn Val Gly Thr Val Ile Tyr Lys His Leu 8645 8650 8655
Ser Pro Ser Ser Val Leu Ala Asp Leu Val Thr Thr Lys Pro Thr 8660
8665 8670 Ser Pro Met Ala Thr Thr Ser Thr Leu Gly Asn Thr Ser Val
Ser 8675 8680 8685 Thr Ser Thr Pro Ala Phe Pro Glu Thr Met Met Thr
Gln Pro Thr 8690 8695 8700 Ser Ser Leu Thr Ser Gly Leu Arg Glu Ile
Ser Thr Ser Gln Glu 8705 8710 8715 Thr Ser Ser Ala Thr Glu Arg Ser
Ala Ser Leu Ser Gly Met Pro 8720 8725 8730 Thr Gly Ala Thr Thr Lys
Val Ser Arg Thr Glu Ala Leu Ser Leu 8735 8740 8745 Gly Arg Thr Ser
Thr Pro Gly Pro Ala Gln Ser Thr Ile Ser Pro 8750 8755 8760 Glu Ile
Ser Thr Glu Thr Ile Thr Arg Ile Ser Thr Pro Leu Thr 8765 8770 8775
Thr Thr Gly Ser Ala Glu Met Thr Ile Thr Pro Lys Thr Gly His 8780
8785 8790 Ser Gly Ala Ser Ser Gln Gly Thr Phe Thr Leu Asp Thr Ser
Ser 8795 8800 8805 Arg Ala Ser Trp Pro Gly Thr His Ser Ala Ala Thr
His Arg Ser 8810 8815 8820 Pro His Ser Gly Met Thr Thr Pro Met Ser
Arg Gly Pro Glu Asp 8825 8830 8835 Val Ser Trp Pro Ser Arg Pro Ser
Val Glu Lys Thr Ser Pro Pro 8840 8845 8850 Ser Ser Leu Val Ser Leu
Ser Ala Val Thr Ser Pro Ser Pro Leu 8855 8860 8865 Tyr Ser Thr Pro
Ser Glu Ser Ser His Ser Ser Pro Leu Arg Val 8870 8875 8880 Thr Ser
Leu Phe Thr Pro Val Met Met Lys Thr Thr Asp Met Leu 8885 8890 8895
Asp Thr Ser Leu Glu Pro Val Thr Thr Ser Pro Pro Ser Met Asn 8900
8905 8910 Ile Thr Ser Asp Glu Ser Leu Ala Thr Ser Lys Ala Thr Met
Glu 8915 8920 8925 Thr Glu Ala Ile Gln Leu Ser Glu Asn Thr Ala Val
Thr Gln Met 8930 8935 8940 Gly Thr Ile Ser Ala Arg Gln Glu Phe Tyr
Ser Ser Tyr Pro Gly 8945 8950 8955 Leu Pro Glu Pro Ser Lys Val Thr
Ser Pro Val Val Thr Ser Ser 8960 8965 8970 Thr Ile Lys Asp Ile Val
Ser Thr Thr Ile Pro Ala Ser Ser Glu 8975 8980 8985 Ile Thr Arg Ile
Glu Met Glu Ser Thr Ser Thr Leu Thr Pro Thr 8990 8995 9000 Pro Arg
Glu Thr Ser Thr Ser Gln Glu Ile His Ser Ala Thr Lys 9005 9010 9015
Pro Ser Thr Val Pro Tyr Lys Ala Leu Thr Ser Ala Thr Ile Glu 9020
9025 9030 Asp Ser Met Thr Gln Val Met Ser Ser Ser Arg Gly Pro Ser
Pro 9035 9040 9045 Asp Gln Ser Thr Met Ser Gln Asp Ile Ser Thr Glu
Val Ile Thr 9050 9055 9060 Arg Leu Ser Thr Ser Pro Ile Lys Thr Glu
Ser Thr Glu Met Thr 9065 9070 9075 Ile Thr Thr Gln Thr Gly Ser Pro
Gly Ala Thr Ser Arg Gly Thr 9080 9085 9090 Leu Thr Leu Asp Thr Ser
Thr Thr Phe Met Ser Gly Thr His Ser 9095 9100 9105 Thr Ala Ser Gln
Gly Phe Ser His Ser Gln Met Thr Ala Leu Met 9110 9115 9120 Ser Arg
Thr Pro Gly Asp Val Pro Trp Leu Ser His Pro Ser Val 9125 9130 9135
Glu Glu Ala Ser Ser Ala Ser Phe Ser Leu Ser Ser Pro Val Met 9140
9145 9150 Thr Ser Ser Ser Pro Val Ser Ser Thr Leu Pro Asp Ser Ile
His 9155 9160 9165 Ser Ser Ser Leu Pro Val Thr Ser Leu Leu Thr Ser
Gly Leu Val 9170 9175 9180 Lys Thr Thr Glu Leu Leu Gly Thr Ser Ser
Glu Pro Glu Thr Ser 9185 9190 9195 Ser Pro Pro Asn Leu Ser Ser Thr
Ser Ala Glu Ile Leu Ala Ile 9200 9205 9210 Thr Glu Val Thr Thr Asp
Thr Glu Lys Leu Glu Met Thr Asn Val 9215 9220 9225 Val Thr Ser Gly
Tyr Thr His Glu Ser Pro Ser Ser Val Leu Ala 9230 9235 9240 Asp Ser
Val Thr Thr Lys Ala Thr Ser Ser Met Gly Ile Thr Tyr 9245 9250 9255
Pro Thr Gly Asp Thr Asn Val Leu Thr Ser Thr Pro Ala Phe Ser 9260
9265 9270 Asp Thr Ser Arg Ile Gln Thr Lys Ser Lys Leu Ser Leu Thr
Pro 9275 9280 9285 Gly Leu Met Glu Thr Ser Ile Ser Glu Glu Thr Ser
Ser Ala Thr 9290 9295 9300 Glu Lys Ser Thr Val Leu Ser Ser Val Pro
Thr Gly Ala Thr Thr 9305 9310 9315 Glu Val Ser Arg Thr Glu Ala Ile
Ser Ser Ser Arg Thr Ser Ile 9320 9325 9330 Pro Gly Pro Ala Gln Ser
Thr Met Ser Ser Asp Thr Ser Met Glu 9335 9340 9345 Thr Ile Thr Arg
Ile Ser Thr Pro Leu Thr Arg Lys Glu Ser Thr 9350 9355 9360 Asp Met
Ala Ile Thr Pro Lys Thr Gly Pro Ser Gly Ala Thr Ser 9365 9370 9375
Gln Gly Thr Phe Thr Leu Asp Ser Ser Ser Thr Ala Ser Trp Pro 9380
9385 9390 Gly Thr His Ser Ala Thr Thr Gln Arg Phe Pro Gln Ser Val
Val 9395 9400 9405 Thr Thr Pro Met Ser Arg Gly Pro Glu Asp Val Ser
Trp Pro Ser 9410 9415 9420 Pro Leu Ser Val Glu Lys Asn Ser Pro Pro
Ser Ser Leu Val Ser 9425 9430 9435 Ser Ser Ser Val Thr Ser Pro Ser
Pro Leu Tyr Ser Thr Pro Ser 9440 9445 9450 Gly Ser Ser His Ser Ser
Pro Val Pro Val Thr Ser Leu Phe Thr 9455 9460 9465 Ser Ile Met Met
Lys Ala Thr Asp Met Leu Asp Ala Ser Leu Glu 9470 9475 9480 Pro Glu
Thr Thr Ser Ala Pro Asn Met Asn Ile Thr Ser Asp Glu 9485 9490 9495
Ser Leu Ala Ala Ser Lys Ala Thr Thr Glu Thr Glu Ala Ile His 9500
9505 9510 Val Phe Glu Asn Thr Ala Ala Ser His Val Glu Thr Thr Ser
Ala 9515 9520 9525 Thr Glu Glu Leu Tyr Ser Ser Ser Pro Gly Phe Ser
Glu Pro Thr 9530 9535 9540 Lys Val Ile Ser Pro Val Val Thr Ser Ser
Ser Ile Arg Asp Asn 9545 9550 9555 Met Val Ser Thr Thr Met Pro Gly
Ser Ser Gly Ile Thr Arg Ile 9560 9565 9570 Glu Ile Glu Ser Met Ser
Ser Leu Thr Pro Gly Leu Arg Glu Thr 9575 9580 9585 Arg Thr Ser Gln
Asp Ile Thr Ser Ser Thr Glu Thr Ser Thr Val 9590 9595 9600 Leu Tyr
Lys Met Pro Ser Gly Ala Thr Pro Glu Val Ser Arg Thr 9605 9610 9615
Glu Val Met Pro Ser Ser Arg Thr Ser Ile Pro Gly Pro Ala Gln 9620
9625 9630 Ser Thr Met Ser Leu Asp Ile Ser Asp Glu Val Val Thr Arg
Leu 9635 9640 9645 Ser Thr Ser Pro Ile Met Thr Glu Ser Ala Glu Ile
Thr Ile Thr 9650 9655 9660 Thr Gln Thr Gly Tyr Ser Leu Ala Thr Ser
Gln Val Thr Leu Pro 9665 9670 9675 Leu Gly Thr Ser Met Thr Phe Leu
Ser Gly Thr His Ser Thr Met 9680 9685 9690 Ser Gln Gly Leu Ser His
Ser Glu Met Thr Asn Leu Met Ser Arg 9695 9700 9705 Gly Pro Glu Ser
Leu Ser Trp Thr Ser Pro Arg Phe Val Glu Thr 9710 9715 9720 Thr Arg
Ser Ser Ser Ser Leu Thr Ser Leu Pro Leu Thr Thr Ser 9725 9730 9735
Leu Ser Pro Val Ser Ser Thr Leu Leu Asp Ser Ser Pro Ser Ser 9740
9745 9750 Pro Leu Pro Val Thr Ser Leu Ile Leu Pro Gly Leu Val Lys
Thr 9755 9760 9765 Thr Glu Val Leu Asp Thr Ser Ser Glu Pro Lys Thr
Ser Ser Ser 9770 9775 9780 Pro Asn
Leu Ser Ser Thr Ser Val Glu Ile Pro Ala Thr Ser Glu 9785 9790 9795
Ile Met Thr Asp Thr Glu Lys Ile His Pro Ser Ser Asn Thr Ala 9800
9805 9810 Val Ala Lys Val Arg Thr Ser Ser Ser Val His Glu Ser His
Ser 9815 9820 9825 Ser Val Leu Ala Asp Ser Glu Thr Thr Ile Thr Ile
Pro Ser Met 9830 9835 9840 Gly Ile Thr Ser Ala Val Asp Asp Thr Thr
Val Phe Thr Ser Asn 9845 9850 9855 Pro Ala Phe Ser Glu Thr Arg Arg
Ile Pro Thr Glu Pro Thr Phe 9860 9865 9870 Ser Leu Thr Pro Gly Phe
Arg Glu Thr Ser Thr Ser Glu Glu Thr 9875 9880 9885 Thr Ser Ile Thr
Glu Thr Ser Ala Val Leu Tyr Gly Val Pro Thr 9890 9895 9900 Ser Ala
Thr Thr Glu Val Ser Met Thr Glu Ile Met Ser Ser Asn 9905 9910 9915
Arg Ile His Ile Pro Asp Ser Asp Gln Ser Thr Met Ser Pro Asp 9920
9925 9930 Ile Ile Thr Glu Val Ile Thr Arg Leu Ser Ser Ser Ser Met
Met 9935 9940 9945 Ser Glu Ser Thr Gln Met Thr Ile Thr Thr Gln Lys
Ser Ser Pro 9950 9955 9960 Gly Ala Thr Ala Gln Ser Thr Leu Thr Leu
Ala Thr Thr Thr Ala 9965 9970 9975 Pro Leu Ala Arg Thr His Ser Thr
Val Pro Pro Arg Phe Leu His 9980 9985 9990 Ser Glu Met Thr Thr Leu
Met Ser Arg Ser Pro Glu Asn Pro Ser 9995 10000 10005 Trp Lys Ser
Ser Leu Phe Val Glu Lys Thr Ser Ser Ser Ser Ser 10010 10015 10020
Leu Leu Ser Leu Pro Val Thr Thr Ser Pro Ser Val Ser Ser Thr 10025
10030 10035 Leu Pro Gln Ser Ile Pro Ser Ser Ser Phe Ser Val Thr Ser
Leu 10040 10045 10050 Leu Thr Pro Gly Met Val Lys Thr Thr Asp Thr
Ser Thr Glu Pro 10055 10060 10065 Gly Thr Ser Leu Ser Pro Asn Leu
Ser Gly Thr Ser Val Glu Ile 10070 10075 10080 Leu Ala Ala Ser Glu
Val Thr Thr Asp Thr Glu Lys Ile His Pro 10085 10090 10095 Ser Ser
Ser Met Ala Val Thr Asn Val Gly Thr Thr Ser Ser Gly 10100 10105
10110 His Glu Leu Tyr Ser Ser Val Ser Ile His Ser Glu Pro Ser Lys
10115 10120 10125 Ala Thr Tyr Pro Val Gly Thr Pro Ser Ser Met Ala
Glu Thr Ser 10130 10135 10140 Ile Ser Thr Ser Met Pro Ala Asn Phe
Glu Thr Thr Gly Phe Glu 10145 10150 10155 Ala Glu Pro Phe Ser His
Leu Thr Ser Gly Phe Arg Lys Thr Asn 10160 10165 10170 Met Ser Leu
Asp Thr Ser Ser Val Thr Pro Thr Asn Thr Pro Ser 10175 10180 10185
Ser Pro Gly Ser Thr His Leu Leu Gln Ser Ser Lys Thr Asp Phe 10190
10195 10200 Thr Ser Ser Ala Lys Thr Ser Ser Pro Asp Trp Pro Pro Ala
Ser 10205 10210 10215 Gln Tyr Thr Glu Ile Pro Val Asp Ile Ile Thr
Pro Phe Asn Ala 10220 10225 10230 Ser Pro Ser Ile Thr Glu Ser Thr
Gly Ile Thr Ser Phe Pro Glu 10235 10240 10245 Ser Arg Phe Thr Met
Ser Val Thr Glu Ser Thr His His Leu Ser 10250 10255 10260 Thr Asp
Leu Leu Pro Ser Ala Glu Thr Ile Ser Thr Gly Thr Val 10265 10270
10275 Met Pro Ser Leu Ser Glu Ala Met Thr Ser Phe Ala Thr Thr Gly
10280 10285 10290 Val Pro Arg Ala Ile Ser Gly Ser Gly Ser Pro Phe
Ser Arg Thr 10295 10300 10305 Glu Ser Gly Pro Gly Asp Ala Thr Leu
Ser Thr Ile Ala Glu Ser 10310 10315 10320 Leu Pro Ser Ser Thr Pro
Val Pro Phe Ser Ser Ser Thr Phe Thr 10325 10330 10335 Thr Thr Asp
Ser Ser Thr Ile Pro Ala Leu His Glu Ile Thr Ser 10340 10345 10350
Ser Ser Ala Thr Pro Tyr Arg Val Asp Thr Ser Leu Gly Thr Glu 10355
10360 10365 Ser Ser Thr Thr Glu Gly Arg Leu Val Met Val Ser Thr Leu
Asp 10370 10375 10380 Thr Ser Ser Gln Pro Gly Arg Thr Ser Ser Ser
Pro Ile Leu Asp 10385 10390 10395 Thr Arg Met Thr Glu Ser Val Glu
Leu Gly Thr Val Thr Ser Ala 10400 10405 10410 Tyr Gln Val Pro Ser
Leu Ser Thr Arg Leu Thr Arg Thr Asp Gly 10415 10420 10425 Ile Met
Glu His Ile Thr Lys Ile Pro Asn Glu Ala Ala His Arg 10430 10435
10440 Gly Thr Ile Arg Pro Val Lys Gly Pro Gln Thr Ser Thr Ser Pro
10445 10450 10455 Ala Ser Pro Lys Gly Leu His Thr Gly Gly Thr Lys
Arg Met Glu 10460 10465 10470 Thr Thr Thr Thr Ala Leu Lys Thr Thr
Thr Thr Ala Leu Lys Thr 10475 10480 10485 Thr Ser Arg Ala Thr Leu
Thr Thr Ser Val Tyr Thr Pro Thr Leu 10490 10495 10500 Gly Thr Leu
Thr Pro Leu Asn Ala Ser Met Gln Met Ala Ser Thr 10505 10510 10515
Ile Pro Thr Glu Met Met Ile Thr Thr Pro Tyr Val Phe Pro Asp 10520
10525 10530 Val Pro Glu Thr Thr Ser Ser Leu Ala Thr Ser Leu Gly Ala
Glu 10535 10540 10545 Thr Ser Thr Ala Leu Pro Arg Thr Thr Pro Ser
Val Phe Asn Arg 10550 10555 10560 Glu Ser Glu Thr Thr Ala Ser Leu
Val Ser Arg Ser Gly Ala Glu 10565 10570 10575 Arg Ser Pro Val Ile
Gln Thr Leu Asp Val Ser Ser Ser Glu Pro 10580 10585 10590 Asp Thr
Thr Ala Ser Trp Val Ile His Pro Ala Glu Thr Ile Pro 10595 10600
10605 Thr Val Ser Lys Thr Thr Pro Asn Phe Phe His Ser Glu Leu Asp
10610 10615 10620 Thr Val Ser Ser Thr Ala Thr Ser His Gly Ala Asp
Val Ser Ser 10625 10630 10635 Ala Ile Pro Thr Asn Ile Ser Pro Ser
Glu Leu Asp Ala Leu Thr 10640 10645 10650 Pro Leu Val Thr Ile Ser
Gly Thr Asp Thr Ser Thr Thr Phe Pro 10655 10660 10665 Thr Leu Thr
Lys Ser Pro His Glu Thr Glu Thr Arg Thr Thr Trp 10670 10675 10680
Leu Thr His Pro Ala Glu Thr Ser Ser Thr Ile Pro Arg Thr Ile 10685
10690 10695 Pro Asn Phe Ser His His Glu Ser Asp Ala Thr Pro Ser Ile
Ala 10700 10705 10710 Thr Ser Pro Gly Ala Glu Thr Ser Ser Ala Ile
Pro Ile Met Thr 10715 10720 10725 Val Ser Pro Gly Ala Glu Asp Leu
Val Thr Ser Gln Val Thr Ser 10730 10735 10740 Ser Gly Thr Asp Arg
Asn Met Thr Ile Pro Thr Leu Thr Leu Ser 10745 10750 10755 Pro Gly
Glu Pro Lys Thr Ile Ala Ser Leu Val Thr His Pro Glu 10760 10765
10770 Ala Gln Thr Ser Ser Ala Ile Pro Thr Ser Thr Ile Ser Pro Ala
10775 10780 10785 Val Ser Arg Leu Val Thr Ser Met Val Thr Ser Leu
Ala Ala Lys 10790 10795 10800 Thr Ser Thr Thr Asn Arg Ala Leu Thr
Asn Ser Pro Gly Glu Pro 10805 10810 10815 Ala Thr Thr Val Ser Leu
Val Thr His Pro Ala Gln Thr Ser Pro 10820 10825 10830 Thr Val Pro
Trp Thr Thr Ser Ile Phe Phe His Ser Lys Ser Asp 10835 10840 10845
Thr Thr Pro Ser Met Thr Thr Ser His Gly Ala Glu Ser Ser Ser 10850
10855 10860 Ala Val Pro Thr Pro Thr Val Ser Thr Glu Val Pro Gly Val
Val 10865 10870 10875 Thr Pro Leu Val Thr Ser Ser Arg Ala Val Ile
Ser Thr Thr Ile 10880 10885 10890 Pro Ile Leu Thr Leu Ser Pro Gly
Glu Pro Glu Thr Thr Pro Ser 10895 10900 10905 Met Ala Thr Ser His
Gly Glu Glu Ala Ser Ser Ala Ile Pro Thr 10910 10915 10920 Pro Thr
Val Ser Pro Gly Val Pro Gly Val Val Thr Ser Leu Val 10925 10930
10935 Thr Ser Ser Arg Ala Val Thr Ser Thr Thr Ile Pro Ile Leu Thr
10940 10945 10950 Phe Ser Leu Gly Glu Pro Glu Thr Thr Pro Ser Met
Ala Thr Ser 10955 10960 10965 His Gly Thr Glu Ala Gly Ser Ala Val
Pro Thr Val Leu Pro Glu 10970 10975 10980 Val Pro Gly Met Val Thr
Ser Leu Val Ala Ser Ser Arg Ala Val 10985 10990 10995 Thr Ser Thr
Thr Leu Pro Thr Leu Thr Leu Ser Pro Gly Glu Pro 11000 11005 11010
Glu Thr Thr Pro Ser Met Ala Thr Ser His Gly Ala Glu Ala Ser 11015
11020 11025 Ser Thr Val Pro Thr Val Ser Pro Glu Val Pro Gly Val Val
Thr 11030 11035 11040 Ser Leu Val Thr Ser Ser Ser Gly Val Asn Ser
Thr Ser Ile Pro 11045 11050 11055 Thr Leu Ile Leu Ser Pro Gly Glu
Leu Glu Thr Thr Pro Ser Met 11060 11065 11070 Ala Thr Ser His Gly
Ala Glu Ala Ser Ser Ala Val Pro Thr Pro 11075 11080 11085 Thr Val
Ser Pro Gly Val Ser Gly Val Val Thr Pro Leu Val Thr 11090 11095
11100 Ser Ser Arg Ala Val Thr Ser Thr Thr Ile Pro Ile Leu Thr Leu
11105 11110 11115 Ser Ser Ser Glu Pro Glu Thr Thr Pro Ser Met Ala
Thr Ser His 11120 11125 11130 Gly Val Glu Ala Ser Ser Ala Val Leu
Thr Val Ser Pro Glu Val 11135 11140 11145 Pro Gly Met Val Thr Ser
Leu Val Thr Ser Ser Arg Ala Val Thr 11150 11155 11160 Ser Thr Thr
Ile Pro Thr Leu Thr Ile Ser Ser Asp Glu Pro Glu 11165 11170 11175
Thr Thr Thr Ser Leu Val Thr His Ser Glu Ala Lys Met Ile Ser 11180
11185 11190 Ala Ile Pro Thr Leu Ala Val Ser Pro Thr Val Gln Gly Leu
Val 11195 11200 11205 Thr Ser Leu Val Thr Ser Ser Gly Ser Glu Thr
Ser Ala Phe Ser 11210 11215 11220 Asn Leu Thr Val Ala Ser Ser Gln
Pro Glu Thr Ile Asp Ser Trp 11225 11230 11235 Val Ala His Pro Gly
Thr Glu Ala Ser Ser Val Val Pro Thr Leu 11240 11245 11250 Thr Val
Ser Thr Gly Glu Pro Phe Thr Asn Ile Ser Leu Val Thr 11255 11260
11265 His Pro Ala Glu Ser Ser Ser Thr Leu Pro Arg Thr Thr Ser Arg
11270 11275 11280 Phe Ser His Ser Glu Leu Asp Thr Met Pro Ser Thr
Val Thr Ser 11285 11290 11295 Pro Glu Ala Glu Ser Ser Ser Ala Ile
Ser Thr Thr Ile Ser Pro 11300 11305 11310 Gly Ile Pro Gly Val Leu
Thr Ser Leu Val Thr Ser Ser Gly Arg 11315 11320 11325 Asp Ile Ser
Ala Thr Phe Pro Thr Val Pro Glu Ser Pro His Glu 11330 11335 11340
Ser Glu Ala Thr Ala Ser Trp Val Thr His Pro Ala Val Thr Ser 11345
11350 11355 Thr Thr Val Pro Arg Thr Thr Pro Asn Tyr Ser His Ser Glu
Pro 11360 11365 11370 Asp Thr Thr Pro Ser Ile Ala Thr Ser Pro Gly
Ala Glu Ala Thr 11375 11380 11385 Ser Asp Phe Pro Thr Ile Thr Val
Ser Pro Asp Val Pro Asp Met 11390 11395 11400 Val Thr Ser Gln Val
Thr Ser Ser Gly Thr Asp Thr Ser Ile Thr 11405 11410 11415 Ile Pro
Thr Leu Thr Leu Ser Ser Gly Glu Pro Glu Thr Thr Thr 11420 11425
11430 Ser Phe Ile Thr Tyr Ser Glu Thr His Thr Ser Ser Ala Ile Pro
11435 11440 11445 Thr Leu Pro Val Ser Pro Gly Ala Ser Lys Met Leu
Thr Ser Leu 11450 11455 11460 Val Ile Ser Ser Gly Thr Asp Ser Thr
Thr Thr Phe Pro Thr Leu 11465 11470 11475 Thr Glu Thr Pro Tyr Glu
Pro Glu Thr Thr Ala Ile Gln Leu Ile 11480 11485 11490 His Pro Ala
Glu Thr Asn Thr Met Val Pro Arg Thr Thr Pro Lys 11495 11500 11505
Phe Ser His Ser Lys Ser Asp Thr Thr Leu Pro Val Ala Ile Thr 11510
11515 11520 Ser Pro Gly Pro Glu Ala Ser Ser Ala Val Ser Thr Thr Thr
Ile 11525 11530 11535 Ser Pro Asp Met Ser Asp Leu Val Thr Ser Leu
Val Pro Ser Ser 11540 11545 11550 Gly Thr Asp Thr Ser Thr Thr Phe
Pro Thr Leu Ser Glu Thr Pro 11555 11560 11565 Tyr Glu Pro Glu Thr
Thr Ala Thr Trp Leu Thr His Pro Ala Glu 11570 11575 11580 Thr Ser
Thr Thr Val Ser Gly Thr Ile Pro Asn Phe Ser His Arg 11585 11590
11595 Gly Ser Asp Thr Ala Pro Ser Met Val Thr Ser Pro Gly Val Asp
11600 11605 11610 Thr Arg Ser Gly Val Pro Thr Thr Thr Ile Pro Pro
Ser Ile Pro 11615 11620 11625 Gly Val Val Thr Ser Gln Val Thr Ser
Ser Ala Thr Asp Thr Ser 11630 11635 11640 Thr Ala Ile Pro Thr Leu
Thr Pro Ser Pro Gly Glu Pro Glu Thr 11645 11650 11655 Thr Ala Ser
Ser Ala Thr His Pro Gly Thr Gln Thr Gly Phe Thr 11660 11665 11670
Val Pro Ile Arg Thr Val Pro Ser Ser Glu Pro Asp Thr Met Ala 11675
11680 11685 Ser Trp Val Thr His Pro Pro Gln Thr Ser Thr Pro Val Ser
Arg 11690 11695 11700 Thr Thr Ser Ser Phe Ser His Ser Ser Pro Asp
Ala Thr Pro Val 11705 11710 11715 Met Ala Thr Ser Pro Arg Thr Glu
Ala Ser Ser Ala Val Leu Thr 11720 11725 11730 Thr Ile Ser Pro Gly
Ala Pro Glu Met Val Thr Ser Gln Ile Thr 11735 11740 11745 Ser Ser
Gly Ala Ala Thr Ser Thr Thr Val Pro Thr Leu Thr His 11750 11755
11760 Ser Pro Gly Met Pro Glu Thr Thr Ala Leu Leu Ser Thr His Pro
11765 11770 11775 Arg Thr Glu Thr Ser Lys Thr Phe Pro Ala Ser Thr
Val Phe Pro 11780 11785 11790 Gln Val Ser Glu Thr Thr Ala Ser Leu
Thr Ile Arg Pro Gly Ala 11795 11800 11805 Glu Thr Ser Thr Ala Leu
Pro Thr Gln Thr Thr Ser Ser Leu Phe 11810 11815 11820 Thr Leu Leu
Val Thr Gly Thr Ser Arg Val Asp Leu Ser Pro Thr 11825 11830 11835
Ala Ser Pro Gly Val Ser Ala Lys Thr Ala Pro Leu Ser Thr His 11840
11845 11850 Pro Gly Thr Glu Thr Ser Thr Met Ile Pro Thr Ser Thr Leu
Ser 11855 11860 11865 Leu Gly Leu Leu Glu Thr Thr Gly Leu Leu Ala
Thr Ser Ser Ser 11870 11875 11880 Ala Glu Thr Ser Thr Ser
Thr Leu Thr Leu Thr Val Ser Pro Ala 11885 11890 11895 Val Ser Gly
Leu Ser Ser Ala Ser Ile Thr Thr Asp Lys Pro Gln 11900 11905 11910
Thr Val Thr Ser Trp Asn Thr Glu Thr Ser Pro Ser Val Thr Ser 11915
11920 11925 Val Gly Pro Pro Glu Phe Ser Arg Thr Val Thr Gly Thr Thr
Met 11930 11935 11940 Thr Leu Ile Pro Ser Glu Met Pro Thr Pro Pro
Lys Thr Ser His 11945 11950 11955 Gly Glu Gly Val Ser Pro Thr Thr
Ile Leu Arg Thr Thr Met Val 11960 11965 11970 Glu Ala Thr Asn Leu
Ala Thr Thr Gly Ser Ser Pro Thr Val Ala 11975 11980 11985 Lys Thr
Thr Thr Thr Phe Asn Thr Leu Ala Gly Ser Leu Phe Thr 11990 11995
12000 Pro Leu Thr Thr Pro Gly Met Ser Thr Leu Ala Ser Glu Ser Val
12005 12010 12015 Thr Ser Arg Thr Ser Tyr Asn His Arg Ser Trp Ile
Ser Thr Thr 12020 12025 12030 Ser Ser Tyr Asn Arg Arg Tyr Trp Thr
Pro Ala Thr Ser Thr Pro 12035 12040 12045 Val Thr Ser Thr Phe Ser
Pro Gly Ile Ser Thr Ser Ser Ile Pro 12050 12055 12060 Ser Ser Thr
Ala Ala Thr Val Pro Phe Met Val Pro Phe Thr Leu 12065 12070 12075
Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asp Met Arg His 12080
12085 12090 Pro Gly Ser Arg Lys Phe Asn Ala Thr Glu Arg Glu Leu Gln
Gly 12095 12100 12105 Leu Leu Lys Pro Leu Phe Arg Asn Ser Ser Leu
Glu Tyr Leu Tyr 12110 12115 12120 Ser Gly Cys Arg Leu Ala Ser Leu
Arg Pro Glu Lys Asp Ser Ser 12125 12130 12135 Ala Thr Ala Val Asp
Ala Ile Cys Thr His Arg Pro Asp Pro Glu 12140 12145 12150 Asp Leu
Gly Leu Asp Arg Glu Arg Leu Tyr Trp Glu Leu Ser Asn 12155 12160
12165 Leu Thr Asn Gly Ile Gln Glu Leu Gly Pro Tyr Thr Leu Asp Arg
12170 12175 12180 Asn Ser Leu Tyr Val Asn Gly Phe Thr His Arg Ser
Ser Met Pro 12185 12190 12195 Thr Thr Ser Thr Pro Gly Thr Ser Thr
Val Asp Val Gly Thr Ser 12200 12205 12210 Gly Thr Pro Ser Ser Ser
Pro Ser Pro Thr Thr Ala Gly Pro Leu 12215 12220 12225 Leu Met Pro
Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr 12230 12235 12240
Glu Glu Asp Met Arg Arg Thr Gly Ser Arg Lys Phe Asn Thr Met 12245
12250 12255 Glu Ser Val Leu Gln Gly Leu Leu Lys Pro Leu Phe Lys Asn
Thr 12260 12265 12270 Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu
Thr Leu Leu Arg 12275 12280 12285 Pro Glu Lys Asp Gly Ala Ala Thr
Gly Val Asp Ala Ile Cys Thr 12290 12295 12300 His Arg Leu Asp Pro
Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu 12305 12310 12315 Tyr Trp
Glu Leu Ser Lys Leu Thr Asn Asp Ile Glu Glu Leu Gly 12320 12325
12330 Pro Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr
12335 12340 12345 His Gln Ser Ser Val Ser Thr Thr Ser Thr Pro Gly
Thr Ser Thr 12350 12355 12360 Val Asp Leu Arg Thr Ser Gly Thr Pro
Ser Ser Leu Ser Ser Pro 12365 12370 12375 Thr Ile Met Ala Ala Gly
Pro Leu Leu Val Pro Phe Thr Leu Asn 12380 12385 12390 Phe Thr Ile
Thr Asn Leu Gln Tyr Gly Glu Asp Met Gly His Pro 12395 12400 12405
Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu 12410
12415 12420 Leu Gly Pro Ile Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr
Ser 12425 12430 12435 Gly Cys Arg Leu Thr Ser Leu Arg Ser Glu Lys
Asp Gly Ala Ala 12440 12445 12450 Thr Gly Val Asp Ala Ile Cys Ile
His His Leu Asp Pro Lys Ser 12455 12460 12465 Pro Gly Leu Asn Arg
Glu Arg Leu Tyr Trp Glu Leu Ser Gln Leu 12470 12475 12480 Thr Asn
Gly Ile Lys Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asn 12485 12490
12495 Ser Leu Tyr Val Asn Gly Phe Thr His Arg Thr Ser Val Pro Thr
12500 12505 12510 Ser Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Gly
Thr Ser Gly 12515 12520 12525 Thr Pro Phe Ser Leu Pro Ser Pro Ala
Thr Ala Gly Pro Leu Leu 12530 12535 12540 Val Leu Phe Thr Leu Asn
Phe Thr Ile Thr Asn Leu Lys Tyr Glu 12545 12550 12555 Glu Asp Met
His Arg Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu 12560 12565 12570
Arg Val Leu Gln Thr Leu Leu Gly Pro Met Phe Lys Asn Thr Ser 12575
12580 12585 Val Gly Leu Leu Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg
Ser 12590 12595 12600 Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala
Ile Cys Thr His 12605 12610 12615 Arg Leu Asp Pro Lys Ser Pro Gly
Val Asp Arg Glu Gln Leu Tyr 12620 12625 12630 Trp Glu Leu Ser Gln
Leu Thr Asn Gly Ile Lys Glu Leu Gly Pro 12635 12640 12645 Tyr Thr
Leu Asp Arg Asn Ser Leu Tyr Val Asn Gly Phe Thr His 12650 12655
12660 Trp Ile Pro Val Pro Thr Ser Ser Thr Pro Gly Thr Ser Thr Val
12665 12670 12675 Asp Leu Gly Ser Gly Thr Pro Ser Ser Leu Pro Ser
Pro Thr Thr 12680 12685 12690 Ala Gly Pro Leu Leu Val Pro Phe Thr
Leu Asn Phe Thr Ile Thr 12695 12700 12705 Asn Leu Lys Tyr Glu Glu
Asp Met His Cys Pro Gly Ser Arg Lys 12710 12715 12720 Phe Asn Thr
Thr Glu Arg Val Leu Gln Ser Leu Leu Gly Pro Met 12725 12730 12735
Phe Lys Asn Thr Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu 12740
12745 12750 Thr Leu Leu Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val
Asp 12755 12760 12765 Ala Ile Cys Thr His Arg Leu Asp Pro Lys Ser
Pro Gly Val Asp 12770 12775 12780 Arg Glu Gln Leu Tyr Trp Glu Leu
Ser Gln Leu Thr Asn Gly Ile 12785 12790 12795 Lys Glu Leu Gly Pro
Tyr Thr Leu Asp Arg Asn Ser Leu Tyr Val 12800 12805 12810 Asn Gly
Phe Thr His Gln Thr Ser Ala Pro Asn Thr Ser Thr Pro 12815 12820
12825 Gly Thr Ser Thr Val Asp Leu Gly Thr Ser Gly Thr Pro Ser Ser
12830 12835 12840 Leu Pro Ser Pro Thr Ser Ala Gly Pro Leu Leu Val
Pro Phe Thr 12845 12850 12855 Leu Asn Phe Thr Ile Thr Asn Leu Gln
Tyr Glu Glu Asp Met His 12860 12865 12870 His Pro Gly Ser Arg Lys
Phe Asn Thr Thr Glu Arg Val Leu Gln 12875 12880 12885 Gly Leu Leu
Gly Pro Met Phe Lys Asn Thr Ser Val Gly Leu Leu 12890 12895 12900
Tyr Ser Gly Cys Arg Leu Thr Leu Leu Arg Pro Glu Lys Asn Gly 12905
12910 12915 Ala Ala Thr Gly Met Asp Ala Ile Cys Ser His Arg Leu Asp
Pro 12920 12925 12930 Lys Ser Pro Gly Leu Asn Arg Glu Gln Leu Tyr
Trp Glu Leu Ser 12935 12940 12945 Gln Leu Thr His Gly Ile Lys Glu
Leu Gly Pro Tyr Thr Leu Asp 12950 12955 12960 Arg Asn Ser Leu Tyr
Val Asn Gly Phe Thr His Arg Ser Ser Val 12965 12970 12975 Ala Pro
Thr Ser Thr Pro Gly Thr Ser Thr Val Asp Leu Gly Thr 12980 12985
12990 Ser Gly Thr Pro Ser Ser Leu Pro Ser Pro Thr Thr Ala Val Pro
12995 13000 13005 Leu Leu Val Pro Phe Thr Leu Asn Phe Thr Ile Thr
Asn Leu Gln 13010 13015 13020 Tyr Gly Glu Asp Met Arg His Pro Gly
Ser Arg Lys Phe Asn Thr 13025 13030 13035 Thr Glu Arg Val Leu Gln
Gly Leu Leu Gly Pro Leu Phe Lys Asn 13040 13045 13050 Ser Ser Val
Gly Pro Leu Tyr Ser Gly Cys Arg Leu Ile Ser Leu 13055 13060 13065
Arg Ser Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Ala Ile Cys 13070
13075 13080 Thr His His Leu Asn Pro Gln Ser Pro Gly Leu Asp Arg Glu
Gln 13085 13090 13095 Leu Tyr Trp Gln Leu Ser Gln Met Thr Asn Gly
Ile Lys Glu Leu 13100 13105 13110 Gly Pro Tyr Thr Leu Asp Arg Asn
Ser Leu Tyr Val Asn Gly Phe 13115 13120 13125 Thr His Arg Ser Ser
Gly Leu Thr Thr Ser Thr Pro Trp Thr Ser 13130 13135 13140 Thr Val
Asp Leu Gly Thr Ser Gly Thr Pro Ser Pro Val Pro Ser 13145 13150
13155 Pro Thr Thr Thr Gly Pro Leu Leu Val Pro Phe Thr Leu Asn Phe
13160 13165 13170 Thr Ile Thr Asn Leu Gln Tyr Glu Glu Asn Met Gly
His Pro Gly 13175 13180 13185 Ser Arg Lys Phe Asn Ile Thr Glu Ser
Val Leu Gln Gly Leu Leu 13190 13195 13200 Lys Pro Leu Phe Lys Ser
Thr Ser Val Gly Pro Leu Tyr Ser Gly 13205 13210 13215 Cys Arg Leu
Thr Leu Leu Arg Pro Glu Lys Asp Gly Val Ala Thr 13220 13225 13230
Arg Val Asp Ala Ile Cys Thr His Arg Pro Asp Pro Lys Ile Pro 13235
13240 13245 Gly Leu Asp Arg Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu
Thr 13250 13255 13260 His Ser Ile Thr Glu Leu Gly Pro Tyr Thr Leu
Asp Arg Asp Ser 13265 13270 13275 Leu Tyr Val Asn Gly Phe Thr Gln
Arg Ser Ser Val Pro Thr Thr 13280 13285 13290 Ser Thr Pro Gly Thr
Phe Thr Val Gln Pro Glu Thr Ser Glu Thr 13295 13300 13305 Pro Ser
Ser Leu Pro Gly Pro Thr Ala Thr Gly Pro Val Leu Leu 13310 13315
13320 Pro Phe Thr Leu Asn Phe Thr Ile Thr Asn Leu Gln Tyr Glu Glu
13325 13330 13335 Asp Met Arg Arg Pro Gly Ser Arg Lys Phe Asn Thr
Thr Glu Arg 13340 13345 13350 Val Leu Gln Gly Leu Leu Met Pro Leu
Phe Lys Asn Thr Ser Val 13355 13360 13365 Ser Ser Leu Tyr Ser Gly
Cys Arg Leu Thr Leu Leu Arg Pro Glu 13370 13375 13380 Lys Asp Gly
Ala Ala Thr Arg Val Asp Ala Val Cys Thr His Arg 13385 13390 13395
Pro Asp Pro Lys Ser Pro Gly Leu Asp Arg Glu Arg Leu Tyr Trp 13400
13405 13410 Lys Leu Ser Gln Leu Thr His Gly Ile Thr Glu Leu Gly Pro
Tyr 13415 13420 13425 Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly
Phe Thr His Gln 13430 13435 13440 Ser Ser Met Thr Thr Thr Arg Thr
Pro Asp Thr Ser Thr Met His 13445 13450 13455 Leu Ala Thr Ser Arg
Thr Pro Ala Ser Leu Ser Gly Pro Met Thr 13460 13465 13470 Ala Ser
Pro Leu Leu Val Leu Phe Thr Ile Asn Phe Thr Ile Thr 13475 13480
13485 Asn Leu Arg Tyr Glu Glu Asn Met His His Pro Gly Ser Arg Lys
13490 13495 13500 Phe Asn Thr Thr Glu Arg Val Leu Gln Gly Leu Leu
Arg Pro Val 13505 13510 13515 Phe Lys Asn Thr Ser Val Gly Pro Leu
Tyr Ser Gly Cys Arg Leu 13520 13525 13530 Thr Leu Leu Arg Pro Lys
Lys Asp Gly Ala Ala Thr Lys Val Asp 13535 13540 13545 Ala Ile Cys
Thr Tyr Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp 13550 13555 13560
Arg Glu Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Ser Ile 13565
13570 13575 Thr Glu Leu Gly Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr
Val 13580 13585 13590 Asn Gly Phe Thr Gln Arg Ser Ser Val Pro Thr
Thr Ser Ile Pro 13595 13600 13605 Gly Thr Pro Thr Val Asp Leu Gly
Thr Ser Gly Thr Pro Val Ser 13610 13615 13620 Lys Pro Gly Pro Ser
Ala Ala Ser Pro Leu Leu Val Leu Phe Thr 13625 13630 13635 Leu Asn
Phe Thr Ile Thr Asn Leu Arg Tyr Glu Glu Asn Met Gln 13640 13645
13650 His Pro Gly Ser Arg Lys Phe Asn Thr Thr Glu Arg Val Leu Gln
13655 13660 13665 Gly Leu Leu Arg Ser Leu Phe Lys Ser Thr Ser Val
Gly Pro Leu 13670 13675 13680 Tyr Ser Gly Cys Arg Leu Thr Leu Leu
Arg Pro Glu Lys Asp Gly 13685 13690 13695 Thr Ala Thr Gly Val Asp
Ala Ile Cys Thr His His Pro Asp Pro 13700 13705 13710 Lys Ser Pro
Arg Leu Asp Arg Glu Gln Leu Tyr Trp Glu Leu Ser 13715 13720 13725
Gln Leu Thr His Asn Ile Thr Glu Leu Gly Pro Tyr Ala Leu Asp 13730
13735 13740 Asn Asp Ser Leu Phe Val Asn Gly Phe Thr His Arg Ser Ser
Val 13745 13750 13755 Ser Thr Thr Ser Thr Pro Gly Thr Pro Thr Val
Tyr Leu Gly Ala 13760 13765 13770 Ser Lys Thr Pro Ala Ser Ile Phe
Gly Pro Ser Ala Ala Ser His 13775 13780 13785 Leu Leu Ile Leu Phe
Thr Leu Asn Phe Thr Ile Thr Asn Leu Arg 13790 13795 13800 Tyr Glu
Glu Asn Met Trp Pro Gly Ser Arg Lys Phe Asn Thr Thr 13805 13810
13815 Glu Arg Val Leu Gln Gly Leu Leu Arg Pro Leu Phe Lys Asn Thr
13820 13825 13830 Ser Val Gly Pro Leu Tyr Ser Gly Cys Arg Leu Thr
Leu Leu Arg 13835 13840 13845 Pro Glu Lys Asp Gly Glu Ala Thr Gly
Val Asp Ala Ile Cys Thr 13850 13855 13860 His Arg Pro Asp Pro Thr
Gly Pro Gly Leu Asp Arg Glu Gln Leu 13865 13870 13875 Tyr Leu Glu
Leu Ser Gln Leu Thr His Ser Ile Thr Glu Leu Gly 13880 13885 13890
Pro Tyr Thr Leu Asp Arg Asp Ser Leu Tyr Val Asn Gly Phe Thr 13895
13900 13905 His Arg Ser Ser Val Pro Thr Thr Ser Thr Gly Val Val Ser
Glu 13910 13915 13920 Glu Pro Phe Thr Leu Asn Phe Thr Ile Asn Asn
Leu Arg Tyr Met 13925 13930 13935 Ala Asp Met Gly Gln Pro Gly Ser
Leu Lys Phe Asn Ile Thr Asp 13940 13945 13950 Asn Val Met Gln His
Leu Leu Ser Pro Leu Phe Gln Arg Ser Ser 13955 13960 13965 Leu Gly
Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser 13970
13975 13980 Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr
Tyr 13985 13990 13995 Leu Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile
Lys Gln Val Phe 14000 14005 14010 His Glu Leu Ser Gln Gln Thr His
Gly Ile Thr Arg Leu Gly Pro 14015 14020 14025 Tyr Ser Leu Asp Lys
Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu 14030 14035 14040 Pro Gly
Pro Asp Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr 14045 14050
14055 Phe Leu Pro Pro Leu Ser Glu Ala Thr Thr Ala Met Gly Tyr His
14060 14065 14070 Leu Lys Thr Leu Thr Leu Asn Phe Thr Ile Ser Asn
Leu Gln Tyr 14075 14080 14085 Ser Pro Asp Met Gly Lys Gly Ser Ala
Thr Phe Asn Ser Thr Glu 14090 14095 14100 Gly Val Leu Gln His Leu
Leu Arg Pro Leu Phe Gln Lys Ser Ser 14105 14110 14115 Met Gly Pro
Phe Tyr Leu Gly Cys Gln Leu Ile Ser Leu Arg Pro 14120 14125 14130
Glu Lys Asp Gly Ala Ala Thr Gly Val Asp Thr Thr Cys Thr Tyr 14135
14140 14145 His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile Gln Gln Leu
Tyr 14150 14155 14160 Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr
Gln Leu Gly Phe 14165 14170 14175 Tyr Val Leu Asp Arg Asp Ser Leu
Phe Ile Asn Gly Tyr Ala Pro 14180 14185 14190 Gln Asn Leu Ser Ile
Arg Gly Glu Tyr Gln Ile Asn Phe His Ile 14195 14200 14205 Val Asn
Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr 14210 14215
14220 Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr
14225 14230 14235 Lys Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys
Leu Val Thr 14240 14245 14250 Asn Leu Thr Met Asp Ser Val Leu Val
Thr Val Lys Ala Leu Phe 14255 14260 14265 Ser Ser Asn Leu Asp Pro
Ser Leu Val Glu Gln Val Phe Leu Asp 14270 14275 14280 Lys Thr Leu
Asn Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln 14285 14290 14295
Leu Val Asp Ile His Val Thr Glu Met Glu Ser Ser Val Tyr Gln 14300
14305 14310 Pro Thr Ser Ser Ser Ser Thr Gln His Phe Tyr Leu Asn Phe
Thr 14315 14320 14325 Ile Thr Asn Leu Pro Tyr Ser Gln Asp Lys Ala
Gln Pro Gly Thr 14330 14335 14340 Thr Asn Tyr Gln Arg Asn Lys Arg
Asn Ile Glu Asp Ala Leu Asn 14345 14350 14355 Gln Leu Phe Arg Asn
Ser Ser Ile Lys Ser Tyr Phe Ser Asp Cys 14360 14365 14370 Gln Val
Ser Thr Phe Arg Ser Val Pro Asn Arg His His Thr Gly 14375 14380
14385 Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala Arg Arg Val Asp
14390 14395 14400 Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr
Arg Asn Gly 14405 14410 14415 Thr Gln Leu Gln Asn Phe Thr Leu Asp
Arg Ser Ser Val Leu Val 14420 14425 14430 Asp Gly Tyr Ser Pro Asn
Arg Asn Glu Pro Leu Thr Gly Asn Ser 14435 14440 14445 Asp Leu Pro
Phe Trp Ala Val Ile Leu Ile Gly Leu Ala Gly Leu 14450 14455 14460
Leu Gly Val Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr 14465
14470 14475 Arg Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln
Cys 14480 14485 14490 Pro Gly Tyr Tyr Gln Ser His Leu Asp Leu Glu
Asp Leu Gln 14495 14500 14505 17425PRTArtificial Sequencesynthetic
174Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser 20 25
17517PRTArtificial Sequencesynthetic 175Met His Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val Ser 1 5 10 15 Gly
17638PRTArtificial Sequencesynthetic 176Gly Tyr Ala Asp Ser Val Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn 1 5 10 15 Ala Lys Asn Ser Leu
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp 20 25 30 Thr Ala Leu
Tyr Tyr Cys 35 17711PRTArtificial Sequencesynthetic 177Trp Gly Gln
Gly Thr Thr Val Thr Val Ser Ser 1 5 10 1788PRTArtificial
SequencesyntheticVARIANT(8)..(8)Xaa = Ala or Ser 178Gly Phe Thr Phe
Asp Asp Tyr Xaa 1 5 1798PRTArtificial
SequencesyntheticVARIANT(8)..(8)Xaa = Lys or Ile 179Ile Ser Trp Asn
Ser Gly Ser Xaa 1 5 18017PRTArtificial
SequencesyntheticVARIANT(3)..(3)Xaa = Tyr or
AspVARIANT(12)..(12)Xaa = Tyr or HisVARIANT(15)..(15)Xaa = Met or
LeuVARIANT(15)..(15)Xaa = Met or Leu 180Ala Lys Xaa Gly Ser Gly Tyr
Gly Lys Phe Tyr Xaa Tyr Gly Xaa Asp 1 5 10 15 Val
181125PRTArtificial Sequencesynthetic 181Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu
Tyr Tyr Cys 85 90 95 Ala Lys Asp Gly Tyr Ser Gly Tyr Gly Tyr Phe
Tyr Tyr Tyr Gly Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val
Thr Val Ser Ser 115 120 125 182330PRTArtificial Sequencesynthetic
182Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130
135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250
255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 325 330 183330PRTArtificial Sequencesynthetic 183Ala
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10
15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser
Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys
Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145
150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265
270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn Arg Phe Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys 325 330 184326PRTArtificial Sequencesynthetic 184Ala Ser Thr
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser
Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25
30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe
Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90 95 Thr Val Glu Arg Lys Cys Cys Val
Glu Cys Pro Pro Cys Pro Ala Pro 100 105 110 Pro Val Ala Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 115 120 125 Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 130 135 140 Val Ser
His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 145 150 155
160 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
165 170 175 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln
Asp Trp 180 185 190 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Gly Leu Pro 195 200 205 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr
Lys Gly Gln Pro Arg Glu 210 215 220 Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu Met Thr Lys Asn 225 230 235 240 Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 245 250 255 Ser Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 260 265 270 Thr
Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 275 280
285 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
290 295 300 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
Ser Leu 305 310 315 320 Ser Leu Ser Pro Gly Lys 325
185326PRTArtificial Sequencesynthetic 185Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50
55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln
Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys
Val Asp Lys 85 90 95 Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro
Pro Cys Pro Ala Pro 100 105 110 Pro Val Ala Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp 115 120 125 Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val Val Val Asp 130 135 140 Val Ser His Glu Asp
Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 145 150 155 160 Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 165 170 175
Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp 180
185 190 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
Pro 195 200 205 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln
Pro Arg Glu 210 215 220 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
Glu Met Thr Lys Asn 225 230 235 240 Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile 245 250 255 Ser Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 260 265 270 Thr Pro Pro Met
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 275 280 285 Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 290 295 300
Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu 305
310 315 320 Ser Leu Ser Pro Gly Lys 325 186327PRTArtificial
Sequencesynthetic 186Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65
70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val
Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser
Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp
Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185
190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu
Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310
315 320 Leu Ser Leu Ser Leu Gly Lys 325 187327PRTArtificial
Sequencesynthetic 187Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr
Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90
95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln
Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro
Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215
220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys
225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser
Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His
Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser 305 310 315 320 Leu Ser
Leu Ser Leu Gly Lys 325 188329PRTArtificial Sequencesynthetic
188Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala
Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 115 120 125
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 130
135 140 Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp
Tyr 145 150 155 160 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
Pro Arg Glu Glu 165 170 175 Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
Val Leu Thr Val Leu His 180 185 190 Gln Asp Trp Leu Asn Gly Lys Glu
Tyr Lys Cys Lys Val Ser Asn Lys 195 200 205 Gly Leu Pro Ser Ser Ile
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 210 215 220 Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 225 230 235 240 Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 245 250
255 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
260 265 270 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
Phe Leu 275 280 285 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
Gln Gly Asn Val 290 295 300 Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His Tyr Thr Gln 305 310 315 320 Lys Ser Leu Ser Leu Ser Pro
Gly Lys 325 189329PRTArtificial Sequencesynthetic 189Ala Ser Thr
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25
30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Pro Val Ala
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 115 120 125 Pro Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 130 135 140 Val Val
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr 145 150 155
160 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
165 170 175 Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
Leu His 180 185 190 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
Val Ser Asn Lys 195 200 205 Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln 210 215 220 Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Asp Glu Leu 225 230 235 240 Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 245 250 255 Ser Asp Ile
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 260 265 270 Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 275 280
285 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
290 295 300 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe
Thr Gln 305 310 315 320 Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
190326PRTArtificial Sequencesynthetic 190Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu
Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50
55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys
Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys
Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
Pro Cys Pro Ala Pro 100 105 110 Pro Val Ala Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro Lys Asp 115 120 125 Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val Val Val Asp 130 135 140 Val Ser Gln Glu Asp
Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 145 150 155 160 Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 165 170 175
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 180
185 190 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
Pro 195 200 205 Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
Pro Arg Glu 210 215 220 Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu
Glu Met Thr Lys Asn 225 230 235 240 Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro Ser Asp Ile 245 250 255 Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 260 265 270 Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg 275 280 285 Leu Thr
Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys 290 295 300
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 305
310 315 320 Ser Leu Ser Leu Gly Lys 325 191326PRTArtificial
Sequencesynthetic 191Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe
Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr
Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90
95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
Lys Asp 115 120 125 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
Val Val Val Asp 130 135 140 Val Ser Gln Glu Asp Pro Glu Val Gln Phe
Asn Trp Tyr Val Asp Gly 145 150 155 160 Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg Glu Glu Gln Phe Asn 165 170 175 Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val Leu His Gln Asp Trp 180 185 190 Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 195 200 205 Ser
Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 210 215
220 Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn
225 230 235 240 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile 245 250 255 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
Asn Asn Tyr Lys Thr 260 265 270 Thr Pro Pro Val Leu Asp Ser Asp Gly
Ser Phe Phe Leu Tyr Ser Arg 275 280 285 Leu Thr Val Asp Lys Ser Arg
Trp Gln Glu Gly Asn Val Phe Ser Cys 290 295 300 Ser Val Met His Glu
Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu 305 310 315 320 Ser Leu
Ser Leu Gly Lys 325 192232PRTArtificial Sequencesynthetic 192Glu
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10
15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145
150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala
Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro
Gly Lys 225 230 193232PRTArtificial Sequencesynthetic 193Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20
25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser
Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu
Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro
Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185
190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr
Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly Lys 225 230
194228PRTArtificial Sequencesynthetic 194Glu Arg Lys Cys Cys Val
Glu Cys Pro Pro Cys Pro Ala Pro Pro Val 1 5 10 15 Ala Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45
His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 50
55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
Thr 65 70 75 80 Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp
Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Gly Leu Pro Ala Pro 100 105 110 Ile Glu Lys Thr Ile Ser Lys Thr Lys
Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser
Arg Glu Glu Met Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ser Val 145 150 155 160 Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175
Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180
185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu 210 215 220 Ser Pro Gly Lys 225 195228PRTArtificial
Sequencesynthetic 195Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys
Pro Ala Pro Pro Val 1 5 10 15 Ala Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp Val Ser 35 40 45 His Glu Asp Pro Glu
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 65 70 75 80 Phe
Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn 85 90
95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro
100 105 110 Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ser Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Met Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met
His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu 210 215
220 Ser Pro Gly Lys 225 196229PRTArtificial Sequencesynthetic
196Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe
1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn
Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys
Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser
Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu
Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125
Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130
135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln
Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu
His Asn Arg Phe Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly
Lys 225 197229PRTArtificial Sequencesynthetic 197Glu Ser Lys Tyr
Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35
40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu
Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165
170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg
Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe
Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly Lys 225
198231PRTArtificial Sequencesynthetic 198Glu Pro Lys Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Pro Val Ala
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 20 25 30 Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 35 40 45
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 50
55 60 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Phe 65 70 75 80 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp 85 90 95 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Gly Leu 100 105 110 Pro Ser Ser Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg 115 120 125 Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu Thr Lys 130 135 140 Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 145 150 155 160 Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 165 170 175
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 180
185 190 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser 195 200 205 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
Gln Lys Ser 210 215 220 Leu Ser Leu Ser Pro Gly Lys 225 230
199231PRTArtificial Sequencesynthetic 199Glu Pro Lys Ser Cys Asp
Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Pro Val Ala
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 20 25 30 Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 35 40 45
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 50
55 60 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
Phe 65 70 75 80 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
His Gln Asp 85 90 95 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn Lys Gly Leu 100 105 110 Pro Ser Ser Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg 115 120 125 Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu Thr Lys 130 135 140 Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 145 150 155 160 Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 165 170 175
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 180
185 190 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser 195 200 205 Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr
Gln Lys Ser 210 215 220 Leu Ser Leu Ser Pro Gly Lys 225 230
200228PRTArtificial Sequencesynthetic 200Glu Ser Lys Tyr Gly Pro
Pro Cys Pro Pro Cys Pro Ala Pro Pro Val 1 5 10 15 Ala Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 50
55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
Gly Leu Pro Ser Ser 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser
Gln Glu Glu Met Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180
185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser
Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu 210 215 220 Ser Leu Gly Lys 225 201228PRTArtificial
Sequencesynthetic 201Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys
Pro Ala Pro Pro Val 1 5 10 15 Ala Gly Pro Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp Val Ser 35 40 45 Gln Glu Asp Pro Glu
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 65 70 75 80 Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90
95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser
100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr
Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys
Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met
His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu 210 215
220 Ser Leu Gly Lys 225
* * * * *